STMicroelectronics (STM) 20-F22 Feb 242023 FY Annual report (foreign)Financial data

Company Profile

Cover Page

Cover Page	12 Months Ended
Cover Page	Dec. 31, 2023 shares
Document Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	1-13546
Entity Registrant Name	STMicroelectronics N.V.
Entity Incorporation, State or Country Code	P7
Entity Address, Address Line One	WTC Schiphol Airport
Entity Address, Address Line Two	Schiphol Boulevard 265
Entity Address, City or Town	Schiphol
Entity Address, Country	NL
Entity Address, Postal Zip Code	1118 BH
Title of 12(b) Security	Common shares, nominal value €1.04 per share
Trading Symbol	STM
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding	902,771,081
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Document Accounting Standard	U.S. GAAP
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Entity Central Index Key	0000932787
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2023
Business Contact
Document Information [Line Items]
Entity Address, Address Line One	39, Chemin du Champ des Filles
Entity Address, Address Line Two	Plan-Les-Ouates
Entity Address, City or Town	Geneva
Entity Address, Country	CH
Entity Address, Postal Zip Code	1228
Contact Personnel Name	Jean-Marc Chery
Local Phone Number	+41 22 929 29 29
City Area Code	22
Contact Personnel Fax Number	41 22 929 29 88

Audit Information

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2023
Audit Information [Abstract]
Auditor Firm ID	1460
Auditor Name	Ernst & Young AG
Auditor location	Geneva, Switzerland

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions	12 Months Ended
Consolidated Statements of Income - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net revenues	$ 17,286	$ 16,128	$ 12,761
Cost of sales	(8,999)	(8,493)	(7,435)
Gross profit	8,287	7,635	5,326
Selling, general and administrative expenses	(1,631)	(1,454)	(1,323)
Research and development expenses	(2,100)	(1,901)	(1,723)
Other income and expenses, net	55	159	141
Impairment, restructuring charges and other related closure costs	0	0	(2)
Operating income	4,611	4,439	2,419
Interest income (expense), net	171	58	(29)
Other components of pension benefit costs	(19)	(11)	(10)
Loss on financial instruments, net	0	0	(43)
Income (loss) before income tax benefit (expense)	4,763	4,486	2,337
Income tax expense	(541)	(520)	(331)
Net income	4,222	3,966	2,006
Net income attributable to noncontrolling interest	(11)	(6)	(6)
Net income attributable to parent company stockholders	$ 4,211	$ 3,960	$ 2,000
Earnings per share, basic ( in usd per share)	$ 4.66	$ 4.37	$ 2.21
Earnings per share, diluted (in usd per share)	$ 4.46	$ 4.19	$ 2.16
Revenues from sale of products
Net revenues	$ 17,239	$ 16,083	$ 12,729
Other revenues
Net revenues	$ 47	$ 45	$ 32

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 4,222	$ 3,966	$ 2,006
Derivative instruments:
Change in fair value of cash-flow hedge	33	(108)	(79)
Reclassification for net (gains)/losses realized and included in net income	(5)	170	(16)
Total change in unrealized gains/losses on cash-flow hedge	28	62	(95)
Available-for-sale debt securities:
Change in fair value of available-for-sale debt securities	5	(14)	(1)
Reclassification for net (gains)/losses realized and included in net income	0	0	0
Total change in unrealized gains/losses on available-for sale debt securities	5	(14)	(1)
Defined benefit plans:
Actuarial gains/(losses) arising during the period	(19)	62	52
Amortization of actuarial gains losses included in net income	6	3	6
Total change in unrealized gains/losses on defined benefit plans	(13)	65	58
Change in foreign currency translation	133	(148)	(189)
Other comprehensive income (loss), net of tax	153	(35)	(227)
Total comprehensive income	4,375	3,931	1,779
Less: comprehensive income (loss) attributable to noncontrolling interest	11	7	6
Total comprehensive income attributable to the Company's stockholders	$ 4,364	$ 3,924	$ 1,773

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,222	$ 3,258
Short-term deposits	1,226	581
Marketable securities	1,635	679
Trade accounts receivable, net	1,731	1,970
Inventories	2,698	2,583
Other current assets	1,295	734
Total current assets	11,807	9,805
Goodwill	303	297
Other intangible assets, net	367	405
Property, plant and equipment, net	10,554	8,201
Non-current deferred tax assets	592	602
Long-term investments	22	11
Other non-current assets	808	661
Total assets	24,453	19,982
Current liabilities:
Short-term debt	217	175
Trade accounts payable	1,856	2,122
Other payables and accrued liabilities	1,525	1,385
Dividends payable to stockholders	54	60
Accrued income tax	78	95
Total current liabilities	3,730	3,837
Long-term debt	2,710	2,542
Post-employment benefit obligations	372	331
Long-term deferred tax liabilities	54	60
Other long-term liabilities	735	454
Total liabilities	7,601	7,224
Equity, Attributable to Parent [Abstract]
Common stock (preferred stock: 540,000,000 shares authorized, not issued; common stock: Euro 1.04 par value, 1,200,000,000 shares authorized, 911,281,920 shares issued, 902,771,081 shares outstanding as of December 31, 2023)	1,157	1,157
Additional paid-in-capital	2,866	2,631
Retained earnings	12,470	8,713
Accumulated other comprehensive income	613	460
Treasury stock	(377)	(268)
Total parent company stockholders' equity	16,729	12,693
Noncontrolling interest	123	65
Total stockholders' equity	16,852	12,758
Total liabilities and stockholders' equity	$ 24,453	$ 19,982

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - € / shares	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, shares authorized (in shares)	540,000,000
Common stock, nominal value (in EUR per share)	€ 1.04
Common stock, shares authorized (in shares)	1,200,000,000
Common stock, shares issued (in shares)	911,281,920	911,281,920
Common stock, shares outstanding (in shares)	902,771,081	903,865,763	906,518,057

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Transition effect of update in accounting standard	Common stock	Additional paid-In capital	Additional paid-In capital Transition effect of update in accounting standard	Treasury stock	Retained earnings	Retained earnings Transition effect of update in accounting standard	Accumulated other comprehensive income (loss)	Noncontrolling interest
Beginning Balance at Dec. 31, 2020	$ 8,506		$ 1,157	$ 3,062		$ (93)	$ 3,599		$ 723	$ 58
Repurchase of common stock	(485)					(485)
Settlement of senior convertible bonds	(530)			(750)		220
Stock-based compensation expense	221			221		158	(158)
Comprehensive income (loss):
Net income	2,006						2,000			6
Other comprehensive income (loss), net of tax	(227)								(227)
Total comprehensive income	1,779
Dividends	(218)						(218)
Ending Balance at Dec. 31, 2021	9,273		1,157	2,533		(200)	5,223		496	64
Repurchase of common stock	(346)					(346)
Stock-based compensation expense	215			215		278	(278)
Comprehensive income (loss):
Net income	3,966						3,960			6
Other comprehensive income (loss), net of tax	(35)								(36)	1
Total comprehensive income	3,931
Dividends to noncontrolling interest	(6)									(6)
Dividends	(217)						(217)
Ending Balance at Dec. 31, 2022	12,758	$ (92)	1,157	2,631	$ (117)	(268)	8,713	$ 25	460	65
Capital contribution from noncontrolling interest	52									52
Repurchase of common stock	(346)					(346)
Stock-based compensation expense	236			235		237	(237)			1
Comprehensive income (loss):
Net income	4,222						4,211			11
Other comprehensive income (loss), net of tax	153								153
Total comprehensive income	4,375
Dividends to noncontrolling interest	(6)									(6)
Dividends	(217)						(217)
Ending Balance at Dec. 31, 2023	$ 16,852		$ 1,157	$ 2,866		$ (377)	$ 12,470		$ 613	$ 123

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical)	12 Months Ended
Consolidated Statements of Equity (Parenthetical)	Dec. 31, 2022 $ / shares
Common stock
Dividends, per share (in usd per share)	$ 0.24

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net income	$ 4,222	$ 3,966	$ 2,006
Items to reconcile net income and cash flows from operating activities:
Depreciation and amortization	1,561	1,216	1,045
Interest and amortization of issuance costs on convertible bonds	1	1	36
Interest on settled convertible bonds	0	0	(40)
Loss on financial instruments, net	0	0	43
Non-cash stock-based compensation	236	215	221
Other non-cash items	(125)	(69)	(153)
Deferred income tax	19	3	45
Impairment, restructuring charges and other related closure costs, net of cash payments	0	0	2
Changes in assets and liabilities:
Trade receivables, net	229	(231)	(307)
Inventories	(72)	(650)	(188)
Trade payables	(238)	240	95
Other assets and liabilities, net	159	511	255
Net cash from operating activities	5,992	5,202	3,060
Cash flows used in investing activities:
Payment for purchase of tangible assets	(4,439)	(3,549)	(1,840)
Proceeds from capital grants and other contributions	320	21	10
Proceeds from sale of tangible assets	8	4	2
Payment for purchase of marketable securities	(1,653)	(687)	0
Proceeds from matured marketable securities	750	0	132
Net proceeds from (investment in) short-term deposits	(645)	(293)	290
Payment for purchase of intangible assets	(97)	(87)	(97)
Payment for purchase of financial assets	10	0	17
Proceeds from sale of financial assets	0	0	2
Net cash used in investing activities	(5,766)	(4,591)	(1,518)
Cash flows from (used in) financing activities:
Proceeds from long-term debt	329	200	788
Repayment of issued convertible bonds	0	0	(1,223)
Repayment of long-term debt	(169)	(134)	(134)
Repurchase of common stock	(346)	(346)	(485)
Dividends paid to stockholders	(223)	(212)	(205)
Dividends paid to noncontrolling interest	(6)	(6)	(6)
Proceeds from noncontrolling interest	52	0	0
Proceeds from advances on capital grants	152	0	0
Payment for withholding tax on vested shares	(54)	(44)	(49)
Payment for deferred consideration on business acquisitions	0	(25)	0
Other financing activities	(2)	0	0
Net cash used in financing activities	(267)	(567)	(1,314)
Effect of changes in exchange rates	5	(11)	(9)
Net cash increase (decrease)	(36)	33	219
Cash and cash equivalents at beginning of the period	3,258	3,225	3,006
Cash and cash equivalents at end of the period	3,222	3,258	3,225
Supplemental Cash Flow Information [Abstract]
Interest paid	31	2	2
Income tax paid	$ 489	$ 416	$ 279

The Company

The Company	12 Months Ended
The Company	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	THE COMPANY STMicroelectronics N.V. (the “Company”) is registered in the Netherlands with its corporate legal seat in Amsterdam, the Netherlands, and its corporate headquarters located in Geneva, Switzerland.

Accounting Policies

Accounting Policies	12 Months Ended
Accounting Policies	Dec. 31, 2023
Accounting Policies [Abstract]
Accounting Policies	ACCOUNTING POLICIES The accounting policies of the Company conform to accounting principles generally accepted in the United States of America (“U.S. GAAP”). All balances and values in the current and prior periods are in millions of U.S. dollars, except share and per-share amounts. Under Article 35 of the Company’s Articles of Association, the financial year extends from January 1 to December 31, which is the period-end of each fiscal year. 2.1 Basis of presentation and consolidation The Company's consolidated financial statements include the assets, liabilities, results of operations and cash flows of its wholly-owned and majority-owned subsidiaries, after elimination of intercompany transactions and balances. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are deconsolidated from the date that control ceases. The Company assesses each investment in equity securities to determine whether the investee is a Variable Interest Entity (“VIE”). The Company consolidates the VIEs for which the Company is determined to be the primary beneficiary. The primary beneficiary of a VIE is the party that: (i) has the power to direct the most significant activities of the VIE and (ii) is obligated to absorb losses or has the rights to receive returns that would be considered significant to the VIE. When the Company owns some, but not all, of the voting stock of a consolidated entity, the shares held by third parties represent a noncontrolling interest. The consolidated financial statements are prepared based on the total amount of assets and liabilities and income and expenses of the consolidated subsidiaries. However, the portion of these items that does not belong to the Company’s shareholders is reported in the line “Noncontrolling interest” of the consolidated financial statements. 2.2 Use of estimates The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions. The primary areas that require significant estimates and judgments by management include, but are not limited to: • sales allowances for discounts, price protection, product returns and other rebates, • inventory obsolescence reserves and normal manufacturing capacity thresholds to determine costs capitalized in inventory, • recognition and measurement of loss contingencies, • valuation at fair value of assets acquired and liabilities assumed on business acquisitions, and measurement of any contingent consideration, • annual and trigger-based impairment review of goodwill and intangible assets, as well as the assessment of events which could trigger impairment testing on tangible assets, • assessment of the Company’s long-lived assets economic useful lives, • assumptions used in measuring expected credit losses and impairment charges on financial assets, • assumptions used in assessing the number of awards expected to vest on stock-based compensation plans, • assumptions used in calculating net defined pension benefit obligations and other long-term employee benefits, • determination of the amount of tax expected to be paid and tax benefit expected to be received, including deferred income tax assets, valuation allowance and provisions for uncertain tax positions and claims. The Company bases the estimates and assumptions on historical experience and on various other factors such as market trends, market information used by market participants and the latest available business plans that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. While the Company regularly evaluates its estimates and assumptions, the actual results experienced by the Company could differ materially and adversely from those estimates. 2.3 Foreign currency The U.S. dollar is the reporting currency of the Company. The U.S. dollar is the currency of the primary economic environment in which the Company operates since the worldwide semiconductor industry uses the U.S. dollar as a currency of reference for actual pricing in the market. Furthermore, the majority of the Company’s transactions are denominated in U.S. dollars, and revenues from external sales in U.S. dollars largely exceed revenues in any other currency. However, certain significant costs are incurred in the countries of the Eurozone and other non-U.S. dollar currency areas. The functional currency of each subsidiary of the Company is either the local currency or the U.S. dollar, depending on the basis of the economic environment in which each subsidiary operates. Foreign currency transactions, including operations in local currency when the U.S. dollar is the functional currency, are measured into the functional currency using the prevailing exchange rate. Foreign exchange gains and losses resulting from the re-measurement at reporting date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized in the line “Other income and expenses, net” of the consolidated statements of income. For consolidation purposes, the results and financial position of the subsidiaries whose functional currency is different from the U.S. dollar are translated into the reporting currency as follows: (a) assets and liabilities for each consolidated balance sheet presented are translated into U.S. dollars using exchange rates at the balance sheet dates; (b) income and expenses for each consolidated statement of income presented are translated into U.S dollars using the monthly exchange rates; (c) the resulting exchange differences are reported as Currency Translation Adjustments (“CTA”), a component of “Other comprehensive income (loss)” in the consolidated statements of comprehensive income. 2.4 Cash and cash equivalents Cash and cash equivalents include cash on hand, deposits held at call with external financial institutions and other short-term highly liquid investments with effective maturities of three months or less. They are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Short-term deposits representing cash equivalents with maturity beyond three months and below one year are reported as current assets in the line “Short-term deposits” of the consolidated balance sheets. 2.5 Trade accounts receivable Trade accounts receivable are amounts due from customers for goods sold and services rendered to third parties in the ordinary course of business. The Company uses a lifetime expected losses allowance for all trade receivables. The allowance includes reasonable assumptions about future credit trends. The historical loss rates are adjusted to reflect current and forward-looking information on macro-economic factors affecting the ability of the Company’s customers to settle the receivables. Adjustments to the expected credit losses allowance are reported on the line “Selling, general and administrative expenses” in the consolidated statements of income and write-offs, if any, are recorded against the expected credit losses allowance. In the event of transfers of receivables such as factoring, the Company derecognizes the receivables only to the extent that the Company has surrendered control over the receivables in exchange for a consideration other than beneficial interest in the transferred receivables. 2.6 Inventories Inventories are stated at the lower of cost and net realizable value. Actual cost is based on an adjusted standard cost, which approximates cost on a first-in, first-out basis for all categories of inventory (raw materials, work-in-process, finished products). Actual cost is therefore dependent on the Company’s manufacturing performance and is based on the normal utilization of its production capacity. In case of underutilization of manufacturing facilities, the costs associated with unused capacity are not included in the valuation of inventories but charged directly to cost of sales. Net realizable value is based upon the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Inventory reserve is estimated for excess uncommitted inventory based on historical sales data, order backlog and production plans. The Company performs, on a continuous basis, write-offs of inventories, which have the characteristics of slow-moving, old production dates and technical obsolescence. The Company evaluates its inventory to identify obsolete or slow-selling items, as well as inventory that is not of saleable quality and records a specific reserve if the Company estimates the inventory will eventually be written off. 2.7 Income taxes Income tax for the period comprises current and deferred income tax. Income tax expense represents the income tax expected to be paid related to the current year taxable profit in each tax jurisdiction. Deferred income tax is recognized for all temporary differences arising between the tax bases of assets and liabilities and their carrying amount in the consolidated financial statements. Deferred tax assets are also recognized on temporary differences arising from tax losses carried forward and tax credits. Deferred tax liabilities are not recognized on the initial recognition of goodwill as a result of a business combination. Deferred income tax is determined using tax rates and laws that are enacted at the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. The effect on deferred tax assets and liabilities from changes in tax laws and tax rates is recognized on the line “Income tax expense” in the consolidated statements of income in the period in which the law is enacted. Deferred income tax assets are recognized in full but the Company assesses whether future taxable profit will be available against which temporary differences can be utilized. A valuation allowance is provided for deferred tax assets when management considers it is more likely than not that they will not be realized. The Company recognizes a deferred tax liability on undistributed earnings of subsidiaries when there is a presumption that taxable earnings will be remitted to the parent. A deferred tax asset is recognized on compensation for the grant of stock awards to the extent that such charge constitutes a temporary difference in the subsidiaries’ local tax jurisdictions. Changes in the stock price do not result in any adjustments to the deferred tax asset prior to vesting. At each reporting date, the Company assesses all significant income tax positions in all tax jurisdictions to determine any uncertain tax positions. The Company uses a two-step process for the evaluation of uncertain tax positions. The first step consists in assessing whether the tax benefit must be recognized. The second step consists in measuring the amount of tax benefit to be recognized on each uncertain tax position. In step 1 (recognition), the Company assesses whether a tax position, based solely on its technical merits, is more likely than not to be sustained upon examination. Only tax positions with a sustainability threshold higher than 50% are recognized. In Step 2 (measurement), the Company determines the amount of recognizable tax benefit. The measurement methodology is based on a “cumulative probability” approach, resulting in the recognition of the largest amount that is greater than 50% likely of being realized upon settlement with the taxing authority. The Company accrues for interest and penalties on uncertain tax liabilities reported on the consolidated balance sheets. Interests and penalties are classified as components of income tax expense in the consolidated statements of income. 2.8 Business combinations and goodwill The acquisition method of accounting is applied to all business combinations. The identifiable assets acquired, liabilities assumed, and equity instruments issued are measured at acquisition date fair value. Any contingent consideration is recorded at acquisition date fair value and remeasured at each reporting date. Acquisition-related transaction costs and restructuring costs related to the acquired business are expensed as incurred. Acquired in-process research and development (“IPR&D”) is capitalized and recorded as an intangible asset at acquisition date, subject to impairment testing until the research or development is completed. The excess of the consideration transferred over the acquisition-date fair value of the identifiable assets acquired and liabilities assumed, net of related deferred tax impacts, is recorded as goodwill. In case of a bargain purchase, the Company reassesses whether it has correctly identified all of the assets acquired and all of the liabilities assumed, the noncontrolling interest in the acquiree, if any, the Company’s previously held equity interest in the acquiree, if any, and the consideration transferred. If after this review, a bargain purchase is still indicated, it is recognized in earnings attributable to parent company stockholders. The purchase of additional interests in a partially owned subsidiary is treated as an equity transaction as well as all transactions concerning the sale of subsidiary stock or the issuance of stock by the partially owned subsidiary, assuming there is no change in control of the subsidiary. In the case of a sale of subsidiary shares, whereby the Company no longer maintains control of the subsidiary, the Company recognizes a gain or loss in earnings. Goodwill is carried at cost less accumulated impairment losses, if any. Goodwill is not amortized but is tested for impairment at least annually, and more frequently whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. Goodwill subject to potential impairment is tested at the reporting unit level. The impairment test determines whether the fair value of each reporting unit under which goodwill is allocated is lower than the total carrying amount of relevant net assets allocated to such reporting unit, including its allocated goodwill. The Company records an impairment loss on goodwill when a reporting unit’s carrying value exceeds its fair value. Significant management judgments and estimates are used in forecasting the future discounted cash flows associated with the reporting unit, including: the applicable industry’s sales volume forecast and selling price evolution, the reporting unit’s market penetration and its revenues evolution, the market acceptance of certain new technologies and products, the relevant cost structure, the discount rates applied using a weighted average cost of capital and the perpetuity rates used in calculating cash flow terminal values. 2.9 Intangible assets with definite useful lives Intangible assets subject to amortization include intangible assets purchased from third parties recorded at cost and intangible assets acquired in business combinations initially recorded at fair value. Amortization begins when the intangible asset is available for its intended use. Amortization reflects the pattern in which the asset’s economic benefits are consumed, which usually consists in applying the straight-line method to allocate the cost of the intangible assets over their estimated useful lives. The carrying value of intangible assets with definite useful lives is evaluated whenever changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its fair value. The Company evaluates the remaining useful life of an intangible asset at each reporting date to determine whether events and circumstances warrant a revision to the remaining period of amortization. Technologies and licenses Separately acquired technologies and licenses are recorded at historical cost. Technologies and licenses acquired in a business combination are initially recognized at acquisition date fair value. Technologies and licenses have a useful life which usually ranges from 3 to 11 years and are carried at cost less accumulated amortization and impairment losses, if any. Computer software Separately acquired computer software is recorded at historical cost. Costs associated with maintaining computer software programs are expensed as incurred and reported as “Cost of sales”, “Selling, general and administrative expenses”, or “Research and development expenses” in the consolidated statements of income according to their intended use. The capitalization of costs for internally generated software developed by the Company for its internal use begins when the preliminary project stage is completed and when the Company, implicitly or explicitly, authorizes and commits to funding a computer software project. It must be probable that the project will be completed and will be used to perform the function intended. Amortization of computer software begins when the software is available for its intended use and is calculated using the straight-line method over the estimated useful life, which does not exceed 4 years. 2.10 Property, plant and equipment Property, plant and equipment are stated at historical cost, net of accumulated depreciation and any impairment losses. Property, plant and equipment acquired in a business combination are initially recognized at acquisition date fair value. Major additions and improvements are capitalized, while minor replacements and repairs are expensed and reported as “Cost of sales”, “Selling, general and administrative expenses”, or “Research and development expenses” in the consolidated statements of income according to their intended use. Land is not depreciated. Depreciation on fixed assets is computed using the straight-line method over their estimated useful lives, as follows: Buildings 33 years Facilities and leasehold improvements 5-10 years Machinery and equipment 2-10 years Computer and R&D equipment 3-6 years Other 2-5 years The Company also evaluates, and adjusts if appropriate, the assets’ useful lives. Property, plant and equipment are periodically reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or a group of assets may not be recoverable. Several impairment indicators exist for making this assessment, such as: restructuring plans, significant changes in the technology, market, economic or legal environment in which the Company operates, available evidence of obsolescence of the asset, or indication that its economic performance is, or will be, worse than expected. In determining the recoverability of assets to be held and used, the Company initially assesses whether the carrying value of the tangible assets or group of assets exceeds the undiscounted cash flows associated with these assets. If exceeded, the Company then evaluates whether an impairment charge is required by determining if the asset’s carrying value also exceeds its fair value. This fair value is normally estimated by the Company based on independent market appraisals or the sum of discounted future cash flows, using market assumptions such as the utilization of the Company’s fabrication facilities and the ability to upgrade such facilities, change in the selling price and the adoption of new technologies. Any impairment loss is reported on the same income statement line as the depreciation expense recorded on the impaired group of assets, except in case of closure of operating sites or major restructuring plans and reorganizations. In such case, any impairment loss is reported on the line “Impairment, restructuring charges and other related closure costs” in the consolidated statements of income. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are included in “Other income and expenses, net” in the consolidated statements of income. The Company did not hold any significant assets held for sale as of December 31, 2023 and December 31, 2022. 2.11 Leases A lease contract is a contract, or part of a contract, that conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If a lease is identified, classification between finance or operating is determined at lease commencement. Most leases entered by the Company are operating leases. Operating lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. The rate implicit in the lease should be used as a discount rate whenever that rate is readily determinable. In most cases, this rate is not readily determinable and therefore, the Company uses its incremental borrowing rate, which is derived from information available at the lease commencement date. The Company considers its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. Operating lease right-of-use assets are based on the corresponding lease liability adjusted for any lease payments made at or before commencement, initial direct costs, and lease incentives. Right-of-use assets are included in the line “Property, plant and equipment, net” of the consolidated balance sheets. Operating lease liabilities due within one year are included in the line “Other payables and accrued liabilities”, while non-current operating lease liabilities are included in the line “Other long-term liabilities” of the Company’s consolidated balance sheets. Operating lease expenses are recognized in the consolidated statements of income, on a straight-line basis since the lease commencement date over the lease period and reported as “Cost of sales”, “Selling, general and administrative expenses”, or “Research and development expenses”, according to the intended use of the leased asset. Finance lease liabilities due within one year are included in the line “Short-term debt”, while non-current finance lease liabilities are included in the line “Long-term debt” of the Company’s consolidated balance sheets. Right-of-use assets for finance leases are depreciated on a straight-line basis since the lease commencement date over the lease period or the estimated useful life of the leased asset in case of transfer of ownership or purchase option that is reasonably certain to be exercised. The depreciation expense is reported as “Cost of sales”, “Selling, general and administrative expenses”, or “Research and development expenses”, according to the intended use of the leased asset. Certain lease contracts contain options to extend the lease. On these contracts, the Company estimates the lease term by including the extended duration when it is reasonably certain for the Company to exercise that option. In addition, for short-term leases, defined as leases with a term of twelve months or less, the Company elected the practical expedient to not recognize an associated lease liability and right-of-use asset. The short-term lease election is made at the commencement date only. Additionally, lease contracts with a sum of lease payments not exceeding $5,000 are excluded from recognition on the consolidated balance sheet. The right-of-use asset is a non-monetary asset while the lease liability is a monetary liability. When accounting for a lease that is denominated in a foreign currency, the lease liability is remeasured using the current exchange rate, while the right-of-use asset is measured using the historical exchange rate as of the commencement date. The Company does not separate lease and non-lease components and instead accounts for each separate lease component and the non-lease components associated with that lease component as a single lease component. Variable lease payments that depend on an index or a rate are included in the lease payments and are measured using the prevailing index or rate at the measurement date. Changes to index and rate-based variable lease payments are recognized in earnings in the period of the change. 2.12 Loss contingencies In determining loss contingencies, the Company considers the likelihood of the incurrence of a liability as well as the ability to reasonably estimate the amount of such loss or liability. An estimated loss from a loss contingency is accrued when information available indicates that it is probable that a liability has been incurred at the date of the consolidated financial statements and when the amount of the loss can be reasonably estimated. 2.13 Long-term debt (a) Convertible debt On January 1, 2022, the Company adopted the new guidance on distinguishing liabilities from equity by applying the modified retrospective approach, with the impact upon transition recorded in retained earnings for instruments outstanding as of the date of adoption of the new guidance. Prior to the new guidance, components of convertible debt instruments that may be settled in cash upon conversion based on a net-share settlement basis were accounted for separately as long-term debt and equity when the conversion feature of the convertible bonds constituted an embedded equity instrument. When an equity instrument was identified, proceeds from issuance were allocated between debt and equity by measuring first the liability component and then determining the equity component as a residual amount. The liability component was measured as the fair value of a similar non-convertible debt, which resulted in the recognition of a debt discount. In subsequent periods, the Company amortized the debt discount through earnings in the line “Interest income (expense), net” of the consolidated statements of income, using the effective interest method, based on the contractual maturity of the debt. The equity component, reported on the line “Additional paid-in capital” of the consolidated statement of equity, was not remeasured. Deferred taxes were recognized on the difference between the carrying amount of the liability component and its tax basis. In case of conversion from the bondholders, the fair value of the consideration transferred was allocated between the liability component and the equity component. The difference between the carrying amount of the debt at the settlement date and the fair value of the debt component was recorded in earnings as a loss on debt extinguishment and reported in the line “Loss on financial instruments, net” of the consolidated statements of income. The liability component was measured as the fair value of a similar non-convertible debt prior to settlement. The reacquired equity component was recorded in equity and reported on the line “Additional paid-in capital” of the consolidated statement of equity. The new accounting guidance adopted on January 1, 2022 has eliminated the cash conversion model described above. At initial recognition, total cash proceeds received at issuance are reported as financial debt and no equity conversion instrument is recorded separately in equity. On subsequent periods, the carrying value of the convertible debt is incremented up to its nominal value over the amortization pattern of any unamortized debt discount and issuance costs. Debt issuance costs are reported as a deduction of debt. They are subsequently amortized through earnings on the line “Interest income (expense), net” of the consolidated statements of income, using the effective interest rate method. (b) Bank loans Bank loans and non-convertible senior bonds are recognized at the amount of cash proceeds received, net of debt issuance costs incurred. They are subsequently reported at amortized cost; any difference between the proceeds (net of debt issuance costs) and the principal amount is recognized through earnings on the line “Interest income (expense), net” of the consolidated statements of income over the period of the borrowings using the effective interest method. 2.14 Employee benefits (a) Pension obligations The Company sponsors various pension schemes for its employees. These schemes conform to local regulations and practices in the countries in which the Company operates. Such plans include both defined benefit and defined contribution plans. For defined benefit pension plans, the liability recognized in the consolidated balance sheets is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The funded status of the defined benefit plans is calculated as the difference between plan assets and the projected benefit obligations. Estimates are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input from independent actuaries. Actuarial gains and losses arising from changes in actuarial assumptions are recognized in “Accumulated other comprehensive income (loss)” in the consolidated statements of equity and are charged or credited to earnings over the employees’ average remaining service period using the corridor amortization method. Past service costs are recognized in earnings on the line “Other components of pension benefit costs” of the consolidated statements of income if the changes to the pension scheme are not conditional on the employees remaining in service for a specified period. Other past service costs are recognized in “Accumulated other comprehensive income (loss)” in the consolidated statements of equity and are amortized on a straight-line basis over the average remaining service period. The net periodic benefit cost of the year is determined based on the assumptions used at the end of the previous year. The service cost component of net periodic benefit costs is presented in the same income statement line as other employee compensation costs arising from services rendered during the period. The other components of the net periodic benefit cost are presented separately, outside operating income, on the line “Other components of pension benefit costs” of the consolidated statements of income. These elements include: interest cost; expected return on plan assets; amortization of transition (asset) obligation; amortization of prior service cost; amortization of net (gain) loss; (gain) loss recognized due to curtailment or settlement and; cost of special termination benefits. For defined contribution pension plans, the Company pays contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or voluntary basis. The Company has no further payment obligations once the contributions have been paid. The contributions are recognized as employee benefit expense when they are due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available. (b) Termination benefits Termination benefits are payable when an employee is involuntarily terminated, or whenever an employee accepts voluntary termination in exchange for termination benefits. For the accounting treatment and timing of recognition of involuntary termination benefits, the Company distinguishes between one-time termination benefit arrangements and ongoing termination benefit arrangements. A one-time termination benefit arrangement is established by a termination plan and applies to a specified termination event. One-time involuntary termination benefits are recognized as a liability when the termination plan meets certain criteria and has been communicated to employees. If employees are required to render future service in order to receive these one-time termination benefits, the liability is recognized ratably over the future service period. Termination benefits other than one-time termination benefits are termination benefits for which the communication criterion is not met but that are committed to by management, or termination obligations that are not specifically determined in a new and single plan. These termination benefits are all legal, contractual and past practice termination obligations to be paid to employees in case of involuntary termination. These termination benefits are accrued for when commitment creates a present obligation to others for the benefits expected to be paid, when it is probable that employees will be entitled to the benefits and the amount can be reasonably estimated. In case of special termination benefits related to voluntary redundancy programs, the Company recognizes a provision for voluntary termination benefits at the date on

Short-Term Deposits and Marketa

Short-Term Deposits and Marketable Securities	12 Months Ended
Short-Term Deposits and Marketable Securities	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Short-Term Deposits and Marketable Securities	SHORT-TERM DEPOSITS AND MARKETABLE SECURITIES To optimize the return yield on its short-term investments, the Company invested $1,226 million of available cash in short-term deposits as of December 31, 2023, compared to $581 million as of December 31, 2022. The Company also invested available liquidity in marketable securities. Changes in the fair value of marketable securities are detailed in the tables below: December 31, Purchase Accretion Proceeds Change in December 31, U.S. Treasury debt securities 679 1,653 47 (750) 6 1,635 Total 679 1,653 47 (750) 6 1,635 * Other Comprehensive Income December 31, Purchase Accretion Proceeds Change in December 31, U.S. Treasury debt securities — 687 8 — (16) 679 Total — 687 8 — (16) 679 * Other Comprehensive Income In 2023, the Company invested $1,653 million available cash in U.S. Treasury bonds. The debt securities have an average rating of Aaa/AA+/AA+ from Moody’s, S&P and Fitch, respectively, with a weighted average maturity of 1.6 years. The debt securities are reported as current assets on the line “Marketable securities” on the consolidated balance sheet, since they represent investments of funds available for current operations. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of the amortized cost basis. The bonds are classified as available-for-sale financial assets and recorded at fair value as of December 31, 2023. The fair value measurement corresponds to a Level 1 fair value hierarchy measurement. The aggregate amortized cost basis of these securities totaled $1,645 million as of December 31, 2023. Marketable securities totaling $750 million at principal amount were transferred to financial institutions as part of short-term securities lending transactions, in compliance with corporate policies. The Company, acting as the securities lender, does not hold any collateral in this unsecured securities lending transaction. The Company retains effective control on the transferred securities. As of December 31, 2022, the Company held $679 million in marketable securities classified as available-for-sale debt securities. The below table details debt securities that were in an unrealized loss position as of December 31, 2023: December 31, 2023 Less than 12 months More than 12 months Total Description Fair Value Unrealized Fair Value Unrealized Fair Value Unrealized U.S. Treasury Bonds 429 (12) 157 (1) 586 (13) Total 429 (12) 157 (1) 586 (13) Debt securities that were in an unrealized gain position as of December 31, 2023, were reported at a fair value of $1,049 million with an unrealized gain of $4 million. The Company did not report any debt securities that were in an unrealized loss position for more than one year as of December 31, 2022.

Trade Accounts Receivable, Net

Trade Accounts Receivable, Net	12 Months Ended
Trade Accounts Receivable, Net	Dec. 31, 2023
Receivables [Abstract]
Trade Accounts Receivable, Net	TRADE ACCOUNTS RECEIVABLE, NET Trade accounts receivable, net consist of the following: December 31, December 31, 2023 2022 Trade accounts receivable 1,750 1,991 Current expected credit losses allowance ("CECLA") (19) (21) Total 1,731 1,970 The Company uses a lifetime expected losses allowance for all trade receivables based on failure rates, as applied to the gross amounts of trade accounts receivable. The allowance also includes reasonable assumptions about future credit trends. The historical loss rates are adjusted to reflect current and forward-looking information on macro-economic factors affecting the ability of the Company’s customers to settle the receivables. In addition to the factors already embedded in the failure rates, as applied on trade accounts receivable, the Company has identified cyclicality and uncertainties around continued growth for the semiconductor industry and its serviceable available market to be the most relevant factors. These macro-economic factors are weighted into different economic scenarios, in line with estimates and methodologies applied by other business entities, including financial institutions. On that basis, the changes in reported CECLA for the year ended December 31, 2023 are presented below: CECLA As of December 31, 2022 (21) Current-period adjustment to CECLA 2 CECLA As of December 31, 2023 (19) Adjustments to the expected credit losses allowance are reported in the line “Selling, general and administrative expenses” in the consolidated statements of income.

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventories	INVENTORIES Inventories consist of the following: December 31, December 31, 2023 2022 Raw materials 298 349 Work-in-process 1,745 1,490 Finished products 655 744 Total 2,698 2,583

Other Current Assets

Other Current Assets	12 Months Ended
Other Current Assets	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	OTHER CURRENT ASSETS Other current assets are detailed below: December 31, December 31, Public funding receivables 651 190 Taxes and other government receivables 241 270 Advances and prepayments 180 125 Loans and deposits 10 10 Interest receivable 27 22 Derivative instruments 58 56 Other current assets 128 61 Total 1,295 734 Public funding receivables are described in Note 7. Taxes and other government receivables mainly include receivables related to value-added tax, primarily in European tax jurisdictions. Advances and prepayments include prepaid amounts associated with multi-annual supply and service agreements. Derivative instruments are further described in Note 26. Other current assets include a $28 million contribution to be received in 2024 from a third party as part of a collaborative agreement associated with the ongoing capacity expansion project for the 300mm wafer fab in Crolles, France. Total contributions received from the third party as part of this collaborative agreement totaled $54 million, reported as "Proceeds from capital grants and other contributions" in the statement of cash flows for the year ended December 31, 2023. The Company applies a current expected credit losses model on all financial assets measured at amortized cost, including deposits, loans and receivables. The major portion of other current assets to which this model applies corresponds to government receivables. Due to the existing history of zero-default on receivables originated by governments, the expected credit losses are assumed to be not significant as of December 31, 2023 and December 31, 2022. Other current assets presented in the table above within the lines “Loans and deposits” and “Other current assets” are composed of amounts not deemed at exposure of default. Consequently, no loss allowance was reported on those current assets as of December 31, 2023 and December 31, 2022.

Public Funding

Public Funding	12 Months Ended
Public Funding	Dec. 31, 2023
Government Assistance [Abstract]
Public Funding	PUBLIC FUNDING The main government assistance received by the Company are classified under four general categories: funding for Research and Development (R&D), R&D and Innovation activities (RDI), funding for First Industrial Deployment activities (FID) and capital investments for pilot lines and other industrial activities. Receivables related to public funding totaled $861 million as of December 31, 2023, of which $651 million reported on the line “Other current assets” and $210 million reported on the line “Other non-current assets”, as collection is expected beyond 12 months. The receivables related to public funding included $378 million of capital grants associated with capital investments projects for the Company's 300mm wafer fab in Crolles, France and its silicon carbide manufacturing activities in Italy. These public funding programs also set forth a clawback mechanism according to which the public government agencies will require, at specific future testing dates, the remeasurement of the aid, which may trigger future payments by the Company. No provision was recorded as of December 31, 2023 in relation to this clawback mechanism. Receivables related to public funding amounted to $346 million, of which $190 million reported on the line “Other current assets” and $156 million reported on the line “Other non-current assets” of the consolidated balance sheet as of December 31, 2022. Research tax credit receivables totaled $246 million and were reported on the line “Other non-current assets” of the consolidated balance sheet as of December 31, 2023. Research tax credit receivables totaled $294 million and were reported on the line “Other non-current assets” of the consolidated balance sheet as of December, 31, 2022. In 2023, the Company and Sanan Optoelectronics jointly created SANAN, STMicroelectronics Co., Ltd. ("SST JV"), for high-volume 200mm SiC device manufacturing in China. SST JV has been identified as a VIE for which the Company is the primary beneficiary. As such, SST JV was fully consolidated as of December 31, 2023, as further described in Note 12. The newly incorporated entity is part of a capital funding scheme with regional government agencies. As of December 31, 2023, long-term liabilities related to public funding included $152 million advances from capital grants received as part of this funding program. Liabilities related to other public funding programs totaled $292 million as of December 31, 2023, of which $96 million reported on the line “Other payables and accrued liabilities” and $196 million reported on the line “Other long-term liabilities” of the consolidated balance sheet. Current liabilities related to public funding include $44 million grants subject to a financial return, which depended on future cumulative sales of a certain product group over a five-year period. As of December 31, 2022, liabilities related to public funding amounted to $88 million, of which, $37 million advances from grants reported in “Other payables and accrued liabilities” and $51 million reported on the line “Other long-term liabilities”. Additionally, $711 million and $95 million capital investment grants were reported as a reduction of Property, plant and equipment, net as of December 31, 2023 and December 31, 2022 respectively. Tax incentives reducing the carrying amount of Property, plant and equipment are further described in Note 10 and in Note 23. For the year ended December 31, 2023, the Company recorded $201 million of public funding related to R&D and innovation activities, reported on the line “ Other income and expenses, net The Company also benefits from research tax credits and other tax incentives to foster research and innovation activities, together with capital investments in certain tax jurisdictions, primarily in France and Italy. These research tax credits and tax incentive schemes are further described in Note 23. In addition, the impact on depreciation expense of tax incentives received in certain tax jurisdictions and reducing the carrying amount of “Property, plant and equipment, net”, are described in Note 10 and in Note 23.

Goodwill

Goodwill	12 Months Ended
Goodwill	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	GOODWILL Goodwill allocated to reportable segments as of December 31, 2023 and 2022 and changes in the carrying amount of goodwill during the years ended December 31, 2023 and 2022 are as follows: ADG AMS MDG Total December 31, 2021 83 2 228 313 Foreign currency translation (9) — (7) (16) December 31, 2022 74 2 221 297 Foreign currency translation 2 — 4 6 December 31, 2023 76 2 225 303

Other Intangible Assets, Net

Other Intangible Assets, Net	12 Months Ended
Other Intangible Assets, Net	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangible Assets, Net	OTHER INTANGIBLE ASSETS, NET Other intangible assets, net are detailed below: December 31, 2023 Gross Accumulated Net Technologies & licenses 764 (547) 217 Purchased & internally developed software 509 (415) 94 Technologies in progress 56 — 56 Total 1,329 (962) 367 December 31, 2022 Gross Accumulated Net Technologies & licenses 776 (507) 269 Purchased & internally developed software 602 (507) 95 Technologies in progress 41 — 41 Total 1,419 (1,014) 405 Fully amortized intangible assets that are no longer in use have been removed from the above tabular presentation. Comparative periods have been adjusted accordingly. The line “Technologies in progress” in the table above also includes internally developed software under construction and software not ready for their intended use. Amortization expense related to intangible assets subject to amortization was $97 million, $103 million and $93 million for the years ended December 31, 2023, 2022 and 2021, respectively. Estimated future amortization expense related to intangible assets as of December 31, 2023 is as follows: Year 2024 111 2025 84 2026 56 2027 30 2028 19 Thereafter 67 Total 367 In 2023, the Company recorded a total $42 million impairment loss, of which $25 million reported in the line “Research and development expenses” and $17 million in the line "Cost of sales" of the consolidated statement of income. The impairment loss was related primarily to technologies acquired as part of certain business combinations.

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
Property, Plant and Equipment, Net	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	PROPERTY, PLANT AND EQUIPMENT, NET Property, plant and equipment, net are detailed below: December 31, 2023 Gross Accumulated Net Land 118 — 118 Buildings 1,306 (606) 700 Facilities & leasehold improvements 4,346 (3,117) 1,229 Machinery and equipment 21,486 (15,139) 6,347 Computer and R&D equipment 421 (330) 91 Operating lease right-of-use assets 431 (153) 278 Finance lease right-of-use assets 68 (7) 61 Other tangible assets 115 (97) 18 Construction in progress 1,712 — 1,712 Total 30,003 (19,449) 10,554 December 31, 2022 Gross Accumulated Net Land 83 — 83 Buildings 1,116 (563) 553 Facilities & leasehold improvements 3,877 (2,895) 982 Machinery and equipment 18,751 (14,023) 4,728 Computer and R&D equipment 398 (319) 79 Operating lease right-of-use assets 311 (118) 193 Finance lease right-of-use assets 57 (2) 55 Other tangible assets 112 (95) 17 Construction in progress 1,511 — 1,511 Total 26,216 (18,015) 8,201 The line “Construction in progress” in the table above includes property, plant and equipment under construction, and equipment under qualification that are not ready for their intended use. In 2023, the Company transferred from construction in progress to definitive long-lived assets, approximately $131 million corresponding to assets dedicated to its new silicon carbide substrates plant in Catania, Italy, where operations started in December 2023. The depreciation charge was $1,464 million, $1,113 million and $952 million in 2023, 2022 and 2021, respectively. Tax incentives and capital investment funding reported as a reduction of tangible assets totaled $713 million, $25 million and $13 million, in 2023, 2022 and 2021, respectively. Tax incentives and public funding reduced depreciation charges by $69 million, $56 million and $61 million in 2023, 2022 and 2021, respectively. The Company reported $620 million of capital grants as a reduction of “Property, plant and equipment, net” on the consolidated balance sheet as of December 31, 2023, in relation to two new funding schemes associated with the capacity expansion in one of its manufacturing facilities in France and its new silicon carbide manufacturing activities in Italy, of which $239 million was received in cash in 2023 and reported as cash inflows from investing activities in the consolidated statement of cash flows for the year ended December 31, 2023. A $12 million grant income was recognized as compensation of depreciation expense in 2023 as part of these capital funding schemes. Capital investment public funding is described in Note 7. Tax incentives related to capital expenditures is further described in Note 23. In 2023, the Company and Sanan Optoelectronics jointly created SANAN, STMicroelectronics Co., Ltd. for high-volume 200mm SiC device manufacturing in China. SST JV has been identified as a VIE for which the Company is the primary beneficiary. As such, SST JV was fully consolidated as of December 31, 2023, as further described in Note 12. As of December 31, 2023, a total amount of $38 million was reported as "Property, plant and equipment, net" on the consolidated balance sheet as of December 31, 2023. For the years ended December 31, 2023, 2022 and 2021, the Company sold property, plant and equipment for cash proceeds of $8 million, $4 million and $2 million, respectively.

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2023
Lessee Disclosure [Abstract]
Leases	LEASES The Company leases land, buildings, cars and certain equipment (including IT equipment) which have remaining lease terms between less than one year and 50 years. Operating and finance leases consisted of the following: December 31, December 31, Right-of-use assets Operating leases 278 193 Finance leases 61 55 Total right-of-use assets 339 248 Lease liabilities Current 68 59 Operating leases 58 52 Finance leases 10 7 Non-current 243 191 Operating leases 188 141 Finance leases 55 50 Total lease liabilities 311 250 Maturities of lease liabilities are as follows: Operating Leases Finance Leases December 31, 2024 66 10 76 2025 49 6 55 2026 35 6 41 2027 25 29 54 2028 22 2 24 Thereafter 106 31 137 Total future undiscounted cash outflows 303 84 387 Effect of discounting (57) (19) (76) Total lease liabilities 246 65 311 Operating and finance lease terms and discount rates are as follows: December 31, December 31, Weighted average remaining lease term (in years) – operating leases 8.94 9.46 Weighted average remaining lease term (in years) – finance leases 10.24 9.89 Weighted average discount rate – operating lease 3.61 % 3.12 % Weighted average discount rate – finance lease 3.82 % 3.86 % Operating and finance lease cost and cash paid are as follows: 2023 2022 Operating lease cost 71 62 Finance lease cost Amortization of right-of-use assets 5 2 Interest 3 1 Operating lease cash paid 74 63 Finance lease cash paid 4 — Non-cash transaction right-of-use assets obtained in exchange for new lease liabilities are as follows: 2023 2022 Operating leases 114 60 Finance leases 8 55

Long-Term Investments and Varia

Long-Term Investments and Variable Interest Entities	12 Months Ended
Long-Term Investments and Variable Interest Entities	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Long-Term Investments and Variable Interest Entities	LONG-TERM INVESTMENTS AND VARIABLE INTEREST ENTITIES December 31, December 31, Long-term investments 22 11 Total 22 11 Long-term investments are equity securities with no readily determinable fair value for which the Company has elected to apply the cost method as a measurement alternative. Long-term investments include a $9 million interest in DNP Photomask Europe S.p.A (“DNP”). In 2023, the Company paid $10 million to acquire a minor equity stake in a start up. The investment is related to the development of Silicon Photonics technology for the RF Communications business. In 2023, the Company and Sanan Optoelectronics jointly created SANAN, STMicroelectronics Co., Ltd. for high-volume 200mm SiC device manufacturing activities in China. The purpose of the joint venture is to support the rising demand for the Company's SiC devices for car electrification and industrial power and energy applications in China. With the creation and future operations of SST JV, the Company seeks to create a fully integrated vertical value chain aiming at serving the Chinese electrification market. Sanan Optoelectronics will build a separate 200mm SiC substrate manufacturing facility to fulfill SST JV's needs. SST JV will produce SiC devices exclusively for the Company, using the Company's proprietary SiC manufacturing process technology and know how and serving as a dedicated foundry to support the Company's demand for Chinese customers. The Company has identified SST JV as a VIE, primarily based on the disproportionality between its 49% equity interest rights and its economic interest and operating role in the joint venture. Indeed the significant activities of SST JV involve or are conducted on behalf of the Company as the sole customer of the joint venture. Moreover, through its key role in the successful process qualification and future manufacturing efficiency based on its SiC manufacturing process technology, the Company has the power to control the activities that most significantly impact SST JV's future economic performance. Additionally, based on the nature of the risks impacting SST JV's future economic performance, the Company will absorb the potential losses of SST JV or the right to receive benefits downstream the whole integrated SiC device value chain. Consequently, the Company has a controlling financing interest in SST JV and is the primary beneficiary of the VIE. As the primary beneficiary of SST JV, the Company fully consolidates the VIE, with the recognition of 51% non-controlling interest. Non-controlling interest amounted to $52 million as of December 31, 2023, which corresponds to the capital contribution received from Sanan Optoelectronics upon creation and first consolidation of SST JV. No gain or loss was recognized on the initial consolidation of the VIE as no fair value measurement was required, the joint venture being a newly incorporated entity. Profit and loss reported by the VIE for the year ended December 31, 2023 was not material. The carrying amount of SST JV's assets and liabilities, together with their classification in the consolidated balance sheet as of December 31, 2023, are separately disclosed in Note 7, Note 10 and Note 17.

Other Non-Current Assets

Other Non-Current Assets	12 Months Ended
Other Non-Current Assets	Dec. 31, 2023
Investments, All Other Investments [Abstract]
Other Non-Current Assets	OTHER NON-CURRENT ASSETS Other non-current assets are detailed below: December 31, December 31, 2023 2022 Equity securities 31 26 Public funding receivables 210 156 Taxes and other government receivables 22 — French research tax credit receivable 246 294 Defined benefit plans 15 9 Prepayments and deposits to third parties 224 107 Derivative instruments 2 13 Other non-current assets 58 56 Total 808 661 Public funding receivables, including French research tax credit receivable, are described in Note 7. Prepayments and deposits to third parties include receivables related to long-term supply agreements involving purchase of raw materials, capacity commitments, cloud-hosting arrangements, and other services. In 2023 and 2022, the Company entered into factoring transactions to accelerate the realization in cash of certain long-term receivables. The Company sold without recourse $118 million and $110 million of these receivables in the years ended December 31, 2023 and 2022 respectively, with a financial cost of $5 million and $1 million respectively. The major portion of other non-current assets to which the expected credit loss model applies are long-term State receivables. Due to the existing history of zero-default on receivables originated by governments, the expected credit losses are assumed to be negligible as of December 31, 2023 and December 31, 2022. Other non-current assets presented in the table above on the line “Other non-current assets” are composed of individually not significant amounts not deemed to have exposure of default. Consequently, no significant expected credit loss allowance was reported on other non-current assets at reporting date.

Other Payables and Accrued Liab

Other Payables and Accrued Liabilities	12 Months Ended
Other Payables and Accrued Liabilities	Dec. 31, 2023
Payables and Accruals [Abstract]
Other Payables and Accrued Liabilities	OTHER PAYABLES AND ACCRUED LIABILITIES Other payables and accrued liabilities are detailed below: December 31, December 31, Employee related liabilities 679 599 Employee compensated absences 228 196 Taxes other than income taxes 81 68 Advances from customers 186 225 Liabilities related to public funding 96 37 Derivative instruments 4 35 Defined benefit and contribution plans 49 39 Royalties 30 32 Current operating lease liabilities 58 52 Others 114 102 Total 1,525 1,385 Advances from customers are primarily related to multi-annual capacity reservation and volume commitment agreements signed in 2023 and 2022 with certain customers. Some of these arrangements include take-or-pay clauses, according to which the Company is entitled to receive the full amount of the contractual committed fees in case of non-compliant orders from those customers. Certain agreements include penalties in case the Company is not able to fulfill its contractual obligations. No significant provision for those penalties was reported on the consolidated balance sheets as of December 31, 2023 and December 31, 2022. Liabilities related to public funding are described in Note 7. Derivative instruments are further described in Note 26. Defined benefit and defined contribution plans and other long-term employee benefits are further described in Note 16. Lease liabilities are described in Note 11.

Long-Term Debt

Long-Term Debt	12 Months Ended
Long-Term Debt	Dec. 31, 2023
Debt Disclosure [Abstract]
Long-term debt	LONG-TERM DEBT Long-term debt consisted of the following: December 31, December 31, 2023 2022 Funding program loans from European Investment Bank ("EIB"): 4.72% due 2028, floating interest rate at Euribor +0.589% 141 163 4.52% due 2029, floating interest rate at Euribor +0.564% 162 183 4.47% due 2031, floating interest rate at Euribor +0.473% 296 322 4.54% due 2031, floating interest rate at Euribor +0.550% 146 159 4.52% due 2033, floating interest rate at Euribor +0.558% 332 — Credit Facility from Cassa Depositi e Prestiti SpA ("CDP") 4.64% due 2027, floating interest rate at Euribor +0.690% 97 120 4.49% due 2028, floating interest rate at Euribor +0.550% 92 107 4.79% due 2029, floating interest rate at Euribor +0.850% 95 107 Dual tranche senior unsecured convertible bonds zero-coupon, due 2025 (Tranche A) 748 748 zero-coupon, due 2027 (Tranche B) 748 747 Finance leases: 3.86% due 2027, fixed interest rate 38 38 3.78% due 2042, fixed interest rate 25 19 1.75% due 2042, fixed interest rate 2 — Other funding program loans: 0.29% (weighted average), due 2024-2028, fixed interest rate 5 4 Total long-term debt 2,927 2,717 Less current portion (217) (175) Total long-term debt, less current portion 2,710 2,542 Long-term debt is denominated in the following currencies: December 31, December 31, U.S. dollar 1,496 1,495 Euro 1,431 1,222 Total 2,927 2,717 On August 4, 2020, the Company issued a $1.5 billion principal amount of dual tranche senior unsecured convertible bonds (Tranche A and Tranche B for $750 million each tranche), due 2025 and 2027, respectively. Tranche A bonds were issued at 105.8% as zero-coupon bonds while Tranche B bonds were issued at 104.5% as zero-coupon bonds. The conversion price at issuance was $43.62 for Tranche A equivalent to a 47.5% conversion premium and $45.10 for Tranche B, equivalent to a 52.5% conversion premium. These conversion features correspond to an equivalent of 4,585 shares per each Tranche A bond $200,000 par value and an equivalent of 4,435 shares per each Tranche B bond $200,000 par value. The bonds are convertible by the bondholders or are callable by the issuer upon certain conditions, on a net-share settlement basis, except if the issuer elects a full-cash or full-share conversion as an alternative settlement. The net proceeds from the bond offering were $1,567 million, after deducting issuance costs paid by the Company. As per contractual terms, the bondholders have full conversion rights on Tranche A bonds, starting August 2023. In terms of Tranche B, up until August 2024, the bonds can be converted by the bondholders with a contingent feature of 130% of the conversion price, measured at quarter-end for the following quarter. After that date, the bondholders will have full conversion rights. As per contractual terms, starting August 2023, Tranche A bonds are callable by the Company with a 130% contingent feature, with the exercise of its call rights being preceded by the release, by the Company, of an Optional Redemption Notice. The same feature applies for Tranche B bonds but only after August 2024. As of December 31, 2023, the Company stock price exceeded the conversion price of the senior unsecured convertible bonds. However, the 130% stock price contingent feature was not met. Consequently, Tranche A bonds are not callable by the Company and bondholders cannot exercise their conversion rights on Tranche B bonds. The convertible debt was reported as Long-term debt in the consolidated balance sheets as of December 31, 2023 and December 31, 2022, based on its original maturity, after having considered several factors, such as the uncertainty around the timing of the potential exercise of the conversion rights by bondholders and the call rights by the Company. Aggregate future maturities of total long-term debt (including current portion) at principal amount are as follows: December 31, 2023 2024 217 2025 962 2026 212 2027 947 2028 198 Thereafter 395 Total 2,931 The difference between the total aggregated future maturities in the preceding table and the total carrying amount of long-term debt is due to unamortized issuance costs on the dual tranche senior unsecured convertible bonds. Credit facilities The Company’s long-term debt contained standard conditions but does not impose minimum financial ratios. The Company had unutilized committed medium-term credit facilities with core relationship banks totalling $1,030 million as of December 31, 2023. The EIB Loans are comprised of three long-term amortizing credit facilities as part of R&D funding programs. The first one, signed in August 2017, is a €500 million loan in relation to R&D and capital expenditures in the European Union for the years 2017 and 2018. The entire amount was fully drawn in Euros corresponding to $303 million outstanding as of December 31, 2023. The second one, signed in 2020, is a €500 million credit facility agreement with EIB to support R&D and capital expenditure programs in Italy and France. The amount was fully drawn in Euros representing $442 million outstanding as of December 31, 2023. In 2022, the Company signed a third long-term amortizing credit facility with EIB of €600 million, out of which, €300 million was withdrawn representing $332 million outstanding as of December 31, 2023. In January 2024, an amount of $300 million was withdrawn under this credit facility. The CDP loans are comprised of two long-term credit facilities. The first, signed in 2021, is a €150 million loan, fully drawn in Euros, of which $97 million were outstanding as of December 31, 2023. The second one, signed in 2022, is a €200 million loan, fully drawn in Euros, of which $187 million was outstanding as of December 31, 2023.

Post-Employment and Other Long-

Post-Employment and Other Long-Term Employees Benefits	12 Months Ended
Post-Employment and Other Long-Term Employees Benefits	Dec. 31, 2023
Retirement Benefits [Abstract]
Post-Employment and Other Long-Term Employees Benefits	POST-EMPLOYMENT AND OTHER LONG-TERM EMPLOYEES BENEFITS The Company and its subsidiaries have a number of defined benefit pension plans, mainly unfunded, and other long-term employees’ benefits covering employees in various countries. The defined benefit plans provide pension benefits based on years of service and employee compensation levels. The other long-term employees’ plans provide benefits due during the employees’ period of service after certain seniority levels. The Company uses December 31 as measurement date for its plans. Eligibility is generally determined in accordance with local statutory requirements. For Italian termination indemnity plan (“TFR”), generated before July 1, 2007, the Company measures the vested benefits to which Italian employees are entitled as if the amounts were immediately due as of December 31, 2023, in compliance with U.S. GAAP guidance on determining vested benefit obligations for defined benefit pension plans. The changes in benefit obligation and plan assets were as follows: Pension Benefits Other Long-Term Benefits December 31, December 31, December 31, December 31, Change in benefit obligation: Benefit obligation at beginning of year 886 1,165 86 94 Service cost 28 33 17 17 Interest cost 35 27 3 1 Employee contributions 5 4 — — Plan amendments (1) — — — Benefits paid (18) (22) (9) (6) Effect of settlement (1) (14) — — Actuarial (gain) loss 39 (260) (2) (15) Foreign currency translation 35 (47) 4 (5) Benefit obligation at end of year 1,008 886 99 86 Change in plan assets: Plan assets at fair value at beginning of year 567 743 — — Actual return on plan assets 38 (157) — — Employer contributions 26 25 — — Employee contributions 5 4 — — Benefits paid (4) (9) — — Effect of settlement (1) (14) — — Business combination — — — — Foreign currency translation 23 (25) — — Plan assets at fair value at end of year 654 567 — — Funded status (354) (319) (99) (86) Amounts recorded in the consolidated balance sheets Other investments and other non-current assets 15 9 — — Other payables and accrued liabilities (15) (11) (7) (5) Other non-current liabilities — — (92) (81) Post-employment benefit obligations (354) (317) — — Net amount recorded (354) (319) (99) (86) The actuarial losses incurred in 2023 were primarily due to a decrease in discount rates applied against future expected benefit payments and resulted in an increase of the benefit obligation mainly for the plans located in the United States, France and Switzerland. The actuarial gains incurred in 2022 were primarily due to an increase in discount rates applied against future expected benefit payments and resulted in a decrease of the benefit obligation mainly for the plans located in France, in the United States and Switzerland. Actual return on plan assets reflect changes in market conditions during each reporting year. The components of accumulated other comprehensive loss (income) before tax effects were as follows: Actuarial Prior service Total Accumulated other comprehensive loss as of 142 2 144 Net amount generated/arising in current year (80) — (80) Amortization (3) (1) (4) Foreign currency translation adjustment (10) — (10) Accumulated other comprehensive loss as of 49 1 50 Net amount generated/arising in current year 25 (1) 24 Amortization (6) (1) (7) Foreign currency translation adjustment 1 — 1 Accumulated other comprehensive loss as of 69 (1) 68 The accumulated benefit obligations were as follows: Pension Benefits Other Long-Term Benefits December 31, December 31, December 31, December 31, Accumulated benefit obligations 808 778 35 25 For pension plans and other long-term benefits with accumulated benefit obligations in excess of plan assets, the accumulated benefit obligation and fair value of plan assets were $411 million and $182 million, respectively, as of December 31, 2023 and $409 million and $139 million, respectively, as of December 31, 2022. For pension plans with projected benefit obligations in excess of plan assets, the benefit obligation and fair value of plan assets were $950 million and $478 million, respectively, as of December 31, 2023 and $839 million and $427 million, respectively, as of December 31, 2022. The components of the net periodic benefit cost included the following: Pension Benefits Other Long-term Benefits Year ended Year ended Year ended Year ended Year ended Year ended Service cost 28 33 36 17 17 13 Interest cost 35 27 21 3 1 1 Expected return on plan assets (24) (23) (24) — — — Amortization of actuarial net loss (gain) 6 6 12 (2) (14) — Amortization of prior service cost 1 1 1 — — — Effect of settlement 1 — — — — — Net periodic benefit cost 47 44 46 18 4 14 Pension benefits components other than service cost, recognized outside of operating income in “Other components of pension benefit costs” in the Company’s consolidated statements of income, were $19 million, $11 million and $10 million in the years ended December 31, 2023, 2022 and 2021, respectively. The weighted average assumptions used to determine the benefit obligation and the periodic benefit costs for pension plans and other long-term benefits were as follows: 2023 2022 2021 Benefit obligation Discount rate 3.73 % 4.18 % 1.84 % Salary increase rate 2.17 % 2.31 % 2.27 % Net periodic benefit cost Discount rate 4.18 % 1.84 % 1.45 % Salary increase rate 2.31 % 2.27 % 2.43 % Expected long-term rates of return on plan assets 2.66 % 3.19 % 3.44 % The discount rate was determined by reference to market yields on high quality long-term corporate bonds applicable to the respective country of each plan, with terms consistent with the terms of the benefit obligations. In developing the expected long-term rate of return on assets, the Company modelled the expected long-term rates of return for broad categories of investments held by the plan against a number of various potential economic scenarios. The Company’s pension plan asset allocation as of December 31, 2023 and December 31, 2022 is as follows: Percentage of Plan Assets Asset Category 2023 2022 Cash and cash equivalents 1 % 1 % Equity securities 13 % 17 % Government debt securities 11 % 10 % Corporate debt securities 19 % 21 % Investments in funds (a) 15 % 16 % Real estate 1 % 1 % Other (mainly insurance assets – contracts and 40 % 34 % Total 100 % 100 % (a) As of December 31, 2023, investments in funds were composed of commingled and multi-strategy funds invested in diversified portfolios of fixed income (68%) - mainly corporate bonds, equities (24%), time deposits and money market (5%) and other instruments (3%). As of December 31, 2022, investments in funds were composed of commingled and multi-strategy funds invested in diversified portfolios of fixed income (79%) - mainly corporate bonds, time deposits and money market (11%) and other instruments (10%). As of December 31, 2023, the Company’s plan asset allocation was in line with the targets set for each plan. The Company’s detailed pension plan asset allocation including the fair-value measurements of those plan assets as of December 31, 2023 is as follows: Total Quoted Significant Significant Cash and cash equivalents 7 7 — — Equity securities 87 1 86 — Government debt securities 69 — 69 — Corporate debt securities 123 — 101 22 Investment funds 100 14 86 — Real estate 9 — 9 — Other (mainly insurance assets – 259 — 48 211 TOTAL 654 22 399 233 The Company’s detailed pension plan asset allocation including the fair-value measurements of those plan assets as of December 31, 2022 is as follows: Total Quoted Significant Significant Cash and cash equivalents 4 4 — — Equity securities 95 1 94 — Government debt securities 59 — 59 — Corporate debt securities 120 — 98 22 Investment funds 87 1 86 — Real estate 6 — 6 — Other (mainly insurance assets – 194 — 38 156 TOTAL 565 6 381 178 The majority of insurance contract plan assets relate to pension plans for the Company's employees in Switzerland. Those plans are provided by collective pension foundations and contributions are invested in fully insured assets that provide a guaranteed contractual return. As such, the fair value of such assets equals to the employees' accrued savings and calculated using total employer and employee contributions plus any accumulated interest credited, which is substantially equivalent to the related cash surrender value. The approach is consistent with prior years. For plan assets measured at fair value using significant unobservable inputs (Level 3), the reconciliation between January 1, 2023 and December 31, 2023 is presented as follows: Fair Value January 1, 2023 178 Contributions (employer and employee) 21 Actual return on plan assets (b) 4 Net benefit payments (a) 14 Settlements (b) (1) Foreign currency translation adjustment (c) 17 December 31, 2023 233 (a) Net cash flows between benefits paid from the insurance contracts and benefits transferred into the insurance contracts by employees. (b) Included in non operating expenses in the consolidated statement of income. (c) Unrealized gains included in the consolidated statement of comprehensive income. For plan assets measured at fair value using significant unobservable inputs (Level 3), the reconciliation between January 1, 2022 and December 31, 2022 is presented as follows: Fair Value January 1, 2022 167 Contributions (employer and employee) 21 Net benefit payments (a) 9 Settlements (14) Foreign currency translation adjustment (5) December 31, 2022 178 (a) Net cash flows between benefits paid from the insurance contracts and benefits transferred into the insurance contracts by employees. The Company’s investment strategy for its pension plans is to optimize the long-term investment return on plan assets in relation to the liability structure to maintain an acceptable level of risk while minimizing the cost of providing pension benefits and maintaining adequate funding levels in accordance with applicable rules in each jurisdiction. The Company’s practice is to periodically conduct a review of its asset allocation strategy, in such a way that the asset allocation is in line with the targeted asset allocation within reasonable boundaries. The Company’s asset portfolios are managed in such a way as to achieve appropriate diversification in line with the asset allocation strategy. The Company does not manage any assets internally. After considering the funded status of the Company’s defined benefit plans, movements in the discount rate, investment performance and related tax consequences, the Company may choose to make contributions to its pension plans in any given year in excess of required amounts. The Company’s contributions to plan assets were $26 million in 2023 and $25 million in 2022 and the Company expects to contribute $27 million to plan assets in 2024. The Company’s estimated future benefit payments as of December 31, 2023 are as follows: Years Pension Other 2024 59 7 2025 63 8 2026 86 8 2027 54 9 2028 60 8 From 2029 to 2033 375 44

Other Long-Term Liabilities

Other Long-Term Liabilities	12 Months Ended
Other Long-Term Liabilities	Dec. 31, 2023
Other Liabilities, Noncurrent [Abstract]
Other Long-Term Liabilities	OTHER LONG-TERM LIABILITIES Other long-term liabilities are detailed below: December 31, December 31, Non-current operating lease liabilities 188 141 Contingent consideration on business combinations 20 31 Other employee benefits 92 81 Liabilities related to public funding 196 51 Advances received on capital grants 152 — Advances from customers 25 73 Derivative instruments — 4 Others 62 73 Total 735 454 Lease liabilities are described in Note 11. Contingent consideration related to business acquisitions are further described in Note 26. Other long-term employee benefits are described in Note 16. Liabilities related to public funding are described in Note 7. Advances received on capital grants relate to the joint venture the Company and Sanan Optoelectronics created in 2023 for high-volume 200mm SiC device manufacturing activities in China, as described in Note 12. The newly incorporated entity is a party to a regional public funding program, primarily consisting in capital grants received on eligible capital expenditures (infrastructures and equipment). As of December 31, 2023, the Company received $152 million of advances on these capital grants while the capital expenditures had not been incurred yet. Consequently, these advances were reported as long-term liabilities in the consolidated balance sheet as of December 31, 2023. Public funding is further described in Note 7. Advances from customers are described in Note 14 and Note 19. Derivative instruments are described in Note 26. Other long-term liabilities also include individually not significant amounts as of December 31, 2023 and December 31, 2022, presented cumulatively in the line “Others”.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
Shareholders' Equity	Dec. 31, 2023
Equity [Abstract]
Shareholders' Equity	SHAREHOLDERS’ EQUITY 18.1 Outstanding shares The authorized share capital of the Company is Euro 1,810 million, consisting of 1,200,000,000 common shares and 540,000,000 preference shares, each with a nominal value of €1.04. As of December 31, 2023, the number of shares of common stock issued was 911,281,920 shares (911,281,920 as of December 31, 2022). As of December 31, 2023, the number of shares of common stock outstanding was 902,771,081, 903,865,763 as of December 31, 2022 and 906,518,057 as of December 31, 2021. 18.2 Preference shares The 540,000,000 preference shares, when issued, will entitle a holder to full voting rights and to a preferential right to dividends and distributions upon liquidation. The Company is a party to an option agreement regarding the preference shares with Stichting Continuïteit ST (the “Stichting”), entered into on January 22, 2007, with a duration of ten years, an agreement which was extended for another ten years in October 2016. The Managing Board and Supervisory Board, along with the board of the Stichting, have declared that they are jointly of the opinion that the Stichting is independent of the Company. The option agreement provides for the issuance of up to a maximum 540,000,000 preference shares. Any such shares would be issued to the Stichting upon its request and in its sole discretion and upon payment of at least 25% of the par value of the preference shares to be issued. The shares would be issuable in the event of actions which the board of the Stichting determines would be contrary to the Company’s interests, shareholders and other stakeholders and which, in the event of a creeping acquisition or offer for the Company’s common shares, are not supported by the Company’s Managing Board and Supervisory Board. The preference shares may remain outstanding for no longer than two years. The effect of the preference shares may be to deter potential acquirers from effecting an unsolicited acquisition resulting in a change of control as well as to create a level-playing field in the event actions which are considered to be hostile by the Company’s Managing Board and Supervisory Board, as described above, occur and which the board of the Stichting determines to be contrary to the Company’s interests, shareholders and other stakeholders. There were no preference shares issued as of December 31, 2023 and December 31, 2022. 18.3 Treasury stock As of December 31, 2023, the Company owned 8,510,839 shares classified as treasury stock in the consolidated statement of equity compared to 7,416,157 shares as of December 31, 2022 and 4,758,863 shares as of December 31, 2021. The treasury shares have been originally designated for allocation under the Company’s share-based remuneration programs. As of December 31, 2023, 81,022,515 of these treasury shares were transferred to employees under the Company’s share-based remuneration programs, of which 6,502,300 during the year ended December 31, 2023, 6,587,002 shares during the year ended December 31, 2022 and 7,448,615 shares during the year ended December 31, 2021. On July 1, 2021, the Company announced the launch of a share buy-back program of up to $1,040 million to be executed within a three-year period. During 2023, the Company purchased approximately 7.6 million shares of its outstanding common stock for $346 million as part of the program. The Company purchased approximately 9.2 million shares of its outstanding common stock for $346 million during 2022. The Company purchased approximately 3.9 million shares of its outstanding common stock for $172 million during 2021. 18.4 Unvested share awards for the Supervisory Board On an annual basis and until the year 2012, the Compensation Committee (on behalf of the Supervisory Board and with its approval) used to grant stock-based awards (options to acquire common shares of the Company) to the members and professionals of the Supervisory Board (“The Supervisory Board Plan”). The awards were granted at the nominal value of the share of €1.04 (exercise price of the option). The options granted under the Supervisory Board Plan vested and became exercisable immediately, while the shares resulting from these awards vested and therefore became available for trade evenly over three years (one third every year), with no market, performance or service conditions. At the Company’s AGM held on June 21, 2013, it was resolved to abolish and terminate the stock-based compensation for the Supervisory Board members and professionals. The table below summarizes grants under the outstanding stock award plans, as authorized by the Compensation Committee: Year of grant Options Options 2011 172,500 (30,000) 2012 180,000 (22,500) Since 2013 No options granted A summary of the options’ activity by plan for the years ended December 31, 2023 and December 31, 2022 is presented below: Year of grant Outstanding Exercised Expired / Cancelled Outstanding Exercised Expired / Cancelled Outstanding 2011 — — — — — — — 2012 20,000 (5,000) (15,000) — — — — 18.5 Unvested share awards for the employees On an annual basis, the Compensation Committee (on behalf of the Supervisory Board and with its approval) grants stock-based awards to the senior executives and selected employees (the “Employee Plan”). The awards are granted for services rendered under the Employee Plan. There are two types of unvested shares: (1) shares granted to employees, which are subject only to service conditions and vest over the requisite service period, and (2) shares granted to senior executives, for which vesting is subject to performance conditions. For plan 2020, the performance conditions consisted of two external targets (sales evolution and operating income compared to a basket of competitors) weighting for two thirds of the total number of awards granted, and of one internal target (return on net assets compared to the previous period), weighting for one third of the total number of awards granted. For plans 2021, 2022 and 2023, the performance conditions consist of two external targets (sales evolution and operating income compared to a basket of competitors) weighting for two thirds of the total number of awards granted, and of one internal target (Company’s sustainability and diversity performance), weighting for one third of the total number of awards granted. Sustainability and diversity performance include environment/climate, diversity and inclusions indicators, ESG investor index and carbon rating. Stock awards are subject to three-year cliff-vesting for the Company's CEO, while they vest over a grading three-year service period for other employees ( 32% as of the first anniversary of the grant, 32% as of the second anniversary of the grant and 36% as of the third anniversary of the grant). Applicable only to the 2023 plan, stock awards allocated to members of the Executive Committee are also subject to three-year cliff vesting. In addition, for the year 2020, a Special Bonus was granted to the Company’s CEO. The table below summarizes grants outstanding during the year 2023, as authorized by the Compensation Committee: Date of grant Plan name Number of Number of Number of June 17, 2020 2020 CEO Special Bonus 16,000 — — July 23, 2020 2020 Employee Plan 7,437,580 — — December 24, 2020 2020 Employee Plan 562,350 — — July 28, 2021 2021 Employee Plan 6,327,205 — (920,263) December 21, 2021 2021 Employee Plan 213,270 — (60,483) July 27, 2022 2022 Employee Plan 6,243,670 — — December 22, 2022 2022 Employee Plan 287,675 — — July 26, 2023 2023 Employee Plan 5,154,115 — () December 11, 2023 2023 Employee Plan 295,020 — () (*) As of the date of issuance of these consolidated financial statements, a final decision by the Compensation Committee of the Supervisory Board on the achievement of the performance conditions had not been made yet. A summary of the unvested share activity by plan for the year ended December 31, 2023 is presented below: Unvested Shares Unvested as at Granted Forfeited / Cancelled on Vested Unvested as at 2020 CEO Special Bonus 5,334 — — — (5,334) — 2020 Employee Plan 2,780,796 — (11,851) — (2,768,945) — 2021 Employee Plan 3,699,514 — (32,571) — (1,716,700) 1,950,243 2022 Employee Plan 6,496,525 — (80,065) — (2,065,721) 4,350,739 2023 Employee Plan — 5,449,135 (28,730) — — 5,420,405 Total 12,982,169 5,449,135 (153,217) — (6,556,700) 11,721,387 The grant date fair value of unvested shares granted to the CEO under the 2020 CEO Special Bonus Plan was $26.64, which was based on the market price of the shares at the date of the grant. The grant date weighted average fair value of unvested shares granted to employees under the 2020 Employee Plan was $30.17. On March 24, 2021, the Compensation Committee approved the statement that with respect to the shares subject to performance conditions, all three performance conditions were fully met. Consequently, the compensation expense recorded on the 2020 Employee Plan reflects the statement that – for the portion of shares subject to performance conditions – 100% of the awards granted has fully vested, as far as the service condition was met. The grant date weighted average fair value of unvested shares granted to employees under the 2021 Employee Plan was $39.20. On March 23, 2022, the Compensation Committee approved the statement that with respect to the shares subject to performance conditions, two performance conditions were fully met. Consequently, the compensation expense recorded on the 2021 Employee Plan reflects the statement that – for the portion of shares subject to performance conditions – two thirds of the awards granted will fully vest, as far as the service condition is met. The grant date weighted average fair value of unvested shares granted to employees under the 2022 Employee Plan was $35.92. On March 22, 2023, the Compensation Committee approved the statement that with respect to the shares subject to performance conditions, all three performance conditions were fully met. Consequently, the compensation expense recorded on the 2022 Employee Plan reflects the statement that – for the portion of shares subject to performance conditions – 100% of the awards granted will fully vest, as far as the service condition is met. The grant date weighted average fair value of unvested shares granted to employees under the 2023 Employee Plan was $50.96. Moreover, for the portion of the shares subject to performance conditions (2,589,952 shares) the Company estimated the number of awards expected to vest by assessing the probability of achieving the performance conditions. As of the date of issuance of these consolidated financial statements, a final determination by the Compensation Committee of the Supervisory Board of the achievement of the performance conditions had not been made yet. The Company estimated that 100% of the awards subject to performance conditions are expected to vest. Consequently, the compensation expense recorded for the 2023 Employee Plan reflects the expected vesting of 100% of the awards granted with performance conditions, subject to the service condition being met. The assumption of the expected number of awards to be vested upon achievement of the performance conditions is subject to changes based on the final measurement of the conditions, which is expected to occur in the first half of 2024. The following table illustrates the classification of pre-payroll tax and social contribution stock-based compensation expense included in the consolidated statements of income for the years ended December 31, 2023, 2022 and 2021: December 31, December 31, December 31, Cost of sales 40 34 34 R&D 71 69 70 SG&A 125 112 117 Total pre-payroll tax and social contribution 236 215 221 The grant date fair value of the shares that vested in 2023 was $226 million compared to $189 million in 2022 and $181 million in 2021. Stock-based compensation, excluding payroll tax and social contribution, capitalized as part of inventory was $13 million as of December 31, 2023, compared to $11 million as of December 31, 2022 and $9 million as of December 31, 2021. As of December 31, 2023, there was $265 million of total unrecognized compensation cost related to the grant of unvested shares, which is expected to be recognized over a weighted average period of approximately 10 months. The total deferred income tax benefit recognized in the consolidated statements of income related to unvested share-based compensation expense amounted to $17 million, $15 million and $14 million for the years ended December 31, 2023, 2022 and 2021, respectively. 18.6 Accumulated other comprehensive income (loss) attributable to parent company stockholders The table below details the changes in AOCI attributable to the company’s stockholders by component, net of tax, for the years ended December 31, 2023, 2022 and 2021: Gains (Losses) Gains (Losses) Defined Benefit Foreign Currency Total December 31, 2020 61 1 (231) 849 680 Cumulative tax impact (8) — 51 — 43 December 31, 2020, net of tax 53 1 (180) 849 723 OCI before reclassifications (90) (1) 56 (189) (224) Amounts reclassified from AOCI (19) — 13 — (6) OCI for the year ended December 31, 2021 (109) (1) 69 (189) (230) Cumulative tax impact 14 — (11) — 3 OCI for the year ended December 31, 2021, (95) (1) 58 (189) (227) December 31, 2021 (48) — (162) 660 450 Cumulative tax impact 6 — 40 — 46 December 31, 2021, net of tax (42) — (122) 660 496 OCI before reclassifications (126) (16) 80 (149) (211) Amounts reclassified from AOCI 197 — 4 — 201 OCI for the year ended December 31, 2022 71 (16) 84 (149) (10) Cumulative tax impact (9) 2 (19) — (26) OCI for the year ended December 31, 2022, 62 (14) 65 (149) (36) December 31, 2022 23 (16) (78) 511 440 Cumulative tax impact (3) 2 21 — 20 December 31, 2022, net of tax 20 (14) (57) 511 460 OCI before reclassifications 38 6 (24) 133 153 Amounts reclassified from AOCI (5) — 7 — 2 OCI for the year ended December 31, 2023 33 6 (17) 133 155 Cumulative tax impact (5) (1) 4 — (2) OCI for the year ended December 31, 2023, 28 5 (13) 133 153 December 31, 2023 56 (10) (95) 644 595 Cumulative tax impact (8) 1 25 — 18 December 31, 2023, net of tax 48 (9) (70) 644 613 Items reclassified out of Accumulated Other Comprehensive Income for the years ended December 31, 2023, 2022, 2021 are listed in the table below: Details about AOCI components Amounts Amounts Amounts Affected line item in the Gains (Losses) on Cash Flow Foreign exchange derivative $ 1 $ (129) $ 15 Cost of sales Foreign exchange derivative $ 1 $ (15) $ 1 Selling, general and administrative expenses Foreign exchange derivative $ 3 $ (53) $ 3 Research and development expenses $ — $ 27 $ (3) Income tax benefit (expense) $ 5 $ (170) $ 16 Net of tax Defined Benefit Pension Plan Amortization of actuarial gains $ (6) $ (3) $ (12) Other components of pension benefit costs Amortization of prior service cost $ (1) $ (1) $ (1) Other components of pension benefit costs $ 1 $ 1 $ 2 Income tax benefit (expense) $ (6) $ (3) $ (11) Net of tax Total reclassifications for the year $ (1) $ (173) $ 5 Attributable to noncontrolling $ — $ — $ — Attributable to the parent company $ (1) $ (173) $ 5 18.7 Dividends The Company is governed under the laws of the Netherlands. The Articles of Association provide that the net result for the year, after deduction of (i) any amount to set up and maintain reserves required by Dutch Law and the Articles of Association, (ii) if any of our preference shares are issued and outstanding, the dividend to be paid to the holders of preference shares and (iii) the aforementioned allocation to the reserve fund, is subject to the disposition by the General Meeting of Shareholders ("AGM"). The AGM held on May 25, 2023, authorized the distribution of a cash dividend of $0.24 per outstanding share of the Company’s common stock, to be distributed in quarterly installments of $0.06 in each of the second, third and fourth quarters of 2023 and first quarter of 2024. An amount of $55 million corresponding to the first installment, $54 million corresponding to the second installment and $54 million corresponding to the third installment were paid as of December 31, 2023. The amount of $54 million corresponding to the last installment was presented in the line “Dividends payable to stockholders” in the consolidated balance sheet as of December 31, 2023. The AGM held on May 25, 2022 authorized the distribution of a cash dividend of $0.24 per outstanding share of the Company’s common stock, to be distributed in quarterly installments of $0.06 in each of the second, third and fourth quarters of 2022 and first quarter of 2023. The amounts of $55 million corresponding to the first installment, $54 million corresponding to the second installment and $48 million corresponding to the third installment were paid in 2022. An amount of $6 million corresponding to the remaining portion of the third installment and $54 million corresponding to the fourth installment were paid in 2023. The AGM held on May 27, 2021 authorized the distribution of a cash dividend of $0.24 per outstanding share of the Company’s common stock, to be distributed in quarterly installments of $0.06 in each of the second, third and fourth quarters of 2021 and first quarter of 2022. An amount of $54 million corresponding to the first installment, $55 million corresponding to the second installment and $54 million corresponding to the third installment were paid in 2021. An amount of $55 million corresponding to the fourth installment was paid in 2022.

Revenues

Revenues	12 Months Ended
Revenues	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenues	REVENUES 19.1 Nature of goods and services The Company designs, develops, manufactures and markets a broad range of products, including discrete and standard commodity components, application-specific integrated circuits (“ASICs”), full-custom devices and semi-custom devices and application specific standard products (“ASSPs”) for analog, digital and mixed-signal applications. In addition, the Company participates in the manufacturing value chain of smartcard products, which includes the production and sale of both silicon chips and smartcards. The principal activities – separated by reportable segments – from which the Company generates its revenues are described in Note 20. Other revenues consist of license revenue, service revenue related to transferring licenses, patent royalty income, sale of scrap materials and manufacturing by-products. While the majority of the Company’s sales agreements contain standard terms and conditions, the Company may, from time to time, enter into agreements that contain multiple performance obligations or terms and conditions. Those agreements concern principally the revenues from services, where the performance obligation is satisfied over time. The objective when allocating the transaction price is to allocate the transaction price to each performance obligation (or distinct good or service) in an amount that depicts the amount of consideration to which the Company expects to be entitled in exchange for transferring the promised goods or services to the customer. 19.2 Revenue recognition and disaggregation The Company recognizes revenue from products sold to a customer, including distributors, when it satisfies a performance obligation at a point in time by transferring control over a product to the customer. This usually occurs at the time of shipment. The performance obligations linked to the sale of goods contracts have the original expected length of less than one year. The transaction price is determined based on the contract terms, adjusted for price protection, if applicable. The revenues from services are usually linked to performance obligations transferred over time and are recognized in line with the contract terms. In 2023 and 2022, the Company signed several multi-annual capacity reservation and volume commitment arrangements with certain customers. These agreements constitute a binding commitment for the customers to purchase and for the Company to supply allocated commitment volumes in exchange for additional consideration. The consideration related to commitment fees is reported as revenues from sale of products as it is usually based on delivered quantities. Advances from customers received as part of those agreements are described in Note 14 and Note 17. The payment terms typically range between 30 to 90 days. The Company’s consolidated net revenues disaggregated by reportable segment are presented in Note 20. The following tables present the Company’s consolidated net revenues disaggregated by geographical region of shipment, nature and market channel: Year ended December 31, December 31, December 31, Net revenues by geographical region of shipment (1) EMEA 4,836 3,619 2,557 Americas 2,724 2,310 1,525 Asia Pacific 9,726 10,199 8,679 Total net revenues 17,286 16,128 12,761 Net revenues by nature Revenues from sale of products 17,094 15,953 12,560 Revenues from sale of services 145 130 169 Other revenues 47 45 32 Total net revenues 17,286 16,128 12,761 Net revenues by market channel (2) Original Equipment Manufacturers (“OEM”) 11,468 10,764 8,486 Distribution 5,818 5,364 4,275 Total net revenues 17,286 16,128 12,761 (1) Net revenues by geographical region of shipment are classified by location of customer invoiced or reclassified by shipment destination in line with customer demand. For example, products ordered by U.S.-based companies to be invoiced to Asia Pacific affiliates are classified as Asia Pacific revenues. Furthermore, the Company, among the different periods, may be affected by shifts in shipments from one location to another, as requested by customers. (2) Original Equipment Manufacturers (“OEM”) are the end-customers to which the Company provides direct marketing application engineering support, while Distribution refers to the distributors and representatives that the Company engages to distribute its products around the world. The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which the Company recognizes revenue at the amount to which the Company has the right to invoice for services performed. In 2023, 2022 and 2021, the Company’s largest customer, Apple, represented 12.3%, 16.8% and 20.5% of consolidated net revenues, respectively, reported in the ADG, AMS and MDG segments.

Segment Information

Segment Information	12 Months Ended
Segment Information	Dec. 31, 2023
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company designs, develops, manufactures and markets a broad range of products, including discrete and standard commodity components, ASICs, full custom devices and semi-custom devices and ASSPs for analog, digital, and mixed-signal applications. In addition, the Company further participates in the manufacturing value chain of smartcard products, which includes the production and sale of both silicon chips and smartcards. As of December 31, 2023, the Company’s reportable segments were as follows: • Automotive and Discrete Group (ADG) , comprised of dedicated automotive integrated circuits (“ICs”), and discrete and power transistor products. • Analog, MEMS and Sensors Group (AMS) , comprised of analog, smart power, MEMS sensors and actuators, and optical sensing solutions. • Microcontrollers and Digital ICs Group (MDG) , comprised of general-purpose microcontrollers and microprocessors, connected security products (e.g. embedded secured elements and NFC readers), memories (e.g. serial and page EEPROM) and RF and Communications products. Net revenues of “Others” include revenues from sales assembly services and other revenues. For the computation of the segments’ internal financial measurements, the Company uses certain internal rules of allocation for the costs not directly chargeable to the segments, including cost of sales, SG&A expenses and a part of R&D expenses. In compliance with the Company’s internal policies, certain costs are not allocated to the segments, but reported in “Others”. Those comprise unused capacity charges, including reduced manufacturing activity due to COVID-19 and incidents leading to power outage, impairment, restructuring charges and other related closure costs, management reorganization expenses, start-up and phase-out costs, and other unallocated income (expenses) such as: strategic or special R&D programs, certain corporate-level operating expenses, patent claims and litigations, and other costs that are not allocated to product groups, as well as operating earnings of other products. In addition, depreciation and amortization expense is part of the manufacturing costs allocated to the segments and is neither identified as part of the inventory variation nor as part of the unused capacity charges; therefore, it cannot be isolated in cost of sales. Finally, public grants are allocated to the Company’s segments proportionally to the incurred expenses on the sponsored projects. Wafer costs are allocated to the segments based on actual cost. From time to time, with respect to specific technologies, wafer costs are allocated to segments based on market price. The following tables present the Company’s consolidated net revenues and consolidated operating income by reportable segment. Net revenues by reportable segment: December 31, December 31, December 31, ADG 7,848 5,969 4,350 AMS 3,991 4,911 4,587 MDG 5,431 5,228 3,802 Total net revenues of product segments 17,270 16,108 12,739 Others 16 20 22 Total consolidated net revenues 17,286 16,128 12,761 Operating income by reportable segment: December 31, December 31, December 31, ADG 2,497 1,469 512 AMS 690 1,237 1,022 MDG 1,838 1,830 908 Total operating income of product segments 5,025 4,536 2,442 Others (1) (414) (97) (23) Total consolidated operating income 4,611 4,439 2,419 (1) Operating income (loss) of “Others” includes items such as unused capacity charges, including unloading charges due to COVID-19 and incidents leading to power outage, impairment, restructuring charges and other related closure costs, management reorganization costs, start-up and phase-out costs, and other unallocated expenses such as: strategic or special R&D programs, certain corporate-level operating expenses, patent claims and litigations, and other costs that are not allocated to product groups, as well as operating earnings of other products. The reconciliation of operating income of reportable segments to the total consolidated operating income is presented in the below table: December 31, December 31, December 31, Total operating income of reportable segments 5,025 4,536 2,442 Impairment, restructuring charges and — — (2) Impairment loss on intangible assets acquired through recent business combinations (36) — — Start-up and phase-out costs (134) (13) — Unused capacity charges (120) (22) (16) Other unallocated manufacturing results (94) (57) 1 Gain on sale of non-current assets 4 2 3 Strategic and other research and development programs and other non-allocated provisions (1) (34) (7) (9) Total operating loss Others (414) (97) (23) Total consolidated operating income 4,611 4,439 2,419 (1) Includes unallocated income and expenses such as certain corporate-level operating expenses and other income (costs) that are not allocated to the product segments. The following is a summary of operations by entities located within the indicated geographic areas for 2023, 2022 and 2021. Net revenues represent sales to third parties from the country in which each subsidiary is domiciled. The Company is incorporated under Dutch law with head offices located in the Netherlands while the Company’s operational office and headquarters are located in Switzerland. Long-lived assets consist of property, plant and equipment, net. A significant portion of property, plant and equipment expenditures is attributable to front-end and back-end facilities, located in the different countries in which the Company operates. As such, the Company mainly allocates capital spending resources according to geographic areas rather than along product segment areas. Net revenues December 31, December 31, December 31, Switzerland 5,755 4,569 3,282 France 158 153 126 Italy 54 47 56 USA 2,279 1,981 1,253 Singapore 8,138 8,604 7,442 Japan 890 758 586 Other countries 12 16 16 Total net revenues 17,286 16,128 12,761 Property, plant and equipment, net December 31, December 31, Netherlands 3,996 2,753 France 1,837 1,774 Italy 2,108 1,683 Other European countries 170 161 USA 59 52 Singapore 1,347 880 Malaysia 478 365 Other countries 559 533 Total property, plant and equipment, net 10,554 8,201

Other Income and Expenses, Net

Other Income and Expenses, Net	12 Months Ended
Other Income and Expenses, Net	Dec. 31, 2023
Other Income and Expenses [Abstract]
Other Income and Expenses, Net	OTHER INCOME AND EXPENSES, NET Other income and expenses, net consisted of the following: Year ended Year ended Year ended Public funding 201 177 162 Start-up and phase-out costs (134) (13) — Exchange gain (loss), net 5 15 7 Patent costs (12) (8) (10) Gain on sale of non-current assets 6 2 5 COVID-19 incremental costs — (10) (19) Other, net (11) (4) (4) Total 55 159 141 The Company receives public funding from governmental bodies in several jurisdictions. Public funding is further described in Note 7. Start-up costs represent costs incurred in the ramp-up phase of the Company’s newly integrated manufacturing facilities, primarily for the new 300mm fab in Agrate, Italy. Phase-out costs are costs incurred during the closing stage of a Company’s manufacturing facility. Exchange gains and losses, net represent the portion of exchange rate changes on transactions denominated in currencies other than a subsidiary’s functional currency and the changes in fair value of derivative instruments which are not designated as hedges, as described in Note 26. Patent costs mainly include legal and attorney fees and payment for claims, patent pre-litigation consultancy and legal fees. They are reported net of settlements, if any, which primarily include reimbursements of prior patent litigation costs. COVID-19 incremental costs were mainly composed of incremental expenses primarily related to sanitary measures undertaken to protect employees. Starting January 1, 2023, the Company no longer reports Covid-19 related expenses as a component of the line “Other income and expenses, net” in the consolidated statement of income.

Interest Income (Expense), Net

Interest Income (Expense), Net	12 Months Ended
Interest Income (Expense), Net	Dec. 31, 2023
Banking and Thrift, Interest [Abstract]
Interest Income (Expense), Net	INTEREST INCOME (EXPENSE), NET Interest income (expense), net consisted of the following: Year ended Year ended Year ended Income 226 71 13 Expense (55) (13) (42) Total 171 58 (29) Interest income is related to cash and cash equivalents, short-term deposits and marketable securities held by the Company. Interest income, net recorded in 2023 was composed of $226 million of interest income, partially offset by interest expense on borrowings and banking fees of $55 million. Interest expense included the financial cost of the convertible bonds issued by the Company in 2020. On January 1, 2022, the Company adopted the new U.S. GAAP reporting guidance on distinguishing liabilities from equity and EPS. The new guidance was adopted by applying the modified retrospective method, under which prior year periods are not restated. Interest expense recorded in 2021 included a charge of $34 million related to the outstanding senior unsecured convertible bonds, mainly resulting from the non-cash accretion expense, as recorded under the previous accounting guidance. With the adoption of the new guidance, the finance cost of the convertible debt instruments outstanding at the date of adoption is limited to the amortization expense of debt issuance costs. The amortization expense of debt issuance costs amounted to $1 million for the year ended December 31, 2023, $1 million for the year ended December 31, 2022 and $3 million for the year ended December 31, 2021. No borrowing cost was capitalized in 2023, 2022 and 2021. Nominal interest income received in cash on U.S. Treasury Bonds classified as available-for-sale marketable securities amounted to $15 million for the year ended December 31, 2023, $1 million for the year ended December 31, 2022 and $1 million for the year ended December 31, 2021.

Income Tax

Income Tax	12 Months Ended
Income Tax	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Tax	INCOME TAX Income (loss) before income tax is comprised of the following: Year ended Year ended Year ended Income (loss) recorded in the Netherlands (32) (22) (20) Income (loss) from foreign operations 4,795 4,508 2,357 Income (loss) before income tax benefit (expense) 4,763 4,486 2,337 STMicroelectronics N.V. and its subsidiaries are individually liable for income taxes in their jurisdictions. Income tax benefit (expense) is comprised of the following: Year ended Year ended Year ended The Netherlands taxes - current — — — Foreign taxes - current (528) (510) (285) Total current taxes (528) (510) (285) The Netherlands taxes - deferred — — — Foreign taxes - deferred (13) (10) (46) Total deferred taxes (13) (10) (46) Income tax expense (541) (520) (331) Effective tax rate 11 % 12 % 14 % The principal items comprising the differences in income taxes computed at the Netherlands statutory rate of 25.8% in 2023, 25.8% in 2022 and 25% in 2021, and the effective income tax rate are the following: Year ended Year ended Year ended Income tax benefit (expense) computed at (1,229) (1,158) (584) Non-deductible and non-taxable permanent 6 22 4 Change in valuation allowances — 140 (2) Effect of changes in tax laws and similar 149 6 6 Current year tax credits 29 30 39 Other tax and credits 34 (51) (22) Benefits from tax holidays 45 60 49 Net impact of changes to uncertain tax positions (8) (12) (8) Earnings of subsidiaries taxed at different rates 433 443 187 Income tax benefit (expense) (541) (520) (331) In 2022, the variation on the valuation allowance was related to the assessment of the recoverability of the deferred tax assets following the improved stability of profits of the Company in various jurisdictions. The variation in the line "Effect of changes in tax laws and similar" in 2023 mainly relates to the recognition of a net deferred tax asset of $52 million related to a tax credit granted for technological activities, as well as the impact of the conclusion in 2023 of tax authority discussions resulting in the recognition of a net deferred tax asset of $81 million for intangibles recognized for tax purposes. These will be amortized over time and result in a future cash tax benefit. The tax holidays represent a tax exemption period aimed to attract foreign technological investment in certain tax jurisdictions. The effect of the tax benefits, from tax holidays for countries which are profitable, on basic earnings per share wa s $0.05, $0.07 and $0.05 for the years ended December 31, 2023, 2022 and 2021, respectively. These agreements are present in various countries and include programs that reduce up to and including 100% of taxes in years affected by the agreements. The Company’s tax holidays expire at various dates through the year ending December 31, 2029. In certain countries, tax holidays can be renewed depending on the Company still meeting certain conditions at the date of expiration of the current tax holidays. Component of the Net Deferred Tax Asset and Liability Deferred tax assets and liabilities consisted of the following: December 31, December 31, Tax loss carryforwards, tax credits and other tax attributes 886 520 Less unrecognized tax benefits (21) (25) Tax loss carryforwards, tax credits and other tax attributes, net of unrecognized tax 865 495 Inventory valuation 48 42 Fixed asset depreciation 61 55 Increased depreciation incentives 48 83 Capitalized development costs 38 79 Receivables for government funding 152 121 Tax credits granted on capital investments 226 218 Pension 67 62 Stock awards 17 17 Operating lease liabilities 69 50 Commercial accruals 38 27 Other temporary differences 33 27 Total deferred tax assets 1,662 1,276 Valuation allowances (782) (416) Deferred tax assets, net 880 860 Accelerated fixed asset depreciation (40) (37) Acquired intangible assets (24) (23) Advances of government funding (185) (177) Operating lease right-of-use assets (62) (50) Other temporary differences (31) (31) Deferred tax liabilities (342) (318) Net deferred income tax asset 538 542 For a particular tax-paying component of the Company and within a particular tax jurisdiction, all deferred tax liabilities and assets are offset and presented as a single amount in the balance sheet. The Company does not offset deferred tax liabilities and assets attributable to different tax-paying components or to different tax jurisdictions. The above table presents the deferred tax assets and liabilities before offset. The variations in the lines "Tax losses carried forward, tax credits and other tax attributes" and "Valuation allowances” mainly include the recognition of deferred tax assets for a tax credit related to technological activities and the impact of the conclusion of discussions with the tax authorities for intangibles recognized for tax purposes, totaling $479 million decreased by $126 million related to the utilization of the tax losses in several jurisdictions following management’s assessment of the likelihood of future realization of the gross DTA recognized in the period. The “Tax credits granted on capital investments” is mainly related to a 2003 agreement granting the Company certain tax credits for capital investments purchased through the year ending December 31, 2006. Any unused tax credits granted under the agreement will be impacted yearly by a legal inflationary index (currentl y 3.64% p er annum). The credits may be utilized depending on the Company meeting certain program criteria and have no expiration date. In addition to this agreement, starting from 2007 the Company continues to receive tax credits on the yearly capital investments, which may be used to offset that year’s tax liabilities and increases by the legal inflationary rate. However, pursuant to the inability to utilize these credits currently and in future years, the Company did not recognize any deferred tax asset on such tax allowance. As a result, there is no financial impact to the net deferred tax assets of the Company. Deferred tax asset expiration As of December 31, 2023, the Company and its subsidiaries have gross deferred tax assets on tax loss carryforwards, tax credits and other tax attributes that expire starting from 2024. December 31, Year 2023 2024 3 2025 2 2026 2 2027 4 2028 3 Thereafter 872 Total 886 The amount reported on the line “Thereafter” includes tax attributes that expire in 2029 for $276 million and tax credit which will expire in 2030 for $203 million. The majority of the remaining amount has no expiration date. Deferred Tax expense recognized through Other Comprehensive Income In 2023, the Company recognized a defe rred tax expense of $4 million as a component of other comprehensive income (loss), compared to a deferred tax expense of $26 million in 2022. They were related primarily to the tax effects of the recognized unfunded status on defined benefits plan. Deferred tax on undistributed Earnings from foreign subsidiaries The cumulative amount of distributable earnings related to the Company’s investments in foreign subsidiaries and corporate joint ventures was $7,575 million and $7,140 million as of December 31, 2023 and December 31, 2022, respectively. Due to the Company’s legal and tax structure, with the parent company established in the Netherlands, there is no significant tax impact from the distribution of earnings for $6,965 million from investments in foreign subsidiaries and corporate joint ventures. This is because there is no tax impact on dividends paid up to a Dutch holding company by qualifying investments. The amount of distributable earnings becoming taxable upon repatriation amount to $607 million. An amount of $387 million is indefinitely reinvested by the foreign subsidiaries. As of December 31, 2023, a deferred tax liability is recognized for $22 million on the amount of earnings expected to be repatriated in a foreseeable future. Unrecognized Tax Benefits A reconciliation of 2023, 2022 and 2021 beginning and ending amounts of unrecognized tax benefits is as follows: December 31, December 31, December 31, Balance at beginning of year 61 118 48 Additions based on tax positions related to the — 4 72 Additions based on acquisitions related to the — — — Additions for tax positions of prior years 11 13 1 Reduction for tax positions of prior years — (69) (1) Settlements (14) (2) — Reductions due to lapse of statute of limitations (4) — — Foreign currency translation 1 (3) (2) Balance at end of year 55 61 118 In addition, as of December 31, 2023, $21 million of unrecognized tax benefits were classified as a reduction of deferred tax assets (as of December 31, 2022, the amount was $25 million). It is reasonably possible that certain of the uncertain tax positions disclosed in the table above could increase or decrease within the next 12 months due to ongoing tax audits. The Company is not able to make an estimate of the range of the reasonably possible change impacting the annual effective tax rate. Additionally, the Company elected to classify accrued interest and penalties related to uncertain tax positions as components of income tax expense in the consolidated statements of income. They were less than $1 million in 2023, less than $1 million in 2022 and $1 million in 2021. Accrued interest and penalties amounted to $6 million as of December 31, 2023 and $6 million as of December 31, 2022. The tax years that remain open for review from the tax authorities in the Company’s major tax jurisdictions are from 1997 to 2023. Pillar II income taxes Pillar II legislation has been enacted in certain jurisdiction the Company operates (Netherlands, the majority of the European Countries and Switzerland). The legislation will be effective for the Company's financial year beginning January 1, 2024. The Company is in the scope and has performed a preliminary assessment of the potential exposure of the Pillar II incomes taxes. The assessment of the potential exposure to Pillar II income taxes is based on the most recent tax filings, 2022 country-by-country reporting and financial statements for the constituent entities in the Company. Based on the assessment, the Pillar II effective tax rates in most of the jurisdictions are above 15%. However, there is a limited number of jurisdictions where the transitional safe harbour relief does not apply and the Pillar II effective tax rate is slightly below 15%. Therefore, the Company expects a limited tax exposure to Pillar II income taxes in those jurisdictions. Pillar II income taxes impact will depend on the level of 2024 operating results within those jurisdictions as well as potential enactment of the Pillar II legislation or change in tax laws in those jurisdictions.

Earnings per Share

Earnings per Share	12 Months Ended
Earnings per Share	Dec. 31, 2023
Earnings Per Share [Abstract]
Earnings per Share	EARNINGS PER SHARE For the years ended December 31, 2023, 2022 and 2021, earnings per share (“EPS”) was calculated as follows: Year ended Year ended Year ended Basic EPS Net income attributable to parent company as reported 4,211 3,960 2,000 Weighted average number of shares outstanding 903,513,952 905,606,885 904,332,429 Basic EPS 4.66 4.37 2.21 Diluted EPS Net income attributable to parent company as reported 4,211 3,960 2,000 add-back interest expense, net of income tax effect 1 2 — Net income attributable to parent company as adjusted 4,212 3,962 2,000 Weighted average shares outstanding 903,513,952 905,606,885 904,332,429 Dilutive effect of stock awards 6,858,815 6,789,662 9,107,124 Dilutive effect of convertible bonds 33,825,000 33,825,000 11,402,645 Number of shares used in calculating diluted EPS 944,197,767 946,221,547 924,842,198 Diluted EPS 4.46 4.19 2.16 On January 1, 2022, the Company adopted the new guidance on distinguishing liabilities from equity and EPS by applying the modified retrospective method, under which prior year periods are not restated. Under the previous guidance, the Company applied the treasury stock method to determine the dilutive effect of convertible bonds as past experience, existing stated policies, and the contractual terms of the bonds provided a reasonable basis to expect that the settlement would include cash, shares, or a mix of both. With the adoption of the new guidance, the treasury stock method is no longer admitted and the application of the if-converted method is mandatory to determine the dilutive effect of convertible bonds. The senior unsecured convertible bonds issued on August 4, 2020 are consequently fully dilutive, with the total underlying shares presented in the line “Dilutive effect of convertible bonds” of the table above for the years ended December 31, 2023 and December 31, 2022.

Contingencies, Claims and Legal

Contingencies, Claims and Legal Proceedings	12 Months Ended
Contingencies, Claims and Legal Proceedings	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Contingencies, Claims and Legal Proceedings	COMMITMENTS, CONTINGENCIES, CLAIMS AND LEGAL PROCEEDINGS The Company's commitments relate to multi-annual agreements with suppliers when there is a fixed, non-cancelable commitment or when minimum payments are due on a committed delivery schedule. These commitments are primarily comprised of purchase commitments for outsourced foundry wafers ($1.1 billion) and firm contractual commitments related to power purchase and minimum energy efficiency, as part of the Company's actions to become carbon neutral by 2027 on scope 1 and 2 and partially scope 3 ($0.8 billion). The Company is subject to possible loss contingencies arising in the ordinary course of business. These include but are not limited to: product liability claims and/or warranty cost on the products of the Company, contractual disputes, indemnification claims, claims for unauthorized use of third-party intellectual property, employee grievances, tax claims beyond assessed uncertain tax positions as well as claims for environmental damages. In determining loss contingencies, the Company considers the likelihood of impairing an asset or the incurrence of a liability at the date of the consolidated financial statements as well as the ability to reasonably estimate the amount of such loss. The Company records a provision for a loss contingency when information available before the consolidated financial statements are issued or are available to be issued indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the consolidated financial statements and when the amount of loss can be reasonably estimated. The Company regularly re-evaluates claims to determine whether provisions need to be readjusted based on the most current information available to the Company. Changes in these evaluations could result in an adverse material impact on the Company’s results of operations, cash flows or its financial position for the period in which they occur. The Company has received and may in the future receive communications alleging possible infringements of third-party patents or other third-party intellectual property rights. Furthermore, the Company from time to time enters into discussions regarding a broad patent cross license arrangement with other industry participants. There is no assurance that such discussions may be brought to a successful conclusion and result in the intended agreement. The Company may become involved in costly litigation brought against the Company regarding patents, mask works, copyrights, trademarks or trade secrets. In the event that the outcome of any litigation would be unfavorable to the Company, the Company may be required to take a license to third-party patents and/or other intellectual property rights at economically unfavorable terms and conditions, and possibly pay damages for prior use and/or face an injunction, all of which individually or in the aggregate could have a material adverse effect on the Company’s results of operations, cash flows, financial position and/or ability to compete. On December 4, 2023, a jury in the United States District Court for the Western District of Texas in Waco, Texas (USA) returned a verdict in a patent infringement lawsuit in favor of the plaintiff, Purdue University. The Court has not issued final judgment. If the Court issues a final judgment in the plaintiff’s favor, the Company will file post-trial motions and, if they are denied, the Company will file an appeal to the United States Court of Appeals for the Federal Circuit in Washington DC. The risk on this case is considered as possible and, based on the jury verdict, the possible loss is estimated at $32 million. The Company has contractual commitments to various customers which could require the Company to incur costs to repair or replace defective products it supplies to such customer. The duration of these contractual commitments varies and, in certain cases, is indefinite. The Company is otherwise also involved in various lawsuits, claims, inquiries, inspections, investigations and/or proceedings incidental to its business and operations. Such matters, even if not meritorious, could result in the expenditure of significant financial or managerial resources. Any of the foregoing could have a material adverse effect on the Company’s results of operations, cash flows or its financial position. The Company regularly evaluates claims and legal proceedings together with their related probable losses to determine whether they need to be adjusted based on the current information available to the Company. There can be no assurance that its recorded reserves will be sufficient to cover the extent of its potential liabilities. Legal costs associated with claims are expensed as incurred. In the event of litigation which is adversely determined with respect to the Company’s interests, or in the event the Company needs to change its evaluation of a potential third-party claim, based on new evidence or communications, a material adverse effect could impact its operations or financial condition at the time it were to materialize. As of December 31, 2023 and 2022, respectively, provisions for estimated probable losses with respect to claims and legal proceedings were not considered material.

Financial Instruments and Risk

Financial Instruments and Risk Management	12 Months Ended
Financial Instruments and Risk Management	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Financial Instruments and Risk Management	FINANCIAL INSTRUMENTS AND RISK MANAGEMENT 26.1 Financial risk factors The Company is exposed to changes in financial market conditions in the normal course of business due to its operations in different foreign currencies and its ongoing investing and financing activities. The Company’s activities expose it to a variety of financial risks: market risk (including foreign exchange risk, fair value interest rate risk, cash flow interest rate risk and price risk), credit risk and liquidity risk. The Company’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Company’s financial performance. The Company uses derivative financial instruments to hedge certain risk exposures. Financial risk management is carried out by a central treasury department (Corporate Treasury). Additionally, a Treasury Committee, chaired by the Chief Financial Officer, steers treasury activities and ensures compliance with corporate policies. Treasury activities are thus regulated by the Company’s policies, which define procedures, objectives and controls. The policies focus on managing financial risk in terms of exposure to market risk, credit risk and liquidity risk. Treasury controls are subject to internal audits. Most treasury activities are centralized, with any local treasury activities subject to oversight from Corporate Treasury. Corporate Treasury identifies, evaluates and hedges financial risks in close cooperation with the Company’s subsidiaries. It provides written principles for overall risk management, as well as written policies covering specific areas, such as foreign exchange risk, interest rate risk, price risk, credit risk, use of derivative financial instruments, and investments of excess liquidity. The majority of cash and cash equivalents is held in U.S. dollars and Euros and is placed with financial institutions rated at least a single “A” long-term rating from two of the major rating agencies, meaning at least A3 from Moody’s and A- from S&P and Fitch, or better. These ratings are closely and continuously monitored in order to manage exposure to the counterparty’s risk. Hedging transactions are performed only to hedge exposures deriving from operating, investing and financing activities conducted in the normal course of business. Market risk Foreign exchange risk The Company conducts its business globally in various major international currencies. As a result, the Company is exposed to adverse movements in foreign currency exchange rates, primarily regarding the Euro. Foreign exchange risk mainly arises from recognized assets and liabilities at the Company’s subsidiaries and future commercial transactions. Management has set up a policy to require the Company’s subsidiaries to hedge their entire foreign exchange risk exposure with the Company through financial instruments transacted or overseen by Corporate Treasury. Subsidiaries use forward contracts and purchased currency options to manage their foreign exchange risk arising from foreign-currency-denominated assets and liabilities. Foreign exchange risk arises when recognized assets and liabilities are denominated in a currency that is not the entity’s functional currency. These instruments do not qualify as hedging instruments for accounting purposes. Forward contracts and currency options, including collars, are also used by the Company to reduce its exposure to U.S. dollar fluctuations in Euro-denominated forecasted transactions that cover a large part of its R&D and corporate costs expenses as well as a portion of its front-end manufacturing costs of semi-finished goods. The Company also hedges through the use of currency forward contracts certain Singapore dollar-denominated manufacturing forecasted transactions. The derivative instruments used to hedge these forecasted transactions meet the criteria for designation as cash flow hedge. The hedged forecasted transactions have a high probability of occurring for hedge accounting purposes. It is the Company’s policy to have the foreign exchange exposures in all the currencies hedged month by month against the monthly standard rate. At each month end, the forecasted flows for the coming month are hedged together with the fixing of the new standard rate. For this reason, the hedging transactions will have an exchange rate very close to the standard rate at which the forecasted flows will be recorded in the following month. As such, the foreign exchange exposure of the Company, which consists of the balance sheet positions and other contractually agreed transactions, is always close to zero and any movement in the foreign exchange rates will therefore not influence the exchange effect on items of the consolidated statement of income. Any discrepancy between the forecasted values and the actual results is constantly monitored and prompt actions are taken, if needed. Derivative Instruments Not Designated as a Hedge The Company enters into foreign currency forward contracts to reduce its exposure to changes in exchange rates and the associated risk arising from the denomination of certain assets and liabilities in foreign currencies at the Company’s subsidiaries. These include receivables from international sales by various subsidiaries, payables for foreign currency-denominated purchases and certain other assets and liabilities arising from intercompany transactions. The notional amount of these financial instruments totaled $974 million, $931 million and $505 million on December 31, 2023, 2022 and 2021, respectively. The principal currencies covered at the end of the year 2023 are the China Yuan Renminbi, the Singapore dollar, the Euro, the Japanese yen, the Swiss franc, the Indian rupee, the Malaysian ringgit, the Moroccan dirham, the Philippines peso, the Swedish krona, the Taiwan dollar, and the South Korean won. The risk of loss associated with forward contracts is equal to the exchange rate differential from the time the contract is entered into until the time it is settled. The risk of loss associated with purchased currency options is equal to the premium paid when the option is not exercised. Foreign currency forward contracts not designated as cash flow hedge outstanding as of December 31, 2023 have remaining terms of 3 days to 166 days, maturing on average after 47 days. Derivative Instruments Designated as a Hedge To further reduce its exposure to U.S. dollar exchange rate fluctuations, the Company hedges through the use of currency forward contracts and currency options, including collars, certain Euro-denominated forecasted intercompany transactions that cover at year-end a large part of its R&D and SG&A expenses, as well as a portion of its front-end manufacturing costs of semi-finished goods within cost of sales. The Company also hedges through the use of currency forward contracts certain manufacturing transactions within cost of sales denominated in Singapore dollars. The principles regulating the hedging strategy for derivatives designated as cash flow hedge are established as follows: (i) for R&D and corporate costs, up to 80% of the total forecasted transactions; (ii) for manufacturing costs, up to 70% of the total forecasted transactions. In order to follow a dynamic hedge strategy, the Company may change the percentage of the designated hedged item within the limit of 100% of the forecasted transaction. The maximum length of time over which the Company could hedge its exposure to the variability of cash flows for forecasted transactions is 24 months. For the year ended December 31, 2023, the Company recorded a decrease in cost of sales of $1 million and a decrease in operating expenses of $4 million, related to the realized gains incurred on such hedged transactions. For the year ended December 31, 2022, the Company recorded an increase in cost of sales of $129 million and an increase in operating expenses of $68 million, related to the realized losses incurred on such hedged transactions. For the year ended December 31, 2021, the Company recorded a decrease in cost of sales of $15 million and a decrease in operating expenses of $4 million, related to the realized gains incurred on such hedged transactions. The notional amount of foreign currency forward contracts and currency options, including collars, designated as cash flow hedge totaled $2,681 million, $3,192 million and $2,165 million on December 31, 2023, 2022 and 2021, respectively. The forecasted transactions hedged as of December 31, 2023 were determined to have a high probability of occurring. As of December 31, 2023, $55 million of deferred gains on derivative instruments included in “Accumulated other comprehensive income (loss)” in the consolidated statements of equity were expected to be reclassified as earnings during the next 12 months based on the monthly forecasted R&D expenses, corporate costs and semi-finished manufacturing costs. Foreign currency forward contracts and collars designated as cash flow hedge outstanding as of December 31, 2023 have remaining terms of 4 days to 13 months, maturing on average after 113 days. As of December 31, 2023, the Company had the following outstanding derivative instruments that were entered into to hedge Euro-denominated and Singapore dollar-denominated forecasted transactions: In millions of Euros Notional amount for hedge on Notional amount for hedge on Forward contracts 445 951 Currency collars 240 640 In millions of Singapore dollars Notional amount for hedge on Notional amount for hedge on Forward contracts — 219 Cash flow and fair value interest rate risk The Company’s interest rate risk arises from long-term borrowings. Borrowings issued at variable rates expose the Company to cash flow interest rate risk. Borrowings issued at fixed rates expose the Company to fair value interest rate risk. The Company analyses its interest rate exposure on a dynamic basis. Various scenarios are simulated taking into consideration refinancing, renewal of existing positions, alternative financing and hedging. The Company invests primarily on a short-term basis and as such the Company’s liquidity is invested in floating interest rate instruments. As a consequence, the Company is exposed to interest rate risk due to potential mismatch between the return on its short-term floating interest rate investments and the portion of its long-term debt issued at fixed rate. Price risk As part of its ongoing investing activities, the Company may invest in publicly traded equity securities and be exposed to equity security price risk. In order to hedge the exposure to this market risk, the Company may enter into certain derivative hedging transactions. Information on fair value of derivative instruments and their location in the consolidated balance sheets as of December 31, 2023 and December 31, 2022 is presented in the table below: As of December 31, As of December 31, Asset Derivatives Balance sheet classification Fair Fair Derivatives designated as a hedge: Foreign exchange forward contracts Other current assets 46 37 Foreign exchange forward contracts Other non-current assets 2 8 Currency collars Other current assets 7 10 Currency collars Other non-current assets — 5 Total derivatives designated as a hedge: 55 60 Derivatives not designated as a hedge: Foreign exchange forward contracts Other current assets 5 9 Total derivatives not designated as a hedge: 5 9 Total Derivatives 60 69 As of December 31, As of December 31, Liability Derivatives Balance sheet classification Fair Fair Derivatives designated as a hedge: Foreign exchange forward contracts Other payables and (2) (23) Foreign exchange forward contracts Other non-current liabilities — (3) Currency collars Other payables and — (9) Currency collars Other long-term liabilities — (1) Total derivatives designated as a hedge: (2) (36) Derivatives not designated as a hedge: Foreign exchange forward contracts Other payables and (2) (3) Total derivatives not designated as a hedge: (2) (3) Total Derivatives (4) (39) The Company entered into currency collars as combinations of two options, which are reported, for accounting purposes, on a net basis. As of December 31, 2023, the fair value of these collars represented assets for a net amount of $7 million (composed of $8 million assets offset with a $1 million liability). In addition, the Company entered into other derivative instruments, primarily forward contracts, which are governed by standard International Swaps and Derivatives Association (“ISDA”) agreements and are compliant with Protocols of the European Market Infrastructure Regulation (“EMIR”), which are not offset in the statement of financial position and representing total assets of $53 million and liabilities of $4 million as of December 31, 2023. The effect of derivative instruments designated as cash flow hedge on the consolidated statements of income for the year ended December 31, 2023 and December 31, 2022 and on the “Accumulated other comprehensive income (loss)” (“AOCI”) as reported in the consolidated statements of equity as of December 31, 2023 and December 31, 2022 is presented in the table below: Gain (loss) deferred in Location of gain (loss) Gain (loss) reclassified from December 31, December 31, reclassified from OCI into December 31, December 31, Foreign exchange forward 35 14 Cost of sales 1 (83) Foreign exchange forward 4 2 Selling, general and administrative expenses 1 (9) Foreign exchange forward 10 4 Research and development expenses 2 (32) Currency collars 5 1 Cost of sales — (46) Currency collars 1 1 Selling, general and administrative expenses — (6) Currency collars 2 1 Research and development expenses 1 (21) Total 57 23 5 (197) No significant ineffective portion of the cash flow hedge relationships was recorded in earnings for the years ended December 31, 2023 and December 31, 2022. No amount was excluded from effectiveness measurement on foreign exchange forward contracts and collars. The effect on the consolidated statements of income for the year ended December 31, 2023 and December 31, 2022 of derivative instruments not designated as a hedge is presented in the table below: Location of gain Gain (loss) recognized in earnings (loss) recognized December 31, December 31, Foreign exchange forward contracts Other income and expenses, net 2 24 Total 2 24 The Company did not enter into any derivative containing significant credit-risk-related contingent features. Credit risk The expected credit loss and impairment methodology applied on each category of financial assets is further described in each respective note. While cash and cash equivalents are also subject to the expected credit loss model, the identified expected credit loss is deemed to be immaterial. The maximum credit risk exposure for all financial assets is their carrying amount. Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. Credit risk typically arises from cash and cash equivalents, contractual cash flows of debt investments carried at amortized cost, the counterparty of derivative financial instruments and deposits with banks and financial institutions, as well as credit exposure to customers, including outstanding receivables. The Company is exposed to credit risk from its operating activities (primarily for trade receivables) and from its financing activities, including deposits with banks and financial institutions, foreign exchange transactions and other financial instruments. Credit risk is managed at the Group level. The Company selects banks and/or financial institutions that operate with the group based on the criteria of long-term rating from at least two major Rating Agencies and keeping a maximum outstanding amount per instrument with each bank not to exceed 20% of the total. For derivative financial instruments, management has established limits so that, at any time, the fair value of contracts outstanding is not concentrated with any individual counterparty. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. If certain customers are independently rated, these ratings are used. Otherwise, if there is no independent rating, risk control assesses the customer’s credit quality, considering its financial position, past experience and other factors. The utilization of credit limits is regularly monitored. Sales to customers are primarily settled in cash, which mitigates credit risk. As of December 31, 2023 and 2022, no customer represented more than 10% of trade accounts receivable, net. Any remaining concentrations of credit risk with respect to trade receivables are limited due to the large number of customers and their dispersion across many geographic areas. The Company’s investments in instruments carried at amortized cost primarily include receivables towards government bodies. As such, they are investments with immaterial expected credit loss. Any remaining receivable is of low credit risk and is individually not significant. The credit ratings of the investments are monitored for credit deterioration. Liquidity risk Prudent liquidity risk management includes maintaining sufficient cash and cash equivalents, short-term deposits and marketable securities, the availability of funding from committed credit facilities and the ability to close out market positions. The Company’s objective is to maintain a significant cash position and a low debt-to-equity ratio, which ensures adequate financial flexibility. Liquidity management policy is to finance the Company’s investments with net cash from operating activities. Management monitors rolling forecasts of the Company’s liquidity reserve based on expected cash flows. 26.2 Capital risk management The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern in order to create sustainable value, benefits and returns for its stakeholders, as to maintain an optimal capital structure. In order to maintain or adjust its capital structure, the Company may review the amount of dividends paid to shareholders, return capital to shareholders, or issue new shares. Consistent with other peers in the industry, the Company monitors capital on the basis of the net debt-to-equity ratio. This ratio is calculated as the net financial position of the Company, defined as the difference between total cash position (cash and cash equivalents, short-term deposits, marketable securities and restricted cash, if any) and total financial debt (short-term and long-term debt), divided by total parent company stockholders’ equity. 26.3 Fair value measurement The fair value of financial instruments traded in active markets is based on quoted market prices at the balance sheet date. The quoted market price used for financial assets held by the Company is the bid price. If the market for a financial asset is not active and if no observable market price is obtainable, the Company measures fair value by using significant assumptions and estimates. When measuring fair value, the Company makes maximum use of market inputs and minimizes the use of unobservable inputs. The table below details financial assets (liabilities) measured at fair value on a recurring basis as of December 31, 2023: Fair Value Measurements using December 31, Quoted Significant Significant Marketable securities – U.S. Treasury debt securities 1,635 1,635 — — Short-term deposits 1,226 1,226 — — Equity securities measured at fair value through earnings 31 31 — — Derivative assets designated as cash flow hedge 55 — 55 — Derivative assets not designated as cash flow hedge 5 — 5 — Derivative liabilities designated as cash flow hedge (2) — (2) — Derivative liabilities not designated as cash flow hedge (2) — (2) — Contingent consideration on business acquisition (20) — — (20) Total 2,928 2,892 56 (20) The table below details financial assets (liabilities) measured at fair value on a recurring basis as of December 31, 2022: Fair Value Measurements using December 31, Quoted Significant Significant Marketable securities – U.S. Treasury debt securities 679 679 — — Short-term deposits 581 581 — — Equity securities measured at fair value through earnings 26 26 — — Derivative assets designated as cash flow hedge 60 — 60 — Derivative assets not designated as cash flow hedge 9 — 9 — Derivative liabilities designated as cash flow hedge (36) — (36) — Derivative liabilities not designated as cash flow hedge (3) — (3) — Contingent consideration on business acquisitions (31) — — (31) Total 1,285 1,286 30 (31) For liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3), the reconciliation between January 1, 2023 and December 31, 2023 is presented as follows: Fair Value January 1, 2023 31 Changes in fair value measurement (12) Currency translation adjustment 1 December 31, 2023 20 Amount of total gains (losses) for the period included in earnings attributable to liabilities 12 Contingent consideration reported as liabilities on the consolidated balance sheet as of December 31, 2023 and December 31, 2022 is based on the probability that the milestones defining the variable components of the consideration will be achieved. In 2023, the probability of achievement of these variable components was reassessed, resulting in a reduction of $12 million of the fair value of the contingent consideration related to a certain business acquisition from 2020. The Company reported this change in fair value in the line “ Research and development expenses For liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3), the reconciliation between January 1, 2022 and December 31, 2022 is presented as follows: Fair Value January 1, 2022 77 Changes in fair value measurement (35) Currency translation adjustment (4) Payments made (7) December 31, 2022 31 Amount of total gains (losses) for the period included in earnings attributable to liabilities 35 No asset (liability) was measured at fair value on a non-recurring basis using significant unobservable inputs (Level 3) as of December 31, 2023 and December 31, 2022. The Company evaluated in 2023, 2022 and 2021 for impairment the aggregate carrying amount of long-term investments for which the Company applies the cost method as a measurement alternative, as described in Note 2.22. No significant impairment charge was recorded on these investments in 2023, 2022 and 2021. The following table includes additional fair value information on financial assets and liabilities as of December 31, 2023 and 2022: 2023 2022 Level Carrying Estimated Carrying Estimated Cash equivalents (1) 1 2,879 2,879 2,996 2,996 Marketable securities 1 1,635 1,635 679 679 Short-term, deposits 1 1,226 1,226 581 581 Long-term debt – Bank loans (including current portion) 2 1,366 1,366 1,165 1,165 – Finance leases (including current portion) 2 65 65 57 57 – Senior unsecured convertible bonds issued on August 4, 2020 (2) 1 1,496 1,814 1,495 1,561 (1) Cash equivalents primarily correspond to deposits at call with banks. (2) The carrying amount as of December 31, 2023, of the senior unsecured convertible bonds as reported above, corresponds to the nominal value of the bonds, net of $4 million unamortized debt issuance costs. The fair value represented the market price of the bonds trading on the Frankfurt Stock Exchange. The methodologies used to estimate fair value are as follows: Components Methodology used to estimate fair value Debt securities classified as available-for-sale Quoted market prices for identical instruments Foreign exchange forward contracts, currency options and collars Quoted market prices for similar instruments Equity securities measured at fair value through earnings Quoted market prices for identical instruments Equity securities carried at cost as a measurement alternative Valuation of the underlying investments on a new round of third-party financing or upon liquidation Long-term debt and current portion of long-term debt Future cash flows on a borrowing-by-borrowing basis and discounting these future cash flows using the Company's incremental borrowing rates for similar types of borrowing arrangements. For convertible bonds, the fair value represents the market price of the bonds trading on the Frankfurt Stock Exchange Cash and cash equivalents, short-term deposits, accounts receivable, short-term borrowings, and accounts payable The carrying amounts reflected in the consolidated financial statements are considered as reasonable estimates of fair value due to the relatively short period of time between the origination of the instruments and their expected realization.

Related Party Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	RELATED PARTY TRANSACTIONS The below table summarizes transactions incurred in 2023, 2022 and 2021 with companies for which certain members of the Company’s management perform similar policymaking functions. These include, but are not limited to: Orange, Idemia France and Politecnico di Milano. The amounts reported on the below table correspond to transactions up to the date members of the Company's management hold these similar functions. December 31, December 31, December 31, 2023 2022 2021 Sales and services 5 13 8 Purchases and other contributions 27 25 19 Accounts receivable — 5 2 Accounts payable 6 2 — The Company did not hold any significant equity-method investments as of December 31, 2023, 2022 and 2021. Consequently, the Company did not report any material transaction with this type of investees in the corresponding years. The Company made a cash contribution of $1 million for the year ended December 31, 2023 to the ST Foundation, a non-profit organization established to deliver and co-ordinate independent programs in line with its mission. A cash contribution of $1.0 million and $0.5 million was made for each of the years ended December 31, 2022 and 2021, respectively. Certain members of the Foundation’s Board are senior members of the Company’s management.

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
Valuation and Qualifying Accounts	Dec. 31, 2023
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	STMICROELECTRONICS N.V. VALUATION AND QUALIFYING ACCOUNTS Valuation and qualifying accounts deducted from the Balance at Translation Charged to Additions/ Balance (Currency—millions of U.S. dollars) 2023 Accounts Receivable $ 21 $ — $ — $ (2) $ 19 Deferred Tax Assets $ 416 $ 5 $ 360 $ 1 $ 782 2022 Accounts Receivable $ 19 $ — $ — $ 2 $ 21 Deferred Tax Assets $ 576 $ (19) $ (140) $ (1) $ 416 2021 Accounts Receivable $ 16 $ — $ — $ 3 $ 19 Deferred Tax Assets $ 638 $ (24) $ (2) $ (36) $ 576

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS In the first quarter of 2024, the Company announced its product group reorganization to further accelerate the Company's time-to-market and speed of product development innovation and efficiency. This new organization implies a change in segment reporting which will be applied in 2024.

Accounting Policies (Policies)

Accounting Policies (Policies)	12 Months Ended
Accounting Policies (Policies)	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of presentation and consolidation	Basis of presentation and consolidation The Company's consolidated financial statements include the assets, liabilities, results of operations and cash flows of its wholly-owned and majority-owned subsidiaries, after elimination of intercompany transactions and balances. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are deconsolidated from the date that control ceases. The Company assesses each investment in equity securities to determine whether the investee is a Variable Interest Entity (“VIE”). The Company consolidates the VIEs for which the Company is determined to be the primary beneficiary. The primary beneficiary of a VIE is the party that: (i) has the power to direct the most significant activities of the VIE and (ii) is obligated to absorb losses or has the rights to receive returns that would be considered significant to the VIE.
Use of estimates	Use of estimates The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions. The primary areas that require significant estimates and judgments by management include, but are not limited to: • sales allowances for discounts, price protection, product returns and other rebates, • inventory obsolescence reserves and normal manufacturing capacity thresholds to determine costs capitalized in inventory, • recognition and measurement of loss contingencies, • valuation at fair value of assets acquired and liabilities assumed on business acquisitions, and measurement of any contingent consideration, • annual and trigger-based impairment review of goodwill and intangible assets, as well as the assessment of events which could trigger impairment testing on tangible assets, • assessment of the Company’s long-lived assets economic useful lives, • assumptions used in measuring expected credit losses and impairment charges on financial assets, • assumptions used in assessing the number of awards expected to vest on stock-based compensation plans, • assumptions used in calculating net defined pension benefit obligations and other long-term employee benefits, • determination of the amount of tax expected to be paid and tax benefit expected to be received, including deferred income tax assets, valuation allowance and provisions for uncertain tax positions and claims.
Foreign currency	Foreign currency The U.S. dollar is the reporting currency of the Company. The U.S. dollar is the currency of the primary economic environment in which the Company operates since the worldwide semiconductor industry uses the U.S. dollar as a currency of reference for actual pricing in the market. Furthermore, the majority of the Company’s transactions are denominated in U.S. dollars, and revenues from external sales in U.S. dollars largely exceed revenues in any other currency. However, certain significant costs are incurred in the countries of the Eurozone and other non-U.S. dollar currency areas. The functional currency of each subsidiary of the Company is either the local currency or the U.S. dollar, depending on the basis of the economic environment in which each subsidiary operates. Foreign currency transactions, including operations in local currency when the U.S. dollar is the functional currency, are measured into the functional currency using the prevailing exchange rate. Foreign exchange gains and losses resulting from the re-measurement at reporting date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized in the line “Other income and expenses, net” of the consolidated statements of income. For consolidation purposes, the results and financial position of the subsidiaries whose functional currency is different from the U.S. dollar are translated into the reporting currency as follows: (a) assets and liabilities for each consolidated balance sheet presented are translated into U.S. dollars using exchange rates at the balance sheet dates; (b) income and expenses for each consolidated statement of income presented are translated into U.S dollars using the monthly exchange rates; (c) the resulting exchange differences are reported as Currency Translation Adjustments (“CTA”), a component of “Other comprehensive income (loss)” in the consolidated statements of comprehensive income.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents include cash on hand, deposits held at call with external financial institutions and other short-term highly liquid investments with effective maturities of three months or less. They are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Short-term deposits representing cash equivalents with maturity beyond three months and below one year are reported as current assets in the line “Short-term deposits” of the consolidated balance sheets.
Trade accounts receivable	Trade accounts receivable Trade accounts receivable are amounts due from customers for goods sold and services rendered to third parties in the ordinary course of business. The Company uses a lifetime expected losses allowance for all trade receivables. The allowance includes reasonable assumptions about future credit trends. The historical loss rates are adjusted to reflect current and forward-looking information on macro-economic factors affecting the ability of the Company’s customers to settle the receivables. Adjustments to the expected credit losses allowance are reported on the line “Selling, general and administrative expenses” in the consolidated statements of income and write-offs, if any, are recorded against the expected credit losses allowance. In the event of transfers of receivables such as factoring, the Company derecognizes the receivables only to the extent that the Company has surrendered control over the receivables in exchange for a consideration other than beneficial interest in the transferred receivables.
Inventories	Inventories Inventories are stated at the lower of cost and net realizable value. Actual cost is based on an adjusted standard cost, which approximates cost on a first-in, first-out basis for all categories of inventory (raw materials, work-in-process, finished products). Actual cost is therefore dependent on the Company’s manufacturing performance and is based on the normal utilization of its production capacity. In case of underutilization of manufacturing facilities, the costs associated with unused capacity are not included in the valuation of inventories but charged directly to cost of sales. Net realizable value is based upon the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.
Income taxes	Income taxes Income tax for the period comprises current and deferred income tax. Income tax expense represents the income tax expected to be paid related to the current year taxable profit in each tax jurisdiction. Deferred income tax is recognized for all temporary differences arising between the tax bases of assets and liabilities and their carrying amount in the consolidated financial statements. Deferred tax assets are also recognized on temporary differences arising from tax losses carried forward and tax credits. Deferred tax liabilities are not recognized on the initial recognition of goodwill as a result of a business combination. Deferred income tax is determined using tax rates and laws that are enacted at the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. The effect on deferred tax assets and liabilities from changes in tax laws and tax rates is recognized on the line “Income tax expense” in the consolidated statements of income in the period in which the law is enacted. Deferred income tax assets are recognized in full but the Company assesses whether future taxable profit will be available against which temporary differences can be utilized. A valuation allowance is provided for deferred tax assets when management considers it is more likely than not that they will not be realized. The Company recognizes a deferred tax liability on undistributed earnings of subsidiaries when there is a presumption that taxable earnings will be remitted to the parent. A deferred tax asset is recognized on compensation for the grant of stock awards to the extent that such charge constitutes a temporary difference in the subsidiaries’ local tax jurisdictions. Changes in the stock price do not result in any adjustments to the deferred tax asset prior to vesting. At each reporting date, the Company assesses all significant income tax positions in all tax jurisdictions to determine any uncertain tax positions. The Company uses a two-step process for the evaluation of uncertain tax positions. The first step consists in assessing whether the tax benefit must be recognized. The second step consists in measuring the amount of tax benefit to be recognized on each uncertain tax position. In step 1 (recognition), the Company assesses whether a tax position, based solely on its technical merits, is more likely than not to be sustained upon examination. Only tax positions with a sustainability threshold higher than 50% are recognized. In Step 2 (measurement), the Company determines the amount of recognizable tax benefit. The measurement methodology is based on a “cumulative probability” approach, resulting in the recognition of the largest amount that is greater than 50% likely of being realized upon settlement with the taxing authority. The Company accrues for interest and penalties on uncertain tax liabilities reported on the consolidated balance sheets. Interests and penalties are classified as components of income tax expense in the consolidated statements of income.
Business combinations and goodwill	Business combinations and goodwill The acquisition method of accounting is applied to all business combinations. The identifiable assets acquired, liabilities assumed, and equity instruments issued are measured at acquisition date fair value. Any contingent consideration is recorded at acquisition date fair value and remeasured at each reporting date. Acquisition-related transaction costs and restructuring costs related to the acquired business are expensed as incurred. Acquired in-process research and development (“IPR&D”) is capitalized and recorded as an intangible asset at acquisition date, subject to impairment testing until the research or development is completed. The excess of the consideration transferred over the acquisition-date fair value of the identifiable assets acquired and liabilities assumed, net of related deferred tax impacts, is recorded as goodwill. In case of a bargain purchase, the Company reassesses whether it has correctly identified all of the assets acquired and all of the liabilities assumed, the noncontrolling interest in the acquiree, if any, the Company’s previously held equity interest in the acquiree, if any, and the consideration transferred. If after this review, a bargain purchase is still indicated, it is recognized in earnings attributable to parent company stockholders. The purchase of additional interests in a partially owned subsidiary is treated as an equity transaction as well as all transactions concerning the sale of subsidiary stock or the issuance of stock by the partially owned subsidiary, assuming there is no change in control of the subsidiary. In the case of a sale of subsidiary shares, whereby the Company no longer maintains control of the subsidiary, the Company recognizes a gain or loss in earnings. Goodwill is carried at cost less accumulated impairment losses, if any. Goodwill is not amortized but is tested for impairment at least annually, and more frequently whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. Goodwill subject to potential impairment is tested at the reporting unit level. The impairment test determines whether the fair value of each reporting unit under which goodwill is allocated is lower than the total carrying amount of relevant net assets allocated to such reporting unit, including its allocated goodwill. The Company records an impairment loss on goodwill when a reporting unit’s carrying value exceeds its fair value. Significant management judgments and estimates are used in forecasting the future discounted cash flows associated with the reporting unit, including: the applicable industry’s sales volume forecast and selling price evolution, the reporting unit’s market penetration and its revenues evolution, the market acceptance of certain new technologies and products, the relevant cost structure, the discount rates applied using a weighted average cost of capital and the perpetuity rates used in calculating cash flow terminal values.
Intangible assets with definite useful lives	Intangible assets with definite useful lives Intangible assets subject to amortization include intangible assets purchased from third parties recorded at cost and intangible assets acquired in business combinations initially recorded at fair value. Amortization begins when the intangible asset is available for its intended use. Amortization reflects the pattern in which the asset’s economic benefits are consumed, which usually consists in applying the straight-line method to allocate the cost of the intangible assets over their estimated useful lives. The carrying value of intangible assets with definite useful lives is evaluated whenever changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its fair value. The Company evaluates the remaining useful life of an intangible asset at each reporting date to determine whether events and circumstances warrant a revision to the remaining period of amortization. Technologies and licenses Separately acquired technologies and licenses are recorded at historical cost. Technologies and licenses acquired in a business combination are initially recognized at acquisition date fair value. Technologies and licenses have a useful life which usually ranges from 3 to 11 years and are carried at cost less accumulated amortization and impairment losses, if any. Computer software Separately acquired computer software is recorded at historical cost. Costs associated with maintaining computer software programs are expensed as incurred and reported as “Cost of sales”, “Selling, general and administrative expenses”, or “Research and development expenses” in the consolidated statements of income according to their intended use. The capitalization of costs for internally generated software developed by the Company for its internal use begins when the preliminary project stage is completed and when the Company, implicitly or explicitly, authorizes and commits to funding a computer software project. It must be probable that the project will be completed and will be used to perform the function intended. Amortization of computer software begins when the software is available for its intended use and is calculated using the straight-line method over the estimated useful life, which does not exceed 4 years.
Property, plant and equipment	Property, plant and equipment Property, plant and equipment are stated at historical cost, net of accumulated depreciation and any impairment losses. Property, plant and equipment acquired in a business combination are initially recognized at acquisition date fair value. Major additions and improvements are capitalized, while minor replacements and repairs are expensed and reported as “Cost of sales”, “Selling, general and administrative expenses”, or “Research and development expenses” in the consolidated statements of income according to their intended use. Land is not depreciated. Depreciation on fixed assets is computed using the straight-line method over their estimated useful lives, as follows: Buildings 33 years Facilities and leasehold improvements 5-10 years Machinery and equipment 2-10 years Computer and R&D equipment 3-6 years Other 2-5 years The Company also evaluates, and adjusts if appropriate, the assets’ useful lives. Property, plant and equipment are periodically reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or a group of assets may not be recoverable. Several impairment indicators exist for making this assessment, such as: restructuring plans, significant changes in the technology, market, economic or legal environment in which the Company operates, available evidence of obsolescence of the asset, or indication that its economic performance is, or will be, worse than expected. In determining the recoverability of assets to be held and used, the Company initially assesses whether the carrying value of the tangible assets or group of assets exceeds the undiscounted cash flows associated with these assets. If exceeded, the Company then evaluates whether an impairment charge is required by determining if the asset’s carrying value also exceeds its fair value. This fair value is normally estimated by the Company based on independent market appraisals or the sum of discounted future cash flows, using market assumptions such as the utilization of the Company’s fabrication facilities and the ability to upgrade such facilities, change in the selling price and the adoption of new technologies. Any impairment loss is reported on the same income statement line as the depreciation expense recorded on the impaired group of assets, except in case of closure of operating sites or major restructuring plans and reorganizations. In such case, any impairment loss is reported on the line “Impairment, restructuring charges and other related closure costs” in the consolidated statements of income. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are included in “Other income and expenses, net” in the consolidated statements of income. The Company did not hold any significant assets held for sale as of December 31, 2023 and December 31, 2022.
Leases	Leases A lease contract is a contract, or part of a contract, that conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If a lease is identified, classification between finance or operating is determined at lease commencement. Most leases entered by the Company are operating leases. Operating lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. The rate implicit in the lease should be used as a discount rate whenever that rate is readily determinable. In most cases, this rate is not readily determinable and therefore, the Company uses its incremental borrowing rate, which is derived from information available at the lease commencement date. The Company considers its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. Operating lease right-of-use assets are based on the corresponding lease liability adjusted for any lease payments made at or before commencement, initial direct costs, and lease incentives. Right-of-use assets are included in the line “Property, plant and equipment, net” of the consolidated balance sheets. Operating lease liabilities due within one year are included in the line “Other payables and accrued liabilities”, while non-current operating lease liabilities are included in the line “Other long-term liabilities” of the Company’s consolidated balance sheets. Operating lease expenses are recognized in the consolidated statements of income, on a straight-line basis since the lease commencement date over the lease period and reported as “Cost of sales”, “Selling, general and administrative expenses”, or “Research and development expenses”, according to the intended use of the leased asset. Finance lease liabilities due within one year are included in the line “Short-term debt”, while non-current finance lease liabilities are included in the line “Long-term debt” of the Company’s consolidated balance sheets. Right-of-use assets for finance leases are depreciated on a straight-line basis since the lease commencement date over the lease period or the estimated useful life of the leased asset in case of transfer of ownership or purchase option that is reasonably certain to be exercised. The depreciation expense is reported as “Cost of sales”, “Selling, general and administrative expenses”, or “Research and development expenses”, according to the intended use of the leased asset. Certain lease contracts contain options to extend the lease. On these contracts, the Company estimates the lease term by including the extended duration when it is reasonably certain for the Company to exercise that option. In addition, for short-term leases, defined as leases with a term of twelve months or less, the Company elected the practical expedient to not recognize an associated lease liability and right-of-use asset. The short-term lease election is made at the commencement date only. Additionally, lease contracts with a sum of lease payments not exceeding $5,000 are excluded from recognition on the consolidated balance sheet. The right-of-use asset is a non-monetary asset while the lease liability is a monetary liability. When accounting for a lease that is denominated in a foreign currency, the lease liability is remeasured using the current exchange rate, while the right-of-use asset is measured using the historical exchange rate as of the commencement date. The Company does not separate lease and non-lease components and instead accounts for each separate lease component and the non-lease components associated with that lease component as a single lease component. Variable lease payments that depend on an index or a rate are included in the lease payments and are measured using the prevailing index or rate at the measurement date. Changes to index and rate-based variable lease payments are recognized in earnings in the period of the change.
Loss contingencies	Loss contingencies In determining loss contingencies, the Company considers the likelihood of the incurrence of a liability as well as the ability to reasonably estimate the amount of such loss or liability. An estimated loss from a loss contingency is accrued when information available indicates that it is probable that a liability has been incurred at the date of the consolidated financial statements and when the amount of the loss can be reasonably estimated.
Long-term debt	Long-term debt (a) Convertible debt On January 1, 2022, the Company adopted the new guidance on distinguishing liabilities from equity by applying the modified retrospective approach, with the impact upon transition recorded in retained earnings for instruments outstanding as of the date of adoption of the new guidance. Prior to the new guidance, components of convertible debt instruments that may be settled in cash upon conversion based on a net-share settlement basis were accounted for separately as long-term debt and equity when the conversion feature of the convertible bonds constituted an embedded equity instrument. When an equity instrument was identified, proceeds from issuance were allocated between debt and equity by measuring first the liability component and then determining the equity component as a residual amount. The liability component was measured as the fair value of a similar non-convertible debt, which resulted in the recognition of a debt discount. In subsequent periods, the Company amortized the debt discount through earnings in the line “Interest income (expense), net” of the consolidated statements of income, using the effective interest method, based on the contractual maturity of the debt. The equity component, reported on the line “Additional paid-in capital” of the consolidated statement of equity, was not remeasured. Deferred taxes were recognized on the difference between the carrying amount of the liability component and its tax basis. In case of conversion from the bondholders, the fair value of the consideration transferred was allocated between the liability component and the equity component. The difference between the carrying amount of the debt at the settlement date and the fair value of the debt component was recorded in earnings as a loss on debt extinguishment and reported in the line “Loss on financial instruments, net” of the consolidated statements of income. The liability component was measured as the fair value of a similar non-convertible debt prior to settlement. The reacquired equity component was recorded in equity and reported on the line “Additional paid-in capital” of the consolidated statement of equity. The new accounting guidance adopted on January 1, 2022 has eliminated the cash conversion model described above. At initial recognition, total cash proceeds received at issuance are reported as financial debt and no equity conversion instrument is recorded separately in equity. On subsequent periods, the carrying value of the convertible debt is incremented up to its nominal value over the amortization pattern of any unamortized debt discount and issuance costs. Debt issuance costs are reported as a deduction of debt. They are subsequently amortized through earnings on the line “Interest income (expense), net” of the consolidated statements of income, using the effective interest rate method. (b) Bank loans Bank loans and non-convertible senior bonds are recognized at the amount of cash proceeds received, net of debt issuance costs incurred. They are subsequently reported at amortized cost; any difference between the proceeds (net of debt issuance costs) and the principal amount is recognized through earnings on the line “Interest income (expense), net” of the consolidated statements of income over the period of the borrowings using the effective interest method.
Employee benefits	Employee benefits (a) Pension obligations The Company sponsors various pension schemes for its employees. These schemes conform to local regulations and practices in the countries in which the Company operates. Such plans include both defined benefit and defined contribution plans. For defined benefit pension plans, the liability recognized in the consolidated balance sheets is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The funded status of the defined benefit plans is calculated as the difference between plan assets and the projected benefit obligations. Estimates are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input from independent actuaries. Actuarial gains and losses arising from changes in actuarial assumptions are recognized in “Accumulated other comprehensive income (loss)” in the consolidated statements of equity and are charged or credited to earnings over the employees’ average remaining service period using the corridor amortization method. Past service costs are recognized in earnings on the line “Other components of pension benefit costs” of the consolidated statements of income if the changes to the pension scheme are not conditional on the employees remaining in service for a specified period. Other past service costs are recognized in “Accumulated other comprehensive income (loss)” in the consolidated statements of equity and are amortized on a straight-line basis over the average remaining service period. The net periodic benefit cost of the year is determined based on the assumptions used at the end of the previous year. The service cost component of net periodic benefit costs is presented in the same income statement line as other employee compensation costs arising from services rendered during the period. The other components of the net periodic benefit cost are presented separately, outside operating income, on the line “Other components of pension benefit costs” of the consolidated statements of income. These elements include: interest cost; expected return on plan assets; amortization of transition (asset) obligation; amortization of prior service cost; amortization of net (gain) loss; (gain) loss recognized due to curtailment or settlement and; cost of special termination benefits. For defined contribution pension plans, the Company pays contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or voluntary basis. The Company has no further payment obligations once the contributions have been paid. The contributions are recognized as employee benefit expense when they are due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available. (b) Termination benefits Termination benefits are payable when an employee is involuntarily terminated, or whenever an employee accepts voluntary termination in exchange for termination benefits. For the accounting treatment and timing of recognition of involuntary termination benefits, the Company distinguishes between one-time termination benefit arrangements and ongoing termination benefit arrangements. A one-time termination benefit arrangement is established by a termination plan and applies to a specified termination event. One-time involuntary termination benefits are recognized as a liability when the termination plan meets certain criteria and has been communicated to employees. If employees are required to render future service in order to receive these one-time termination benefits, the liability is recognized ratably over the future service period. Termination benefits other than one-time termination benefits are termination benefits for which the communication criterion is not met but that are committed to by management, or termination obligations that are not specifically determined in a new and single plan. These termination benefits are all legal, contractual and past practice termination obligations to be paid to employees in case of involuntary termination. These termination benefits are accrued for when commitment creates a present obligation to others for the benefits expected to be paid, when it is probable that employees will be entitled to the benefits and the amount can be reasonably estimated. In case of special termination benefits related to voluntary redundancy programs, the Company recognizes a provision for voluntary termination benefits at the date on which the employee irrevocably accepts the offer and the amount can be reasonably estimated. (c) Profit-sharing and bonus plans The Company recognizes a liability and an expense for bonuses and profit-sharing plans when a contractual obligation exists or when there is a past practice that has created a present obligation. (d) Other long-term employee benefits The Company provides long-term employee benefits such as seniority awards in certain countries. The entitlement to these benefits is usually conditional on the employee completing a minimum service period. The expected costs of these benefits are accrued over the period of employment. Actuarial gains and losses arising from changes in actuarial assumptions are charged or credited to earnings in the period of the revised estimate. These obligations are valued annually with the assistance of independent qualified actuaries. (e) Share-based compensation The Company accounts for stock-based compensation for all stock-based awards granted to senior executives and selected employees, including awards that vest upon the satisfaction of a service condition and awards that vest upon the satisfaction of both a service condition and a performance condition. Both equity awards vest over a three-year service period while performance-based awards also require the Company’s attainment of certain performance conditions. The Company measures the cost of the awards based on the related grant-date fair value, reflecting the market price of the underlying shares at the date of the grant, reduced by the present value of the dividends expected to be paid during the requisite service period. That cost is recognized ratably over the period during which an employee is required to provide service in exchange for the award. The compensation cost is recorded through earnings with the corresponding amount reported in equity, under “Additional paid-in capital” of the consolidated statements of equity. The compensation cost is calculated based on the number of awards expected to vest, net of an estimated number of awards to be forfeited due to the employees failing to satisfy the service condition or one or more performance conditions. By the end of the vesting period, compensation is recognized only for the awards that ultimately vest.
Share capital	Share capital Ordinary shares are classified as “Common stock” within equity on the consolidated balance sheets. Incremental costs directly attributable to the issuance of new shares are shown in equity as a deduction, net of tax, from the proceeds received. Where the Company purchases its own equity share capital (treasury stock), the consideration paid, including any directly attributable incremental costs (net of income taxes), is deducted from parent company stockholders’ equity until the shares are cancelled, reissued, or disposed of.
Comprehensive income (loss)	Comprehensive income (loss) Comprehensive income (loss) is defined as the change in equity of a business during a period except those changes resulting from investment by and distributions to stockholders. In the consolidated financial statements, “Other comprehensive income (loss)” and “Accumulated other comprehensive income” primarily consists of foreign currency translation adjustments, unrealized gains (losses) on debt securities classified as available-for-sale, unrealized gains (losses) on derivatives designated as cash flow hedge and the accounting for defined benefit plans, net of tax.
Revenue recognition	Revenue recognition Arrangements with customers are considered contracts if all the following criteria are met: (a) parties have approved the contract and are committed to perform their respective obligations; (b) each party’s rights regarding the goods or services to be transferred can be identified; (c) payment terms for the goods or services to be transferred can be identified; (d) the contract has commercial substance and (e) collectability of substantially all of the consideration is probable. The Company recognizes revenue from products sold to a customer, including distributors, when it satisfies a performance obligation by transferring control over a product to the customer. The Company may also enter into several multi-annual capacity reservation and volume commitment arrangements with certain customers. These agreements constitute a binding commitment for the customers to purchase and for the Company to supply allocated commitment volumes in exchange for additional consideration. The consideration related to commitment fees is reported as revenues from sale of products as it is usually based on delivered quantities. In certain circumstances, the Company may enter into agreements that concern principally revenues from services, where the performance obligation is satisfied over time. The objective when allocating the transaction price is to allocate the transaction price to each performance obligation (or distinct good or service) in an amount that depicts the amount of consideration to which the Company expects to be entitled in exchange for transferring the promised goods or services to the customer. The payment terms typically range between 30 to 90 days. Certain customers require the Company to hold inventory as consignment in their hubs and only purchase inventory when they require it. Revenue for sales of such inventory is recognized when, at the customer’s option, the products are withdrawn from the consignment and the Company satisfies a performance obligation by transferring control over a product to the customer. Consistent with standard business practice in the semiconductor industry, price protection is granted to distribution customers on their existing inventory of the Company’s products to compensate them for changes in market prices. The Company accrues a provision for price protection based on a rolling historical price trend computed monthly as a percentage of gross distributor sales. This historical price trend represents differences in recent months between the invoiced price and the final price to the distributor, adjusted to accommodate a significant change in the selling price. The short outstanding inventory time, visibility into the inventory product pricing and long distributor pricing history have enabled the Company to reliably estimate price protection provisions at period-end. The Company records the accrued amounts as a deduction of “Net sales” in the consolidated statements of income at the time of the sale. The Company’s customers occasionally return the Company’s products for technical reasons. The Company’s standard terms and conditions of sale provide that if the Company determines that products do not conform, the Company will repair or replace the non-conforming products, or issue a credit note or rebate of the purchase price. Quality returns are identified shortly after sale in customer quality control testing. The Company records the accrued amounts as a deduction of “Net sales” in the consolidated statements of income, using contractual and historical information. The Company records a provision for warranty costs as a charge against “Cost of sales” in the consolidated statements of income, based on historical trends of warranty costs incurred as a percentage of sales, which management has determined to be a reasonable estimate of the probable losses to be incurred for warranty claims in a period. Any potential warranty claims are subject to the Company’s determination that the Company is at fault for damages, and such claims must usually be submitted within a short period of time following the date of sale. This warranty is given in lieu of all other warranties, conditions or terms expressed or implied by statute or common law. The Company’s contractual terms and conditions typically limit its liability to the sales value of the products which gave rise to the claims. The Company’s insurance policy relating to product liability covers third-party physical damages and bodily injury, indirect financial damages as well as immaterial non-consequential damages caused by defective products.
Public funding	Public funding The Company receives funding from several governmental agencies and income is recognized when all contractual conditions for receipt of these funds are fulfilled and eligible expenditures incurred. Such funding is generally provided to encourage research, development and other innovation activities, industrialization deployment and local economic development. The conditions to receive government funding may include eligibility restrictions, approval by the local governmental authorities, annual budget appropriations, compliance with regulations, as well as specifications regarding objectives and results. Certain specific contracts include obligations to maintain a minimum level of employment and investment during a certain period. There could be penalties if these objectives are not fulfilled. Other contracts contain penalties for breach of contract, which may result in repayment obligations. Funding related to these contracts is recorded when the conditions required by the contracts are met. The Company’s funding programs are classified under two general categories: funding for research, development and other innovative activities, and capital investments. Funding for research, development and innovative activities is the most common form of funding that the Company receives. This public funding is recorded as “Other income and expenses, net” in the consolidated statements of income. The funding is recognized ratably as the related costs are incurred once the agreement with the respective governmental agency has been signed and all applicable conditions are met. Other government assistance, such as funding received for industrialization deployment and local economic development in certain regions, are reported as a deduction of cost of sales or other operating expenses according to the nature of the underlying costs eligible to the grants. French research tax credits (“Crédit Impôt Recherche”) and Italian research tax credits (“Credito d’Imposta Ricerca & Sviluppo”) are deemed to be grants in substance. The French research tax credits are to be paid in cash by the taxing authorities within three years in case they are not deducted from income tax payable during this period of time. The Italian tax credits are compensated against payroll-related social charges. French and Italian tax credits are reported as a reduction of “Research and development expenses” in the consolidated statements of income. Capital investment funding is recorded as a reduction of “Property, plant and equipment, net” on the consolidated balance sheets when the Company has incurred the eligible capital expenditures and when all conditions for eligibility have been fulfilled. Advances from capital grants received on capital investments that have not been incurred yet are reported as in the line "Other long-term liabilities" on the consolidated balance sheets. Capital investment funding is recognized in the Company’s consolidated statements of income by offsetting the depreciation charges of the funded assets during their useful lives. The Company also receives funding, which can be recovered through the reduction of various governmental liabilities, including income tax, value-added tax and employee-related social charges. Funding receivables are reported as non-current assets unless cash settlement features of the receivables evidence that collection is expected within one year. Long-term receivables that do not present any tax attribute or legal restriction are reflected in the consolidated balance sheets at their net present value when the discounting effect is deemed to be significant.
Research and development	Research and developmentResearch and development expenses include costs incurred by the Company, the Company’s share of costs incurred by other research and development interest groups, and costs associated with co-development contracts. Research and development expenses do not include marketing design center costs, which are accounted for as “Selling, general and administrative expenses” in the consolidated statements of income and process engineering, pre-production or process transfer costs which are recorded as “Cost of sales” in the consolidated statements of income. Research and development costs are expensed as incurred. The amortization expense recognized on technologies and licenses purchased by the Company from third parties to facilitate the Company’s research and development activities is reported as “Research and development expenses” in the consolidated statements of income.
Advertising costs	Advertising costsAdvertising costs are expensed as incurred and are recorded as “Selling, general and administrative expenses” in the consolidated statements of income. Advertising expenses for 2023, 2022 and 2021 were $23 million, $18 million and $12 million, respectively.
Start-up and phase-out costs	Start-up and phase-out costsStart-up costs represent costs incurred in the ramp-up phase of the Company's newly integrated manufacturing facilities. The costs of phase-outs are associated with the latest stages of facilities closure when the relevant production volumes become immaterial. Start-up costs and phase-out costs are included in the line “Other income and expenses, net” of the consolidated statements of income.
Investments in equity securities	Investments in equity securities Investments in equity securities that have readily determinable fair values and for which the Company does not have the ability to exercise significant influence are classified as equity securities measured at fair value through earnings. Changes in the fair value of these securities are reported in the consolidated statements of income within “Other income and expenses, net” when these instruments are held within the Company’s operating activities. Gains and losses arising from changes in the fair value of securities not related to operating activities are presented in the consolidated statements of income as non-operating elements within “Gain (loss) on financial instruments, net” in the period in which they arise. The fair values of quoted equity securities are based on current market prices. If the market for a financial asset is not active or if no observable market price is obtainable, the Company measures fair value by using assumptions and estimates. In measuring fair value, the Company makes maximum use of market inputs and minimizes the use of unobservable inputs. For investments in equity securities without readily determinable fair values and for which the Company does not have the ability to exercise significant influence, the Company has elected to apply the cost method as a measurement alternative. Under the cost method of accounting, investments are carried at historical cost, less impairment. An impairment loss is recorded when there are identified events or changes in circumstances that may have a significant adverse effect on the value of the investment. Loss is immediately recorded in the consolidated statements of income on the line “Gain (loss) on financial instruments, net” and is based on the Company’s assessment of any significant and sustained reductions in the investment’s value. Gains and losses on investments sold are determined on the specific identification method and are recorded as non-operating element in the line “Gain (loss) on financial instruments, net” of the consolidated statements of income when the transaction is not related to operating activities. The Company did not hold any material equity securities as of December 31, 2023 and December 31, 2022.
Investments in debt securities	Investments in debt securities Debt securities are included in current assets when they represent investments of funds available for current operations. Changes in fair value of debt securities classified as available-for-sale are recognized as a component of “Other comprehensive income (loss)” in the consolidated statements of comprehensive income. The Company assesses at each balance sheet date whether there is objective evidence that a debt security or group of debt securities is impaired. An unrealized impairment loss exists when the fair value of the instrument declines below its amortized cost basis. An impairment loss is recognized in earnings, through a direct reduction of the value of the asset, when the Company intends to sell the debt security or when it is more likely than not that the Company will be required to sell the instrument before recovery of the amortized cost basis. Moreover, an impairment loss is recognized in earnings through a credit loss allowance for any portion of the unrealized impairment loss resulting from a credit loss. Impairment losses recognized in the consolidated statements of income are not reversed through earnings. The fair values of quoted debt securities are based on current market prices. If the market for a financial asset is not active and if no observable market price is obtainable, the Company measures fair value by using assumptions and estimates. In measuring fair value, the Company makes maximum use of market inputs and minimizes the use of unobservable inputs. The Company did not hold any debt securities classified as held-to-maturity or for which the Company would have elected to apply the fair value option.
Derivative financial instruments and hedging activities	Derivative financial instruments and hedging activities Derivative financial instruments are initially recognized on the date a derivative contract is entered into and are subsequently measured at fair value. The method of recognizing the gain or loss resulting from the derivative instrument depends on whether the derivative is designated as a hedging instrument, and if so, the nature of the hedge transaction. The Company has designated certain derivatives as hedges of a particular risk associated with a highly probable forecasted transaction (cash flow hedge). The Company documents, at inception of the transaction, the relationship between hedging instruments and hedged items, as well as its risk management objectives and strategy for undertaking various hedging transactions. The Company also documents its assessment, both at hedge inception and on an ongoing basis, of whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in cash flows of hedged items. Derivative instruments that are not designated as hedges are measured at fair value through earnings. Cash Flow Hedge As part of its ongoing operating, investing and financing activities, the Company enters into certain derivative transactions that may be designated and may qualify as hedging instruments. To reduce its exposure to U.S. dollar exchange rate fluctuations, the Company hedges certain Euro-denominated forecasted transactions that cover at reporting date a large part of its research and development, and selling, general and administrative expenses as well as a portion of its front-end manufacturing costs of semi-finished goods within cost of sales through the use of currency forward contracts and currency options, including collars. The Company also hedges through the use of currency forward contracts certain Singapore dollar-denominated manufacturing forecasted transactions. The derivative instruments are designated and qualify for cash flow hedge at inception of the contract and on an ongoing basis over the duration of the hedge relationship. They are reflected at their fair value as “Other current assets” or “Other payables and accrued liabilities” in the consolidated balance sheets when settlement is expected to occur within twelve months after the reporting date. They are reported as "Other non-current assets" or "Other long-term liabilities" in the consolidated balance sheets when settlement is expected beyond twelve months. The criteria for designating a derivative as a hedge include the instrument’s effectiveness in risk reduction and matching of the derivative instrument to its underlying transactions with the critical terms of the hedging instrument matching the terms of the hedged forecasted transaction. This enables the Company to conclude that changes in cash flows attributable to the risk being hedged are expected to be substantially offset by the hedging instruments. For derivative instruments designated as cash flow hedge, the change in fair value for the effective portion of the hedge is reported as a component of “Other comprehensive income (loss)” in the consolidated statements of comprehensive income and is reclassified into earnings in the same period in which the hedged transaction affects earnings, and within the same consolidated statements of income line as the hedged transaction. For these derivatives, ineffectiveness appears if the cumulative gain or loss on the derivative hedging instrument exceeds the cumulative change in the expected future cash flows on the hedged transaction. Effectiveness on transactions hedged through purchased options is measured on the full fair value of the option, including time value. Derivative financial instruments not designated as a hedge The Company conducts its business on a global basis in various major international currencies. As a result, the Company is exposed to adverse movements in foreign currency exchange rates. The Company enters into foreign currency forward contracts and currency options to reduce its exposure to changes in exchange rates and the associated risk arising from the denomination of certain assets and liabilities in foreign currencies at the Company's subsidiaries.
Recent accounting pronouncements	Recent accounting pronouncements (a) Accounting pronouncements effective in 2023 No new guidance was adopted in 2023 with a significant impact on the Company's financial statements, financial positions and operations. (b) Accounting pronouncements expected to impact the Company’s operations that are not yet effective and have not been early adopted by the Company In November 2023, the FASB issued new guidance related to segment reporting, which requires incremental disclosures about reportable segments, without changing though the definition of a segment or the guidance for determining reportable segments. The new guidance requires disclosures of significant segment expenses that are (i) regularly provided to (or easily computed from information regularly provided to) the chief operating decision maker ("CODM"); (ii) included in the reported measure of segment profit or loss. The new guidance also requires that an entity discloses, on an annual and interim basis, an amount for "other segment items" by reportable segment, and a description of its composition. Moreover, annual disclosures about a reportable segment's profit or loss and assets become mandatory on interim periods. Finally, the title and position of the CODM, together with an explanation of how the CODM uses the reported measures of segment profit or loss in assessing segment performance and deciding how to allocate resources, are also required. The guidance is effective for the Company's 2024 annual reporting and 2025 interim periods. The guidance will be applied retrospectively, with early adoption permitted. The Company will adopt the new guidance when effective and is currently assessing the impact the new guidance will have on its segment reporting.

Accounting Policies (Tables)

Accounting Policies (Tables)	12 Months Ended
Accounting Policies (Tables)	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Property, Plant and Equipment Useful Lives	Depreciation on fixed assets is computed using the straight-line method over their estimated useful lives, as follows: Buildings 33 years Facilities and leasehold improvements 5-10 years Machinery and equipment 2-10 years Computer and R&D equipment 3-6 years Other 2-5 years

Short-Term Deposits and Marke_2

Short-Term Deposits and Marketable Securities (Tables)	12 Months Ended
Short-Term Deposits and Marketable Securities (Tables)	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Changes in Value of Marketable Securities Reported in Current Assets on Consolidated Balance Sheets	Changes in the fair value of marketable securities are detailed in the tables below: December 31, Purchase Accretion Proceeds Change in December 31, U.S. Treasury debt securities 679 1,653 47 (750) 6 1,635 Total 679 1,653 47 (750) 6 1,635 * Other Comprehensive Income December 31, Purchase Accretion Proceeds Change in December 31, U.S. Treasury debt securities — 687 8 — (16) 679 Total — 687 8 — (16) 679 * Other Comprehensive Income
Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value	The below table details debt securities that were in an unrealized loss position as of December 31, 2023: December 31, 2023 Less than 12 months More than 12 months Total Description Fair Value Unrealized Fair Value Unrealized Fair Value Unrealized U.S. Treasury Bonds 429 (12) 157 (1) 586 (13) Total 429 (12) 157 (1) 586 (13)

Trade Accounts Receivable, Net

Trade Accounts Receivable, Net (Tables)	12 Months Ended
Trade Accounts Receivable, Net (Tables)	Dec. 31, 2023
Receivables [Abstract]
Trade Accounts Receivable, Net	Trade accounts receivable, net consist of the following: December 31, December 31, 2023 2022 Trade accounts receivable 1,750 1,991 Current expected credit losses allowance ("CECLA") (19) (21) Total 1,731 1,970
Schedule of Changes in Reported CECLA	On that basis, the changes in reported CECLA for the year ended December 31, 2023 are presented below: CECLA As of December 31, 2022 (21) Current-period adjustment to CECLA 2 CECLA As of December 31, 2023 (19)

Inventories (Tables)

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following: December 31, December 31, 2023 2022 Raw materials 298 349 Work-in-process 1,745 1,490 Finished products 655 744 Total 2,698 2,583

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
Other Current Assets (Tables)	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	Other current assets are detailed below: December 31, December 31, Public funding receivables 651 190 Taxes and other government receivables 241 270 Advances and prepayments 180 125 Loans and deposits 10 10 Interest receivable 27 22 Derivative instruments 58 56 Other current assets 128 61 Total 1,295 734

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
Goodwill (Tables)	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	Goodwill allocated to reportable segments as of December 31, 2023 and 2022 and changes in the carrying amount of goodwill during the years ended December 31, 2023 and 2022 are as follows: ADG AMS MDG Total December 31, 2021 83 2 228 313 Foreign currency translation (9) — (7) (16) December 31, 2022 74 2 221 297 Foreign currency translation 2 — 4 6 December 31, 2023 76 2 225 303

Other Intangible Assets, Net (T

Other Intangible Assets, Net (Tables)	12 Months Ended
Other Intangible Assets, Net (Tables)	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangible Assets, Net	Other intangible assets, net are detailed below: December 31, 2023 Gross Accumulated Net Technologies & licenses 764 (547) 217 Purchased & internally developed software 509 (415) 94 Technologies in progress 56 — 56 Total 1,329 (962) 367 December 31, 2022 Gross Accumulated Net Technologies & licenses 776 (507) 269 Purchased & internally developed software 602 (507) 95 Technologies in progress 41 — 41 Total 1,419 (1,014) 405
Estimated Future Amortization Expense Related to Intangible Assets	Estimated future amortization expense related to intangible assets as of December 31, 2023 is as follows: Year 2024 111 2025 84 2026 56 2027 30 2028 19 Thereafter 67 Total 367

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
Property, Plant and Equipment, Net (Tables)	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, plant and equipment, net are detailed below: December 31, 2023 Gross Accumulated Net Land 118 — 118 Buildings 1,306 (606) 700 Facilities & leasehold improvements 4,346 (3,117) 1,229 Machinery and equipment 21,486 (15,139) 6,347 Computer and R&D equipment 421 (330) 91 Operating lease right-of-use assets 431 (153) 278 Finance lease right-of-use assets 68 (7) 61 Other tangible assets 115 (97) 18 Construction in progress 1,712 — 1,712 Total 30,003 (19,449) 10,554 December 31, 2022 Gross Accumulated Net Land 83 — 83 Buildings 1,116 (563) 553 Facilities & leasehold improvements 3,877 (2,895) 982 Machinery and equipment 18,751 (14,023) 4,728 Computer and R&D equipment 398 (319) 79 Operating lease right-of-use assets 311 (118) 193 Finance lease right-of-use assets 57 (2) 55 Other tangible assets 112 (95) 17 Construction in progress 1,511 — 1,511 Total 26,216 (18,015) 8,201

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2023
Lessee Disclosure [Abstract]
Schedule of Lessee Operating and Finance Leases	Operating and finance leases consisted of the following: December 31, December 31, Right-of-use assets Operating leases 278 193 Finance leases 61 55 Total right-of-use assets 339 248 Lease liabilities Current 68 59 Operating leases 58 52 Finance leases 10 7 Non-current 243 191 Operating leases 188 141 Finance leases 55 50 Total lease liabilities 311 250
Lessee Operating and Finance Lease Liability Maturity	Maturities of lease liabilities are as follows: Operating Leases Finance Leases December 31, 2024 66 10 76 2025 49 6 55 2026 35 6 41 2027 25 29 54 2028 22 2 24 Thereafter 106 31 137 Total future undiscounted cash outflows 303 84 387 Effect of discounting (57) (19) (76) Total lease liabilities 246 65 311
Schedule of Operating and Finance Lease Term and Discount Rate	Operating and finance lease terms and discount rates are as follows: December 31, December 31, Weighted average remaining lease term (in years) – operating leases 8.94 9.46 Weighted average remaining lease term (in years) – finance leases 10.24 9.89 Weighted average discount rate – operating lease 3.61 % 3.12 % Weighted average discount rate – finance lease 3.82 % 3.86 %
Schedule of Operating and Finance Lease Cost and Cash Paid	Operating and finance lease cost and cash paid are as follows: 2023 2022 Operating lease cost 71 62 Finance lease cost Amortization of right-of-use assets 5 2 Interest 3 1 Operating lease cash paid 74 63 Finance lease cash paid 4 —
Schedule of Right of Use Assets Obtained in Exchange for Operating Lease and Finance Liabilities	Non-cash transaction right-of-use assets obtained in exchange for new lease liabilities are as follows: 2023 2022 Operating leases 114 60 Finance leases 8 55

Long-Term Investments and Var_2

Long-Term Investments and Variable Interest Entities (Tables)	12 Months Ended
	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Long-Term Investments	December 31, December 31, Long-term investments 22 11 Total 22 11

Other Non-Current Assets (Table

Other Non-Current Assets (Tables)	12 Months Ended
Other Non-Current Assets (Tables)	Dec. 31, 2023
Investments, All Other Investments [Abstract]
Other Non-Current Assets	Other non-current assets are detailed below: December 31, December 31, 2023 2022 Equity securities 31 26 Public funding receivables 210 156 Taxes and other government receivables 22 — French research tax credit receivable 246 294 Defined benefit plans 15 9 Prepayments and deposits to third parties 224 107 Derivative instruments 2 13 Other non-current assets 58 56 Total 808 661

Other Payables and Accrued Li_2

Other Payables and Accrued Liabilities (Tables)	12 Months Ended
Other Payables and Accrued Liabilities (Tables)	Dec. 31, 2023
Payables and Accruals [Abstract]
Other Payables and Accrued Liabilities	Other payables and accrued liabilities are detailed below: December 31, December 31, Employee related liabilities 679 599 Employee compensated absences 228 196 Taxes other than income taxes 81 68 Advances from customers 186 225 Liabilities related to public funding 96 37 Derivative instruments 4 35 Defined benefit and contribution plans 49 39 Royalties 30 32 Current operating lease liabilities 58 52 Others 114 102 Total 1,525 1,385

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
Long-Term Debt (Tables)	Dec. 31, 2023
Debt Disclosure [Abstract]
Long-Term Debt	Long-term debt consisted of the following: December 31, December 31, 2023 2022 Funding program loans from European Investment Bank ("EIB"): 4.72% due 2028, floating interest rate at Euribor +0.589% 141 163 4.52% due 2029, floating interest rate at Euribor +0.564% 162 183 4.47% due 2031, floating interest rate at Euribor +0.473% 296 322 4.54% due 2031, floating interest rate at Euribor +0.550% 146 159 4.52% due 2033, floating interest rate at Euribor +0.558% 332 — Credit Facility from Cassa Depositi e Prestiti SpA ("CDP") 4.64% due 2027, floating interest rate at Euribor +0.690% 97 120 4.49% due 2028, floating interest rate at Euribor +0.550% 92 107 4.79% due 2029, floating interest rate at Euribor +0.850% 95 107 Dual tranche senior unsecured convertible bonds zero-coupon, due 2025 (Tranche A) 748 748 zero-coupon, due 2027 (Tranche B) 748 747 Finance leases: 3.86% due 2027, fixed interest rate 38 38 3.78% due 2042, fixed interest rate 25 19 1.75% due 2042, fixed interest rate 2 — Other funding program loans: 0.29% (weighted average), due 2024-2028, fixed interest rate 5 4 Total long-term debt 2,927 2,717 Less current portion (217) (175) Total long-term debt, less current portion 2,710 2,542
Long-Term Debt Denominated by Currencies	Long-term debt is denominated in the following currencies: December 31, December 31, U.S. dollar 1,496 1,495 Euro 1,431 1,222 Total 2,927 2,717
Total Long-Term Debt Outstanding Maturities	Aggregate future maturities of total long-term debt (including current portion) at principal amount are as follows: December 31, 2023 2024 217 2025 962 2026 212 2027 947 2028 198 Thereafter 395 Total 2,931

Post-Employment and Other Lon_2

Post-Employment and Other Long-Term Employees Benefits (Tables)	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Changes in Benefit Obligation and Plan Assets	The changes in benefit obligation and plan assets were as follows: Pension Benefits Other Long-Term Benefits December 31, December 31, December 31, December 31, Change in benefit obligation: Benefit obligation at beginning of year 886 1,165 86 94 Service cost 28 33 17 17 Interest cost 35 27 3 1 Employee contributions 5 4 — — Plan amendments (1) — — — Benefits paid (18) (22) (9) (6) Effect of settlement (1) (14) — — Actuarial (gain) loss 39 (260) (2) (15) Foreign currency translation 35 (47) 4 (5) Benefit obligation at end of year 1,008 886 99 86 Change in plan assets: Plan assets at fair value at beginning of year 567 743 — — Actual return on plan assets 38 (157) — — Employer contributions 26 25 — — Employee contributions 5 4 — — Benefits paid (4) (9) — — Effect of settlement (1) (14) — — Business combination — — — — Foreign currency translation 23 (25) — — Plan assets at fair value at end of year 654 567 — — Funded status (354) (319) (99) (86) Amounts recorded in the consolidated balance sheets Other investments and other non-current assets 15 9 — — Other payables and accrued liabilities (15) (11) (7) (5) Other non-current liabilities — — (92) (81) Post-employment benefit obligations (354) (317) — — Net amount recorded (354) (319) (99) (86)
Accumulated Other Comprehensive Income (Loss) Before Tax Effects	The components of accumulated other comprehensive loss (income) before tax effects were as follows: Actuarial Prior service Total Accumulated other comprehensive loss as of 142 2 144 Net amount generated/arising in current year (80) — (80) Amortization (3) (1) (4) Foreign currency translation adjustment (10) — (10) Accumulated other comprehensive loss as of 49 1 50 Net amount generated/arising in current year 25 (1) 24 Amortization (6) (1) (7) Foreign currency translation adjustment 1 — 1 Accumulated other comprehensive loss as of 69 (1) 68
Schedule of Accumulated Benefit Obligations	The accumulated benefit obligations were as follows: Pension Benefits Other Long-Term Benefits December 31, December 31, December 31, December 31, Accumulated benefit obligations 808 778 35 25
Components of Net Periodic Benefit Cost	The components of the net periodic benefit cost included the following: Pension Benefits Other Long-term Benefits Year ended Year ended Year ended Year ended Year ended Year ended Service cost 28 33 36 17 17 13 Interest cost 35 27 21 3 1 1 Expected return on plan assets (24) (23) (24) — — — Amortization of actuarial net loss (gain) 6 6 12 (2) (14) — Amortization of prior service cost 1 1 1 — — — Effect of settlement 1 — — — — — Net periodic benefit cost 47 44 46 18 4 14
Weighted Average Assumptions Used in Determination of Benefit Obligation and Plan Assets	The weighted average assumptions used to determine the benefit obligation and the periodic benefit costs for pension plans and other long-term benefits were as follows: 2023 2022 2021 Benefit obligation Discount rate 3.73 % 4.18 % 1.84 % Salary increase rate 2.17 % 2.31 % 2.27 % Net periodic benefit cost Discount rate 4.18 % 1.84 % 1.45 % Salary increase rate 2.31 % 2.27 % 2.43 % Expected long-term rates of return on plan assets 2.66 % 3.19 % 3.44 %
Pension Plan Asset Allocation	The Company’s pension plan asset allocation as of December 31, 2023 and December 31, 2022 is as follows: Percentage of Plan Assets Asset Category 2023 2022 Cash and cash equivalents 1 % 1 % Equity securities 13 % 17 % Government debt securities 11 % 10 % Corporate debt securities 19 % 21 % Investments in funds (a) 15 % 16 % Real estate 1 % 1 % Other (mainly insurance assets – contracts and 40 % 34 % Total 100 % 100 % (a) As of December 31, 2023, investments in funds were composed of commingled and multi-strategy funds invested in diversified portfolios of fixed income (68%) - mainly corporate bonds, equities (24%), time deposits and money market (5%) and other instruments (3%). As of December 31, 2022, investments in funds were composed of commingled and multi-strategy funds invested in diversified portfolios of fixed income (79%) - mainly corporate bonds, time deposits and money market (11%) and other instruments (10%).
Pension Plan Asset Allocation Including Fair-Value Measurements	The Company’s detailed pension plan asset allocation including the fair-value measurements of those plan assets as of December 31, 2023 is as follows: Total Quoted Significant Significant Cash and cash equivalents 7 7 — — Equity securities 87 1 86 — Government debt securities 69 — 69 — Corporate debt securities 123 — 101 22 Investment funds 100 14 86 — Real estate 9 — 9 — Other (mainly insurance assets – 259 — 48 211 TOTAL 654 22 399 233 The Company’s detailed pension plan asset allocation including the fair-value measurements of those plan assets as of December 31, 2022 is as follows: Total Quoted Significant Significant Cash and cash equivalents 4 4 — — Equity securities 95 1 94 — Government debt securities 59 — 59 — Corporate debt securities 120 — 98 22 Investment funds 87 1 86 — Real estate 6 — 6 — Other (mainly insurance assets – 194 — 38 156 TOTAL 565 6 381 178
Reconciliation for Plan Assets Measured at Fair Value Using Unobservable Inputs (Level 3)	For plan assets measured at fair value using significant unobservable inputs (Level 3), the reconciliation between January 1, 2023 and December 31, 2023 is presented as follows: Fair Value January 1, 2023 178 Contributions (employer and employee) 21 Actual return on plan assets (b) 4 Net benefit payments (a) 14 Settlements (b) (1) Foreign currency translation adjustment (c) 17 December 31, 2023 233 (a) Net cash flows between benefits paid from the insurance contracts and benefits transferred into the insurance contracts by employees. (b) Included in non operating expenses in the consolidated statement of income. (c) Unrealized gains included in the consolidated statement of comprehensive income. For plan assets measured at fair value using significant unobservable inputs (Level 3), the reconciliation between January 1, 2022 and December 31, 2022 is presented as follows: Fair Value January 1, 2022 167 Contributions (employer and employee) 21 Net benefit payments (a) 9 Settlements (14) Foreign currency translation adjustment (5) December 31, 2022 178 (a) Net cash flows between benefits paid from the insurance contracts and benefits transferred into the insurance contracts by employees.
Estimated Future Benefit Payments	The Company’s estimated future benefit payments as of December 31, 2023 are as follows: Years Pension Other 2024 59 7 2025 63 8 2026 86 8 2027 54 9 2028 60 8 From 2029 to 2033 375 44

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	12 Months Ended
Other Long-Term Liabilities (Tables)	Dec. 31, 2023
Other Liabilities, Noncurrent [Abstract]
Summary of Other Long-Term Liabilities	Other long-term liabilities are detailed below: December 31, December 31, Non-current operating lease liabilities 188 141 Contingent consideration on business combinations 20 31 Other employee benefits 92 81 Liabilities related to public funding 196 51 Advances received on capital grants 152 — Advances from customers 25 73 Derivative instruments — 4 Others 62 73 Total 735 454

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
Shareholders' Equity (Tables)	Dec. 31, 2023
Equity [Abstract]
Summary of Grants Under Outstanding Stock Award Plans	The table below summarizes grants under the outstanding stock award plans, as authorized by the Compensation Committee: Year of grant Options Options 2011 172,500 (30,000) 2012 180,000 (22,500) Since 2013 No options granted The table below summarizes grants outstanding during the year 2023, as authorized by the Compensation Committee: Date of grant Plan name Number of Number of Number of June 17, 2020 2020 CEO Special Bonus 16,000 — — July 23, 2020 2020 Employee Plan 7,437,580 — — December 24, 2020 2020 Employee Plan 562,350 — — July 28, 2021 2021 Employee Plan 6,327,205 — (920,263) December 21, 2021 2021 Employee Plan 213,270 — (60,483) July 27, 2022 2022 Employee Plan 6,243,670 — — December 22, 2022 2022 Employee Plan 287,675 — — July 26, 2023 2023 Employee Plan 5,154,115 — () December 11, 2023 2023 Employee Plan 295,020 — () (*) As of the date of issuance of these consolidated financial statements, a final decision by the Compensation Committee of the Supervisory Board on the achievement of the performance conditions had not been made yet.
Summary of Nonvested Share Activity	A summary of the options’ activity by plan for the years ended December 31, 2023 and December 31, 2022 is presented below: Year of grant Outstanding Exercised Expired / Cancelled Outstanding Exercised Expired / Cancelled Outstanding 2011 — — — — — — — 2012 20,000 (5,000) (15,000) — — — — A summary of the unvested share activity by plan for the year ended December 31, 2023 is presented below: Unvested Shares Unvested as at Granted Forfeited / Cancelled on Vested Unvested as at 2020 CEO Special Bonus 5,334 — — — (5,334) — 2020 Employee Plan 2,780,796 — (11,851) — (2,768,945) — 2021 Employee Plan 3,699,514 — (32,571) — (1,716,700) 1,950,243 2022 Employee Plan 6,496,525 — (80,065) — (2,065,721) 4,350,739 2023 Employee Plan — 5,449,135 (28,730) — — 5,420,405 Total 12,982,169 5,449,135 (153,217) — (6,556,700) 11,721,387
Classification of Pre-Payroll Tax and Social Contribution Stock-Based Compensation Expense Included in Consolidated Statements of Income	The following table illustrates the classification of pre-payroll tax and social contribution stock-based compensation expense included in the consolidated statements of income for the years ended December 31, 2023, 2022 and 2021: December 31, December 31, December 31, Cost of sales 40 34 34 R&D 71 69 70 SG&A 125 112 117 Total pre-payroll tax and social contribution 236 215 221
Changes in AOCI Attributable to Stockholders	The table below details the changes in AOCI attributable to the company’s stockholders by component, net of tax, for the years ended December 31, 2023, 2022 and 2021: Gains (Losses) Gains (Losses) Defined Benefit Foreign Currency Total December 31, 2020 61 1 (231) 849 680 Cumulative tax impact (8) — 51 — 43 December 31, 2020, net of tax 53 1 (180) 849 723 OCI before reclassifications (90) (1) 56 (189) (224) Amounts reclassified from AOCI (19) — 13 — (6) OCI for the year ended December 31, 2021 (109) (1) 69 (189) (230) Cumulative tax impact 14 — (11) — 3 OCI for the year ended December 31, 2021, (95) (1) 58 (189) (227) December 31, 2021 (48) — (162) 660 450 Cumulative tax impact 6 — 40 — 46 December 31, 2021, net of tax (42) — (122) 660 496 OCI before reclassifications (126) (16) 80 (149) (211) Amounts reclassified from AOCI 197 — 4 — 201 OCI for the year ended December 31, 2022 71 (16) 84 (149) (10) Cumulative tax impact (9) 2 (19) — (26) OCI for the year ended December 31, 2022, 62 (14) 65 (149) (36) December 31, 2022 23 (16) (78) 511 440 Cumulative tax impact (3) 2 21 — 20 December 31, 2022, net of tax 20 (14) (57) 511 460 OCI before reclassifications 38 6 (24) 133 153 Amounts reclassified from AOCI (5) — 7 — 2 OCI for the year ended December 31, 2023 33 6 (17) 133 155 Cumulative tax impact (5) (1) 4 — (2) OCI for the year ended December 31, 2023, 28 5 (13) 133 153 December 31, 2023 56 (10) (95) 644 595 Cumulative tax impact (8) 1 25 — 18 December 31, 2023, net of tax 48 (9) (70) 644 613
Schedule of Items Reclassified Out of Accumulated Other Comprehensive Income	Items reclassified out of Accumulated Other Comprehensive Income for the years ended December 31, 2023, 2022, 2021 are listed in the table below: Details about AOCI components Amounts Amounts Amounts Affected line item in the Gains (Losses) on Cash Flow Foreign exchange derivative $ 1 $ (129) $ 15 Cost of sales Foreign exchange derivative $ 1 $ (15) $ 1 Selling, general and administrative expenses Foreign exchange derivative $ 3 $ (53) $ 3 Research and development expenses $ — $ 27 $ (3) Income tax benefit (expense) $ 5 $ (170) $ 16 Net of tax Defined Benefit Pension Plan Amortization of actuarial gains $ (6) $ (3) $ (12) Other components of pension benefit costs Amortization of prior service cost $ (1) $ (1) $ (1) Other components of pension benefit costs $ 1 $ 1 $ 2 Income tax benefit (expense) $ (6) $ (3) $ (11) Net of tax Total reclassifications for the year $ (1) $ (173) $ 5 Attributable to noncontrolling $ — $ — $ — Attributable to the parent company $ (1) $ (173) $ 5

Revenues (Tables)

Revenues (Tables)	12 Months Ended
Revenues (Tables)	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Summary of Consolidated Net Revenues Disaggregated by Reportable Segment, Geographical Region of Shipment, Nature and Market Channel	The following tables present the Company’s consolidated net revenues disaggregated by geographical region of shipment, nature and market channel: Year ended December 31, December 31, December 31, Net revenues by geographical region of shipment (1) EMEA 4,836 3,619 2,557 Americas 2,724 2,310 1,525 Asia Pacific 9,726 10,199 8,679 Total net revenues 17,286 16,128 12,761 Net revenues by nature Revenues from sale of products 17,094 15,953 12,560 Revenues from sale of services 145 130 169 Other revenues 47 45 32 Total net revenues 17,286 16,128 12,761 Net revenues by market channel (2) Original Equipment Manufacturers (“OEM”) 11,468 10,764 8,486 Distribution 5,818 5,364 4,275 Total net revenues 17,286 16,128 12,761 (1) Net revenues by geographical region of shipment are classified by location of customer invoiced or reclassified by shipment destination in line with customer demand. For example, products ordered by U.S.-based companies to be invoiced to Asia Pacific affiliates are classified as Asia Pacific revenues. Furthermore, the Company, among the different periods, may be affected by shifts in shipments from one location to another, as requested by customers. (2) Original Equipment Manufacturers (“OEM”) are the end-customers to which the Company provides direct marketing application engineering support, while Distribution refers to the distributors and representatives that the Company engages to distribute its products around the world.

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
Segment Information (Tables)	Dec. 31, 2023
Segment Reporting [Abstract]
Net Revenues by Product Segment and by Product Line	Net revenues by reportable segment: December 31, December 31, December 31, ADG 7,848 5,969 4,350 AMS 3,991 4,911 4,587 MDG 5,431 5,228 3,802 Total net revenues of product segments 17,270 16,108 12,739 Others 16 20 22 Total consolidated net revenues 17,286 16,128 12,761
Operating Income by Reportable Segment	Operating income by reportable segment: December 31, December 31, December 31, ADG 2,497 1,469 512 AMS 690 1,237 1,022 MDG 1,838 1,830 908 Total operating income of product segments 5,025 4,536 2,442 Others (1) (414) (97) (23) Total consolidated operating income 4,611 4,439 2,419 (1) Operating income (loss) of “Others” includes items such as unused capacity charges, including unloading charges due to COVID-19 and incidents leading to power outage, impairment, restructuring charges and other related closure costs, management reorganization costs, start-up and phase-out costs, and other unallocated expenses such as: strategic or special R&D programs, certain corporate-level operating expenses, patent claims and litigations, and other costs that are not allocated to product groups, as well as operating earnings of other products.
Reconciliation of Operating Income of Reportable Segments to Total Consolidated Operating Income	The reconciliation of operating income of reportable segments to the total consolidated operating income is presented in the below table: December 31, December 31, December 31, Total operating income of reportable segments 5,025 4,536 2,442 Impairment, restructuring charges and — — (2) Impairment loss on intangible assets acquired through recent business combinations (36) — — Start-up and phase-out costs (134) (13) — Unused capacity charges (120) (22) (16) Other unallocated manufacturing results (94) (57) 1 Gain on sale of non-current assets 4 2 3 Strategic and other research and development programs and other non-allocated provisions (1) (34) (7) (9) Total operating loss Others (414) (97) (23) Total consolidated operating income 4,611 4,439 2,419 (1) Includes unallocated income and expenses such as certain corporate-level operating expenses and other income (costs) that are not allocated to the product segments.
Net Revenues	Net revenues December 31, December 31, December 31, Switzerland 5,755 4,569 3,282 France 158 153 126 Italy 54 47 56 USA 2,279 1,981 1,253 Singapore 8,138 8,604 7,442 Japan 890 758 586 Other countries 12 16 16 Total net revenues 17,286 16,128 12,761
Property, Plant & Equipment	Property, plant and equipment, net December 31, December 31, Netherlands 3,996 2,753 France 1,837 1,774 Italy 2,108 1,683 Other European countries 170 161 USA 59 52 Singapore 1,347 880 Malaysia 478 365 Other countries 559 533 Total property, plant and equipment, net 10,554 8,201

Other Income and Expenses, Net

Other Income and Expenses, Net (Tables)	12 Months Ended
Other Income and Expenses, Net (Tables)	Dec. 31, 2023
Other Income and Expenses [Abstract]
Other Income and Expenses, Net	Other income and expenses, net consisted of the following: Year ended Year ended Year ended Public funding 201 177 162 Start-up and phase-out costs (134) (13) — Exchange gain (loss), net 5 15 7 Patent costs (12) (8) (10) Gain on sale of non-current assets 6 2 5 COVID-19 incremental costs — (10) (19) Other, net (11) (4) (4) Total 55 159 141

Interest Income (Expense), Net

Interest Income (Expense), Net (Tables)	12 Months Ended
Interest Income (Expense), Net (Tables)	Dec. 31, 2023
Banking and Thrift, Interest [Abstract]
Summary of Interest Income (Expense), Net	Interest income (expense), net consisted of the following: Year ended Year ended Year ended Income 226 71 13 Expense (55) (13) (42) Total 171 58 (29)

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
Income Tax (Tables)	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income (Loss) before Income Tax	Income (loss) before income tax is comprised of the following: Year ended Year ended Year ended Income (loss) recorded in the Netherlands (32) (22) (20) Income (loss) from foreign operations 4,795 4,508 2,357 Income (loss) before income tax benefit (expense) 4,763 4,486 2,337
Income Tax Benefit (Expense)	Income tax benefit (expense) is comprised of the following: Year ended Year ended Year ended The Netherlands taxes - current — — — Foreign taxes - current (528) (510) (285) Total current taxes (528) (510) (285) The Netherlands taxes - deferred — — — Foreign taxes - deferred (13) (10) (46) Total deferred taxes (13) (10) (46) Income tax expense (541) (520) (331) Effective tax rate 11 % 12 % 14 %
Differences in Income Taxes Computed at Netherlands Statutory Rate and Effective Income Tax Rate	The principal items comprising the differences in income taxes computed at the Netherlands statutory rate of 25.8% in 2023, 25.8% in 2022 and 25% in 2021, and the effective income tax rate are the following: Year ended Year ended Year ended Income tax benefit (expense) computed at (1,229) (1,158) (584) Non-deductible and non-taxable permanent 6 22 4 Change in valuation allowances — 140 (2) Effect of changes in tax laws and similar 149 6 6 Current year tax credits 29 30 39 Other tax and credits 34 (51) (22) Benefits from tax holidays 45 60 49 Net impact of changes to uncertain tax positions (8) (12) (8) Earnings of subsidiaries taxed at different rates 433 443 187 Income tax benefit (expense) (541) (520) (331)
Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities consisted of the following: December 31, December 31, Tax loss carryforwards, tax credits and other tax attributes 886 520 Less unrecognized tax benefits (21) (25) Tax loss carryforwards, tax credits and other tax attributes, net of unrecognized tax 865 495 Inventory valuation 48 42 Fixed asset depreciation 61 55 Increased depreciation incentives 48 83 Capitalized development costs 38 79 Receivables for government funding 152 121 Tax credits granted on capital investments 226 218 Pension 67 62 Stock awards 17 17 Operating lease liabilities 69 50 Commercial accruals 38 27 Other temporary differences 33 27 Total deferred tax assets 1,662 1,276 Valuation allowances (782) (416) Deferred tax assets, net 880 860 Accelerated fixed asset depreciation (40) (37) Acquired intangible assets (24) (23) Advances of government funding (185) (177) Operating lease right-of-use assets (62) (50) Other temporary differences (31) (31) Deferred tax liabilities (342) (318) Net deferred income tax asset 538 542
Gross Deferred Tax Assets On Tax Loss Carryforwards And Investment Credits Expiration Table Text Block	As of December 31, 2023, the Company and its subsidiaries have gross deferred tax assets on tax loss carryforwards, tax credits and other tax attributes that expire starting from 2024. December 31, Year 2023 2024 3 2025 2 2026 2 2027 4 2028 3 Thereafter 872 Total 886
Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits	A reconciliation of 2023, 2022 and 2021 beginning and ending amounts of unrecognized tax benefits is as follows: December 31, December 31, December 31, Balance at beginning of year 61 118 48 Additions based on tax positions related to the — 4 72 Additions based on acquisitions related to the — — — Additions for tax positions of prior years 11 13 1 Reduction for tax positions of prior years — (69) (1) Settlements (14) (2) — Reductions due to lapse of statute of limitations (4) — — Foreign currency translation 1 (3) (2) Balance at end of year 55 61 118

Earnings per Share (Tables)

Earnings per Share (Tables)	12 Months Ended
Earnings per Share (Tables)	Dec. 31, 2023
Earnings Per Share [Abstract]
Summary of Earnings per Share ("EPS")	For the years ended December 31, 2023, 2022 and 2021, earnings per share (“EPS”) was calculated as follows: Year ended Year ended Year ended Basic EPS Net income attributable to parent company as reported 4,211 3,960 2,000 Weighted average number of shares outstanding 903,513,952 905,606,885 904,332,429 Basic EPS 4.66 4.37 2.21 Diluted EPS Net income attributable to parent company as reported 4,211 3,960 2,000 add-back interest expense, net of income tax effect 1 2 — Net income attributable to parent company as adjusted 4,212 3,962 2,000 Weighted average shares outstanding 903,513,952 905,606,885 904,332,429 Dilutive effect of stock awards 6,858,815 6,789,662 9,107,124 Dilutive effect of convertible bonds 33,825,000 33,825,000 11,402,645 Number of shares used in calculating diluted EPS 944,197,767 946,221,547 924,842,198 Diluted EPS 4.46 4.19 2.16

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	12 Months Ended
Financial Instruments and Risk Management (Tables)	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Notional Amounts of Outstanding Derivative Instruments	As of December 31, 2023, the Company had the following outstanding derivative instruments that were entered into to hedge Euro-denominated and Singapore dollar-denominated forecasted transactions: In millions of Euros Notional amount for hedge on Notional amount for hedge on Forward contracts 445 951 Currency collars 240 640 In millions of Singapore dollars Notional amount for hedge on Notional amount for hedge on Forward contracts — 219
Fair Value of Derivative Instruments	Information on fair value of derivative instruments and their location in the consolidated balance sheets as of December 31, 2023 and December 31, 2022 is presented in the table below: As of December 31, As of December 31, Asset Derivatives Balance sheet classification Fair Fair Derivatives designated as a hedge: Foreign exchange forward contracts Other current assets 46 37 Foreign exchange forward contracts Other non-current assets 2 8 Currency collars Other current assets 7 10 Currency collars Other non-current assets — 5 Total derivatives designated as a hedge: 55 60 Derivatives not designated as a hedge: Foreign exchange forward contracts Other current assets 5 9 Total derivatives not designated as a hedge: 5 9 Total Derivatives 60 69 As of December 31, As of December 31, Liability Derivatives Balance sheet classification Fair Fair Derivatives designated as a hedge: Foreign exchange forward contracts Other payables and (2) (23) Foreign exchange forward contracts Other non-current liabilities — (3) Currency collars Other payables and — (9) Currency collars Other long-term liabilities — (1) Total derivatives designated as a hedge: (2) (36) Derivatives not designated as a hedge: Foreign exchange forward contracts Other payables and (2) (3) Total derivatives not designated as a hedge: (2) (3) Total Derivatives (4) (39)
Effect on Consolidated Statements of Income of Derivative Instruments	The effect of derivative instruments designated as cash flow hedge on the consolidated statements of income for the year ended December 31, 2023 and December 31, 2022 and on the “Accumulated other comprehensive income (loss)” (“AOCI”) as reported in the consolidated statements of equity as of December 31, 2023 and December 31, 2022 is presented in the table below: Gain (loss) deferred in Location of gain (loss) Gain (loss) reclassified from December 31, December 31, reclassified from OCI into December 31, December 31, Foreign exchange forward 35 14 Cost of sales 1 (83) Foreign exchange forward 4 2 Selling, general and administrative expenses 1 (9) Foreign exchange forward 10 4 Research and development expenses 2 (32) Currency collars 5 1 Cost of sales — (46) Currency collars 1 1 Selling, general and administrative expenses — (6) Currency collars 2 1 Research and development expenses 1 (21) Total 57 23 5 (197)
Effect on Consolidated Statements of Income of Derivative Instruments Not Designated as Hedge	The effect on the consolidated statements of income for the year ended December 31, 2023 and December 31, 2022 of derivative instruments not designated as a hedge is presented in the table below: Location of gain Gain (loss) recognized in earnings (loss) recognized December 31, December 31, Foreign exchange forward contracts Other income and expenses, net 2 24 Total 2 24
Schedule of Financial Assets (Liabilities) Measured at Fair Value on Recurring Basis	The table below details financial assets (liabilities) measured at fair value on a recurring basis as of December 31, 2023: Fair Value Measurements using December 31, Quoted Significant Significant Marketable securities – U.S. Treasury debt securities 1,635 1,635 — — Short-term deposits 1,226 1,226 — — Equity securities measured at fair value through earnings 31 31 — — Derivative assets designated as cash flow hedge 55 — 55 — Derivative assets not designated as cash flow hedge 5 — 5 — Derivative liabilities designated as cash flow hedge (2) — (2) — Derivative liabilities not designated as cash flow hedge (2) — (2) — Contingent consideration on business acquisition (20) — — (20) Total 2,928 2,892 56 (20) The table below details financial assets (liabilities) measured at fair value on a recurring basis as of December 31, 2022: Fair Value Measurements using December 31, Quoted Significant Significant Marketable securities – U.S. Treasury debt securities 679 679 — — Short-term deposits 581 581 — — Equity securities measured at fair value through earnings 26 26 — — Derivative assets designated as cash flow hedge 60 — 60 — Derivative assets not designated as cash flow hedge 9 — 9 — Derivative liabilities designated as cash flow hedge (36) — (36) — Derivative liabilities not designated as cash flow hedge (3) — (3) — Contingent consideration on business acquisitions (31) — — (31) Total 1,285 1,286 30 (31)
Schedule of Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)	For liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3), the reconciliation between January 1, 2023 and December 31, 2023 is presented as follows: Fair Value January 1, 2023 31 Changes in fair value measurement (12) Currency translation adjustment 1 December 31, 2023 20 Amount of total gains (losses) for the period included in earnings attributable to liabilities 12 For liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3), the reconciliation between January 1, 2022 and December 31, 2022 is presented as follows: Fair Value January 1, 2022 77 Changes in fair value measurement (35) Currency translation adjustment (4) Payments made (7) December 31, 2022 31 Amount of total gains (losses) for the period included in earnings attributable to liabilities 35
Fair Value Information on Other Financial Assets and Liabilities Recorded at Amortized Cost	The following table includes additional fair value information on financial assets and liabilities as of December 31, 2023 and 2022: 2023 2022 Level Carrying Estimated Carrying Estimated Cash equivalents (1) 1 2,879 2,879 2,996 2,996 Marketable securities 1 1,635 1,635 679 679 Short-term, deposits 1 1,226 1,226 581 581 Long-term debt – Bank loans (including current portion) 2 1,366 1,366 1,165 1,165 – Finance leases (including current portion) 2 65 65 57 57 – Senior unsecured convertible bonds issued on August 4, 2020 (2) 1 1,496 1,814 1,495 1,561 (1) Cash equivalents primarily correspond to deposits at call with banks. (2) The carrying amount as of December 31, 2023, of the senior unsecured convertible bonds as reported above, corresponds to the nominal value of the bonds, net of $4 million unamortized debt issuance costs. The fair value represented the market price of the bonds trading on the Frankfurt Stock Exchange.
Schedule of Methodologies Used to Estimate Fair Value	The methodologies used to estimate fair value are as follows: Components Methodology used to estimate fair value Debt securities classified as available-for-sale Quoted market prices for identical instruments Foreign exchange forward contracts, currency options and collars Quoted market prices for similar instruments Equity securities measured at fair value through earnings Quoted market prices for identical instruments Equity securities carried at cost as a measurement alternative Valuation of the underlying investments on a new round of third-party financing or upon liquidation Long-term debt and current portion of long-term debt Future cash flows on a borrowing-by-borrowing basis and discounting these future cash flows using the Company's incremental borrowing rates for similar types of borrowing arrangements. For convertible bonds, the fair value represents the market price of the bonds trading on the Frankfurt Stock Exchange Cash and cash equivalents, short-term deposits, accounts receivable, short-term borrowings, and accounts payable The carrying amounts reflected in the consolidated financial statements are considered as reasonable estimates of fair value due to the relatively short period of time between the origination of the instruments and their expected realization.

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
Related Party Transactions (Tables)	Dec. 31, 2023
Related Party Transactions [Abstract]
Transactions with Related Parties	The below table summarizes transactions incurred in 2023, 2022 and 2021 with companies for which certain members of the Company’s management perform similar policymaking functions. These include, but are not limited to: Orange, Idemia France and Politecnico di Milano. The amounts reported on the below table correspond to transactions up to the date members of the Company's management hold these similar functions. December 31, December 31, December 31, 2023 2022 2021 Sales and services 5 13 8 Purchases and other contributions 27 25 19 Accounts receivable — 5 2 Accounts payable 6 2 —

Accounting Policies - Additiona

Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Summary Of Accounting Policies [Line Items]
Sustainability threshold for uncertain tax position	50%
Cumulative probability threshold for realization of income tax benefits	50%
Significant assets held for sale	$ 0	$ 0
Employees average service period to grant awards	3 years
Advertising expenses	$ 23,000,000	$ 18,000,000	$ 12,000,000
Debt securities	$ 0
French \| Research tax credits
Summary Of Accounting Policies [Line Items]
Tax credit carryforward expiration term	3 years
Minimum
Summary Of Accounting Policies [Line Items]
Revenue recognition expected payment terms	30 days
Maximum
Summary Of Accounting Policies [Line Items]
Revenue recognition expected payment terms	90 days
Maximum \| Leases
Summary Of Accounting Policies [Line Items]
Short term lease payments excluding capitalization amount	$ 5,000
Trademarks and licenses \| Minimum
Summary Of Accounting Policies [Line Items]
Estimated useful lives of intangible assets	3 years
Trademarks and licenses \| Maximum
Summary Of Accounting Policies [Line Items]
Estimated useful lives of intangible assets	11 years
Purchased & internally developed software \| Maximum
Summary Of Accounting Policies [Line Items]
Estimated useful lives of intangible assets	4 years

Accounting Policies - Schedule

Accounting Policies - Schedule of Property, Plant and Equipment Useful Lives (Detail)	Dec. 31, 2023
Buildings
Property, Plant and Equipment [Line Items]
Estimated useful lives of property, plant and equipment, average	33 years
Facilities and leasehold improvements \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of property, plant and equipment, average	5 years
Facilities and leasehold improvements \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of property, plant and equipment, average	10 years
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of property, plant and equipment, average	2 years
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of property, plant and equipment, average	10 years
Computer and R&D equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of property, plant and equipment, average	3 years
Computer and R&D equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of property, plant and equipment, average	6 years
Other \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of property, plant and equipment, average	2 years
Other \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of property, plant and equipment, average	5 years

Short-Term Deposits and Marke_3

Short-Term Deposits and Marketable Securities - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Financing Receivable Recorded Investment [Line Items]
Short-term deposits	$ 1,226	$ 581
Marketable securities	1,635	679	$ 0
Marketable securities, principal amount transferred to short-term securities lending transactions	750
Fair Value		$ 679
Debt securities unrealized gain	4
Unrealized gain
Financing Receivable Recorded Investment [Line Items]
Fair Value	1,049
U.S. Treasury Bonds
Financing Receivable Recorded Investment [Line Items]
Marketable securities	$ 1,653
Weighted average maturity period	1 year 7 months 6 days
Aggregate amortized cost basis of securities	$ 1,645

Short-Term Deposits and Marke_4

Short-Term Deposits and Marketable Securities - Changes in Value of Marketable Securities Reported in Current Assets on Consolidated Balance Sheets (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Marketable Securities [Line Items]
Beginning Balance	$ 679	$ 0
Purchase	1,653	687	$ 0
Accretion	47	8
Proceeds at maturity	(750)	0	(132)
Change in fair value included in OCI	6
Change in fair value included in OCI		(16)
Ending Balance	1,635	679	0
U.S. Treasury Bonds
Marketable Securities [Line Items]
Beginning Balance	679	0
Purchase	1,653	687
Accretion	47	8
Proceeds at maturity	(750)	0
Change in fair value included in OCI	6
Change in fair value included in OCI		(16)
Ending Balance	$ 1,635	$ 679	$ 0

Short-Term Deposits and Marke_5

Short-Term Deposits and Marketable Securities - Debt Securities in an Unrealized Loss Position (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Less than 12 months
Unrealized Losses	$ (12)
More than 12 months
Unrealized Losses	(1)
Total
Fair Value		$ 679
Unrealized Losses	(13)
Unrealized loss
Less than 12 months
Fair Value	429
More than 12 months
Fair Value	157
Total
Fair Value	586
Unrealized gain
Total
Fair Value	1,049
U.S. Treasury Bonds
Less than 12 months
Unrealized Losses	(12)
More than 12 months
Unrealized Losses	(1)
Total
Unrealized Losses	(13)
U.S. Treasury Bonds \| Unrealized loss
Less than 12 months
Fair Value	429
More than 12 months
Fair Value	157
Total
Fair Value	$ 586

Trade Accounts Receivable, Ne_2

Trade Accounts Receivable, Net - Trade Accounts Receivable, Net (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Receivables [Abstract]
Trade accounts receivable	$ 1,750	$ 1,991
Current expected credit losses allowance ("CECLA")	(19)	(21)
Total	$ 1,731	$ 1,970

Trade Accounts Receivable, Ne_3

Trade Accounts Receivable, Net - Schedule of Changes in Reported CECLA (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
CECLA As of December 31, 2022	$ (21)
Current-period adjustment to CECLA	2
CECLA As of December 31, 2023	$ (19)

Inventories - Inventories (Deta

Inventories - Inventories (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 298	$ 349
Work-in-process	1,745	1,490
Finished products	655	744
Total	$ 2,698	$ 2,583

Other Current Assets - Other Cu

Other Current Assets - Other Current Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Public funding receivables	$ 651	$ 190
Taxes and other government receivables	241	270
Advances and prepayments	180	125
Loans and deposits	10	10
Interest receivable	27	22
Derivative instruments	58	56
Other current assets	128	61
Total	$ 1,295	$ 734

Other Current Assets - Addition

Other Current Assets - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other current assets	$ 128	$ 61
Proceeds from collaborators	54
Collaborative arrangement, transaction with party to collaborative arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other current assets	$ 28

Public Funding - Narrative (Det

Public Funding - Narrative (Detail) - USD ($) $ in Millions	12 Months Ended
Public Funding - Narrative (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Government Assistance [Line Items]
Grants receivable	$ 861	$ 346
Public funding receivables	651	190
Public funding receivables	210	156
Liabilities related to public funding	$ 292	88
Term public funding program requirement	5 years
Capital investment grants	$ 711	95
Public funding related to R&D and innovation activities, recognized	$ 201	177
Government assistance, statement of income or comprehensive income [Extensible Enumeration]	Other income and expenses, net
Silicon Carbide Substrates Plant Catania Italy
Government Assistance [Line Items]
Provision aid adjustment mechanism public funding	$ 0
Device Manufacturing China
Government Assistance [Line Items]
Liabilities related to public funding, noncurrent	152
Cost of sales
Government Assistance [Line Items]
Realized gain (loss) on reduction in operating expenses	102	59
Other current assets
Government Assistance [Line Items]
Public funding receivables	651	190
Other current assets \| Wafer Fab Crolles France
Government Assistance [Line Items]
Public funding receivables	378
Other non-current assets
Government Assistance [Line Items]
Public funding receivables	210	156
Other payables and accrued liabilities
Government Assistance [Line Items]
Liabilities related to public funding	96	37
Liabilities related to public funding, current	44
Other non-current liabilities
Government Assistance [Line Items]
Liabilities related to public funding	196	51
Research tax credits \| Other non-current assets
Government Assistance [Line Items]
Research tax credit receivables, noncurrent	246	294
French \| Research and development expenses
Government Assistance [Line Items]
Research tax credit received	$ 126	$ 106

Goodwill - Changes in Carrying

Goodwill - Changes in Carrying Amount of Goodwill (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Goodwill, opening balance	$ 297	$ 313
Foreign currency translation	6	(16)
Goodwill, closing balance	303	297
ADG
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Goodwill, opening balance	74	83
Foreign currency translation	2	(9)
Goodwill, closing balance	76	74
AMS
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Goodwill, opening balance	2	2
Foreign currency translation	0	0
Goodwill, closing balance	2	2
MDG
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Goodwill, opening balance	221	228
Foreign currency translation	4	(7)
Goodwill, closing balance	$ 225	$ 221

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment loss of goodwill	$ 0	$ 0	$ 0

Other Intangible Assets, Net -

Other Intangible Assets, Net - Other Intangible Assets, Net (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 1,329	$ 1,419
Accumulated Amortization	(962)	(1,014)
Net Amount	367	405
Technologies & licenses
Finite Lived Intangible Assets [Line Items]
Gross Amount	764	776
Accumulated Amortization	(547)	(507)
Net Amount	217	269
Purchased & internally developed software
Finite Lived Intangible Assets [Line Items]
Gross Amount	509	602
Accumulated Amortization	(415)	(507)
Net Amount	94	95
Technologies in progress
Finite Lived Intangible Assets [Line Items]
Gross Amount	56	41
Accumulated Amortization	0	0
Net Amount	$ 56	$ 41

Other Intangible Assets, Net _2

Other Intangible Assets, Net - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Amortization expense	$ 97	$ 103	$ 93
Impairment loss on intangible assets acquired through recent business combinations	42
Research and development expenses
Finite Lived Intangible Assets [Line Items]
Impairment loss on intangible assets acquired through recent business combinations	25
Cost of sales
Finite Lived Intangible Assets [Line Items]
Impairment loss on intangible assets acquired through recent business combinations	$ 17
Acquired licenses and technologies
Finite Lived Intangible Assets [Line Items]
Impairment loss on intangible assets acquired through recent business combinations		$ 38	$ 1

Other Intangible Assets, Net _3

Other Intangible Assets, Net - Estimated Future Amortization Expense Related to Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 111
2025	84
2026	56
2027	30
2028	19
Thereafter	67
Net Amount	$ 367	$ 405

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Gross Amount	$ 30,003	$ 26,216
Accumulated Depreciation	(19,449)	(18,015)
Net Amount	10,554	8,201
Land
Property, Plant and Equipment [Line Items]
Gross Amount	118	83
Accumulated Depreciation	0	0
Net Amount	118	83
Buildings
Property, Plant and Equipment [Line Items]
Gross Amount	1,306	1,116
Accumulated Depreciation	(606)	(563)
Net Amount	700	553
Facilities and leasehold improvements
Property, Plant and Equipment [Line Items]
Gross Amount	4,346	3,877
Accumulated Depreciation	(3,117)	(2,895)
Net Amount	1,229	982
Machinery and equipment
Property, Plant and Equipment [Line Items]
Gross Amount	21,486	18,751
Accumulated Depreciation	(15,139)	(14,023)
Net Amount	6,347	4,728
Computer and R&D equipment
Property, Plant and Equipment [Line Items]
Gross Amount	421	398
Accumulated Depreciation	(330)	(319)
Net Amount	91	79
Operating lease right-of-use assets
Property, Plant and Equipment [Line Items]
Gross Amount	431	311
Accumulated Depreciation	(153)	(118)
Net Amount	278	193
Finance lease right-of-use assets
Property, Plant and Equipment [Line Items]
Gross Amount	68	57
Accumulated Depreciation	(7)	(2)
Net Amount	61	55
Other tangible assets
Property, Plant and Equipment [Line Items]
Gross Amount	115	112
Accumulated Depreciation	(97)	(95)
Net Amount	18	17
Construction in progress
Property, Plant and Equipment [Line Items]
Gross Amount	1,712	1,511
Accumulated Depreciation	0	0
Net Amount	$ 1,712	$ 1,511

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Depreciation charge	$ 1,464	$ 1,113	$ 952
Tax incentives and capital investment funding	713	25	13
Reduction in depreciation charges due to public funding	69	56	61
Capital investment grants	711	95
Proceeds from capital grants and other contributions	320	21	10
Proceeds from sale of tangible assets	8	4	2
Impairment of long-lived assets	0	$ 0	$ 0
Property, Plant and Equipment
Property, Plant and Equipment [Line Items]
Capital investment grants	38
Property, Plant and Equipment \| France
Property, Plant and Equipment [Line Items]
Capital investment grants	620
Silicon Carbide Substrates Plant Catania Italy
Property, Plant and Equipment [Line Items]
Definitive long-lived assets	131
Manufacturing Facilities Expansion in France
Property, Plant and Equipment [Line Items]
Reduction in depreciation charges due to public funding	12
Proceeds from capital grants and other contributions	$ 239

Leases - Additional Information

Leases - Additional Information (Detail)	12 Months Ended
Leases - Additional Information (Detail)	Dec. 31, 2023
Minimum
Lessee Lease Description [Line Items]
Remaining lease term	1 year
Maximum
Lessee Lease Description [Line Items]
Remaining lease term	50 years

Leases - Schedule of Operating

Leases - Schedule of Operating and Finance Lease (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Operating leases
Operating leases	$ 278	$ 193
Finance leases	61	55
Total right-of-use assets	339	248
Lease liabilities [Abstract]
Current	68	59
Operating leases	58	52
Finance leases	10	7
Non-current	243	191
Operating leases	188	141
Finance leases	55	50
Total lease liabilities	$ 311	$ 250
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Other payables and accrued liabilities	Other payables and accrued liabilities
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Short-term debt	Short-term debt
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities	Other long-term liabilities
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term debt	Long-term debt

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Operating Leases
2024	$ 66
2025	49
2026	35
2027	25
2028	22
Thereafter	106
Total future undiscounted cash outflows	303
Operating Lease, Liability, Undiscounted Excess Amount	(57)
Total lease liabilities	246
Finance Leases
2024	10
2025	6
2026	6
2027	29
2028	2
Thereafter	31
Total future undiscounted cash outflows	84
Finance Lease, Liability, Undiscounted Excess Amount	(19)
Finance leases:	65
2024	76
2025	55
2026	41
2027	54
2028	24
Thereafter	137
Total future undiscounted cash outflows	387
Effect of discounting	(76)
Lease liabilities	$ 311	$ 250

Leases - Schedule of Operatin_2

Leases - Schedule of Operating and Finance Lease Term and Discount Rate (Detail)	Dec. 31, 2023	Dec. 31, 2022
Lessee Disclosure [Abstract]
Weighted average remaining lease term (in years) – operating leases	8 years 11 months 8 days	9 years 5 months 15 days
Weighted average remaining lease term (in years) – finance leases	10 years 2 months 26 days	9 years 10 months 20 days
Weighted average discount rate – operating lease	3.61%	3.12%
Weighted average discount rate – finance lease	3.82%	3.86%

Leases - Schedule of Operatin_3

Leases - Schedule of Operating and Finance Lease Cost and Cash Paid (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Lessee Disclosure [Abstract]
Operating lease cost	$ 71	$ 62
Finance lease cost
Amortization of right-of-use assets	5	2
Interest	3	1
Operating lease cash paid	74	63
Finance lease cash paid	$ 4	$ 0

Leases - Schedule of Right-of-U

Leases - Schedule of Right-of-Use Assets Obtained in Exchange for New Operating and Finance Lease Liabilities (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Lessee Disclosure [Abstract]
Operating leases	$ 114	$ 60
Finance leases	$ 8	$ 55

Long-Term Investments and Var_3

Long-Term Investments and Variable Interest Entities - Long-Term Investments (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Long-term investments	$ 22	$ 11

Long-Term Investments and Var_4

Long-Term Investments and Variable Interest Entities - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Long Term Investments [Line Items]
Long-term investments	$ 22	$ 11
Payments to acquire investments	10
Noncontrolling interest	123	$ 65
DNP Photomask Europe S.p.A (“DNP”)
Long Term Investments [Line Items]
Long-term investments	9
Variable interest entity, primary beneficiary
Long Term Investments [Line Items]
Noncontrolling interest	$ 52
SANAN STMicroelectronics \| Variable interest entity, primary beneficiary
Long Term Investments [Line Items]
Limited partnership	49%
Subsidiary, ownership percentage, noncontrolling owner	51%

Other Non-Current Assets - Othe

Other Non-Current Assets - Other Non-Current Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Equity securities	$ 31	$ 26
Public funding receivables	210	156
Taxes and other government receivables	22	0
French research tax credit receivable	246	294
Defined benefit plans	15	9
Prepayments and deposits to third parties	224	107
Derivative instruments	2	13
Other non-current assets	58	56
Total	$ 808	$ 661

Other Non-Current Assets - Addi

Other Non-Current Assets - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Non-current assets sold without recourse	$ 118	$ 110
Non-current assets sold , cost	$ 5	$ 1

Other Payables and Accrued Li_3

Other Payables and Accrued Liabilities - Other Payables and Accrued Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Employee related liabilities	$ 679	$ 599
Employee compensated absences	228	196
Taxes other than income taxes	81	68
Advances from customers	186	225
Liabilities related to public funding	96	37
Derivative instruments	4	35
Defined benefit and contribution plans	49	39
Royalties	30	32
Current operating lease liabilities	58	52
Others	114	102
Total	$ 1,525	$ 1,385
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Total	Total

Other Payables and Accrued Li_4

Other Payables and Accrued Liabilities - Additional Information (Detail) $ in Millions	Dec. 31, 2023 USD ($)
Payables and Accruals [Abstract]
Provision for penalties	$ 0

Long-Term Debt - Long-Term Debt

Long-Term Debt - Long-Term Debt (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Long-term debt
Finance leases:	$ 65
Total long-term debt	2,927	$ 2,717
Less current portion	(217)	(175)
Total long-term debt, less current portion	2,710	2,542
4.72% due 2028, floating interest rate at Euribor +0.589%
Loans Payable [Abstract]
Bank loans (including current portion)	$ 141	163
Long-term debt
Interest rate	4.72%
Basis spread on floating rate	0.589%
4.52% due 2029, floating interest rate at Euribor +0.564%
Loans Payable [Abstract]
Bank loans (including current portion)	$ 162	183
Long-term debt
Interest rate	4.52%
Basis spread on floating rate	0.564%
4.47% due 2031, floating interest rate at Euribor +0.473%
Loans Payable [Abstract]
Bank loans (including current portion)	$ 296	322
Long-term debt
Interest rate	4.47%
Basis spread on floating rate	0.473%
4.54% due 2031, floating interest rate at Euribor +0.550%
Loans Payable [Abstract]
Bank loans (including current portion)	$ 146	159
Long-term debt
Interest rate	4.54%
Basis spread on floating rate	0.55%
4.52% due 2033, floating interest rate at Euribor +0.558%
Loans Payable [Abstract]
Bank loans (including current portion)	$ 332	0
Long-term debt
Interest rate	4.52%
Basis spread on floating rate	0.558%
4.64% due 2027, floating interest rate at Euribor +0.690%
Long-term debt
Interest rate	4.64%
Basis spread on floating rate	0.69%
4.64% due 2027, floating interest rate at Euribor +0.690% \| Credit Facility from Cassa Depositi e Prestiti SpA ("CDP")
Loans Payable [Abstract]
Bank loans (including current portion)	$ 97	120
4.49% due 2028, floating interest rate at Euribor +0.550%
Long-term debt
Interest rate	4.49%
Basis spread on floating rate	0.55%
4.49% due 2028, floating interest rate at Euribor +0.550% \| Credit Facility from Cassa Depositi e Prestiti SpA ("CDP")
Loans Payable [Abstract]
Bank loans (including current portion)	$ 92	107
4.79% due 2029, floating interest rate at Euribor +0.850%
Long-term debt
Interest rate	4.79%
Basis spread on floating rate	0.85%
4.79% due 2029, floating interest rate at Euribor +0.850% \| Credit Facility from Cassa Depositi e Prestiti SpA ("CDP")
Loans Payable [Abstract]
Bank loans (including current portion)	$ 95	107
zero-coupon, due 2025 (Tranche A) \| Dual tranche senior unsecured convertible bonds
Long-term debt
Dual tranche senior unsecured convertible bonds	$ 748	748
Interest rate	0%
zero-coupon, due 2027 (Tranche B) \| Dual tranche senior unsecured convertible bonds
Long-term debt
Dual tranche senior unsecured convertible bonds	$ 748	747
Interest rate	0%
3.86% due 2027, fixed interest rate
Long-term debt
Finance leases:	$ 38	38
Interest rate	3.86%
3.78% due 2042, fixed interest rate
Long-term debt
Finance leases:	$ 25	19
Interest rate	3.78%
1.75% due 2042, fixed interest rate
Long-term debt
Finance leases:	$ 2	0
Interest rate	1.75%
0.29% (weighted average), due 2024-2028, fixed interest rate
Long-term debt
Other Loans Payable	$ 5	$ 4
Interest rate	0.29%

Long-Term Debt - Long-Term De_2

Long-Term Debt - Long-Term Debt Denominated by Currencies (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Long-term debt	$ 2,927	$ 2,717
U.S. dollar
Debt Instrument [Line Items]
Long-term debt	1,496	1,495
Euro
Debt Instrument [Line Items]
Long-term debt	$ 1,431	$ 1,222

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) $ / shares in Units, € in Millions	Aug. 04, 2020 USD ($) $ / shares shares	Jan. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Jun. 01, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Aug. 01, 2017 EUR (€)
Medium term credit facilities
Debt Instrument [Line Items]
Unutilized committed medium term credit facilities			$ 1,030,000,000
Support R&D and capital expenditure programs
Debt Instrument [Line Items]
Line of credit outstanding amount \| €					€ 600
Amount outstanding			332,000,000
Credit facility amount withdrawn \| €				€ 300
Support R&D and capital expenditure programs \| Subsequent event
Debt Instrument [Line Items]
Credit facility amount withdrawn		$ 300,000,000
Support R&D and capital expenditure programs \| Europe Union
Debt Instrument [Line Items]
Line of credit outstanding amount \| €								€ 500
Amount outstanding			303,000,000
Support R&D and capital expenditure programs \| Italy and France
Debt Instrument [Line Items]
Line of credit outstanding amount \| €							€ 500
Amount outstanding			442,000,000
New facility agreement with CDP one
Debt Instrument [Line Items]
Line of credit outstanding amount \| €						€ 150
Amount outstanding			97,000,000
New facility agreement with CDP two
Debt Instrument [Line Items]
Line of credit outstanding amount \| €					€ 200
Amount outstanding			$ 187,000,000
Dual tranche senior unsecured convertible bonds
Debt Instrument [Line Items]
Net proceeds from issuance of senior unsecured convertible bonds	$ 1,567,000,000
Dual tranche senior unsecured convertible bonds \| Dual tranche senior unsecured convertible bonds
Debt Instrument [Line Items]
Debt instrument principal amount	$ 1,500,000,000
zero-coupon, due 2025 (Tranche A)
Debt Instrument [Line Items]
Senior unsecured convertible bonds conversion premium rate	47.50%
Debt conversion, converted instrument, shares issued (in shares) \| shares	4,585
Debt conversion, bond par value	$ 200,000
Contingent feature of conversion price	1.30
zero-coupon, due 2025 (Tranche A) \| Dual tranche senior unsecured convertible bonds
Debt Instrument [Line Items]
Debt instrument principal amount	$ 750,000,000
Percentage at which bonds issued	105.80%
Senior unsecured convertible bonds conversion price (in USD per share) \| $ / shares	$ 43.62
zero-coupon, due 2027 (Tranche B)
Debt Instrument [Line Items]
Senior unsecured convertible bonds conversion price (in USD per share) \| $ / shares	$ 45.10
Senior unsecured convertible bonds conversion premium rate	52.50%
Debt conversion, converted instrument, shares issued (in shares) \| shares	4,435
Debt conversion, bond par value	$ 200,000
Contingent feature of conversion price	1.30
zero-coupon, due 2027 (Tranche B) \| Dual tranche senior unsecured convertible bonds
Debt Instrument [Line Items]
Debt instrument principal amount	$ 750,000,000
Percentage at which bonds issued	104.50%
Dual tranche senior unsecured convertible bonds
Debt Instrument [Line Items]
Contingent feature of conversion price	1.30

Long-Term Debt - Total Long-Ter

Long-Term Debt - Total Long-Term Debt Outstanding Maturities (Detail) $ in Millions	Dec. 31, 2023 USD ($)
Debt Disclosure [Abstract]
2024	$ 217
2025	962
2026	212
2027	947
2028	198
Thereafter	395
Total	$ 2,931

Post-Employment and Other Lon_3

Post-Employment and Other Long-Term Employees Benefits - Changes in Benefit Obligation and Plan Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Change in plan assets:
Plan assets at fair value at beginning of year	$ 565
Foreign currency translation	0	$ 0
Plan assets at fair value at end of year	654	565
Pension Benefits
Change in benefit obligation:
Benefit obligation at beginning of year	886	1,165
Service cost	28	33	$ 36
Interest cost	35	27	21
Employee contributions	5	4
Plan amendments	(1)	0
Benefits paid	(18)	(22)
Effect of settlement	(1)	(14)
Actuarial (gain) loss	39	(260)
Foreign currency translation	35	(47)
Benefit obligation at end of year	1,008	886	1,165
Change in plan assets:
Plan assets at fair value at beginning of year	567	743
Actual return on plan assets	38	(157)
Employer contributions	26	25
Employee contributions	5	4
Benefits paid	(4)	(9)
Effect of settlement	(1)	(14)
Business combination	0	0
Foreign currency translation	(23)	25
Plan assets at fair value at end of year	654	567	743
Funded status	(354)	(319)
Net amount recognized in the balance sheet consisted of the following:
Other investments and other non-current assets	15	9
Other payables and accrued liabilities	(15)	(11)
Other non-current liabilities	0	0
Post-employment benefit obligations	(354)	(317)
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position, Total	(354)	(319)
Other Long-Term Benefits
Change in benefit obligation:
Benefit obligation at beginning of year	86	94
Service cost	17	17	13
Interest cost	3	1	1
Employee contributions	0	0
Plan amendments	0	0
Benefits paid	(9)	(6)
Effect of settlement	0	0
Actuarial (gain) loss	(2)	(15)
Foreign currency translation	4	(5)
Benefit obligation at end of year	99	86	$ 94
Change in plan assets:
Plan assets at fair value at beginning of year	0
Plan assets at fair value at end of year	0	0
Funded status	(99)	(86)
Net amount recognized in the balance sheet consisted of the following:
Other investments and other non-current assets	0	0
Other payables and accrued liabilities	(7)	(5)
Other non-current liabilities	(92)	(81)
Post-employment benefit obligations	0	0
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position, Total	$ (99)	$ (86)

Post-Employment and Other Lon_4

Post-Employment and Other Long-Term Employees Benefits - Rollforward Accumulated Other Comprehensive Income (Loss) Before Tax Effects (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Retirement Benefits [Abstract]
Accumulated other comprehensive loss, actuarial (gains)/losses, beginning balance	$ 49	$ 142
Other comprehensive income (loss), defined benefit plan, gain (loss) arising during period, before tax	25	(80)
Amortization, actuarial (gains)/losses	(6)	(3)
Foreign currency translation, actuarial (gains)/losses before tax	1	(10)
Accumulated other comprehensive loss, actuarial (gains)/losses, beginning balance	69	49
Accumulated other comprehensive loss, prior service cost, beginning balance	1	2
Other comprehensive (income) loss, defined benefit plan, prior service cost (credit), before tax	(1)	0
Other comprehensive (income) loss, defined benefit plan, prior service cost (credit), reclassification adjustment from AOCI, before tax	(1)	(1)
Foreign currency translation adjustment	0	0
Accumulated other comprehensive loss, prior service cost, beginning balance	(1)	1
Defined benefit plan, accumulated other comprehensive (income) loss, before tax	50	144
Net amount generated/arising in current year, total	24	(80)
Amortization, total	(7)	(4)
Other comprehensive income of defined benefit plan foreign currency translation before tax	1	(10)
Defined benefit plan, accumulated other comprehensive (income) loss, before tax	$ 68	$ 50

Post-Employment and Other Lon_5

Post-Employment and Other Long-Term Employees Benefits - Schedule of Accumulated Benefit Obligations (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligations	$ 808	$ 778
Other Long-Term Benefits
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligations	$ 35	$ 25

Post-Employment and Other Lon_6

Post-Employment and Other Long-Term Employees Benefits - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Pension plans with accumulated benefit obligations in excess of plan assets, accumulated benefit obligation	$ 411	$ 409
Pension plans with accumulated benefit obligations in excess of plan assets, fair value of plan assets	182	139
Pension plans with expected projected benefit obligations in excess of plan assets, projected benefit obligation	478	427
Pension and other postretirement benefits cost (reversal of cost)	19	11	$ 10
Accrued benefits related to defined contribution pension plans	27	24
Annual cost of defined contribution plans	114	100	$ 101
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Pension plans with benefit obligations in excess of plan assets, benefit obligation	950	839
Employer contributions	26	$ 25
Expected contribution in cash	$ 27

Post-Employment and Other Lon_7

Post-Employment and Other Long-Term Employees Benefits - Components of Net Periodic Benefit Cost (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 28	$ 33	$ 36
Interest cost	35	27	21
Expected return on plan assets	(24)	(23)	(24)
Amortization of actuarial net loss (gain)	6	6	12
Amortization of prior service cost	1	1	1
Effect of settlement	1	0	0
Net periodic benefit cost	47	44	46
Other Long-Term Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	17	17	13
Interest cost	3	1	1
Expected return on plan assets	0	0	0
Amortization of actuarial net loss (gain)	(2)	(14)	0
Amortization of prior service cost	0	0	0
Effect of settlement	0	0	0
Net periodic benefit cost	$ 18	$ 4	$ 14

Post-Employment and Other Lon_8

Post-Employment and Other Long-Term Employees Benefits - Weighted Average Assumptions Used in Determination of Benefit Obligation and Plan Assets (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Benefit Obligation [Abstract]
Discount rate	3.73%	4.18%	1.84%
Salary increase rate	2.17%	2.31%	2.27%
Net Periodic Benefit Cost [Abstract]
Discount rate	4.18%	1.84%	1.45%
Salary increase rate	2.31%	2.27%	2.43%
Expected long-term rates of return on plan assets	2.66%	3.19%	3.44%

Post-Employment and Other Lon_9

Post-Employment and Other Long-Term Employees Benefits - Pension Plan Asset Allocation (Detail)	Dec. 31, 2023	Dec. 31, 2022
Allocation of pension plan assets	100%	100%
Cash and cash equivalents
Allocation of pension plan assets	1%	1%
Equity securities
Allocation of pension plan assets	13%	17%
Government debt securities
Allocation of pension plan assets	11%	10%
Corporate debt securities
Allocation of pension plan assets	19%	21%
Investment in funds
Allocation of pension plan assets	15%	16%
Investment in funds \| Time deposits and money market
Defined benefit plan, plan assets target allocation percentage	5%	11%
Investment in funds \| Corporate debt securities
Defined benefit plan, plan assets target allocation percentage	68%	79%
Investment in funds \| Equity securities
Defined benefit plan, plan assets target allocation percentage	24%
Investment in funds \| Other Instruments
Defined benefit plan, plan assets target allocation percentage	3%	10%
Real estate
Allocation of pension plan assets	1%	1%
Other (mainly insurance assets – contracts and reserves)
Allocation of pension plan assets	40%	34%

Post-Employment and Other Lo_10

Post-Employment and Other Long-Term Employees Benefits - Pension Plan Asset Allocation Including Fair-Value Measurements (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	$ 654	$ 565
Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	7	4
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	87	95
Government debt securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	69	59
Corporate debt securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	123	120
Investment in funds
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	100	87
Real estate
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	9	6
Other (mainly insurance assets – contracts and reserves)
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	259	194
Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	22	6
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	7	4
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Equity securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	1	1
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Government debt securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Corporate debt securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Investment in funds
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	14	1
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Real estate
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Other (mainly insurance assets – contracts and reserves)
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	399	381
Significant Other Observable Inputs (Level 2) \| Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) \| Equity securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	86	94
Significant Other Observable Inputs (Level 2) \| Government debt securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	69	59
Significant Other Observable Inputs (Level 2) \| Corporate debt securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	101	98
Significant Other Observable Inputs (Level 2) \| Investment in funds
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	86	86
Significant Other Observable Inputs (Level 2) \| Real estate
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	9	6
Significant Other Observable Inputs (Level 2) \| Other (mainly insurance assets – contracts and reserves)
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	48	38
Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	233	178	$ 167
Significant Unobservable Inputs (Level 3) \| Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) \| Equity securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) \| Government debt securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) \| Corporate debt securities
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	22	22
Significant Unobservable Inputs (Level 3) \| Investment in funds
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) \| Real estate
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) \| Other (mainly insurance assets – contracts and reserves)
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	$ 211	$ 156

Post-Employment and Other Lo_11

Post-Employment and Other Long-Term Employees Benefits - Reconciliation for Plan Assets Measured at Fair Value Using Unobservable Inputs (Level 3) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Change in plan assets:
Plan assets at fair value at beginning of year	$ 565
Foreign currency translation	0	$ 0
Plan assets at fair value at end of year	654	565
Significant Unobservable Inputs (Level 3)
Change in plan assets:
Plan assets at fair value at beginning of year	178	167
Contributions (employer and employee)	21	21
Actual return on plan assets	4
Benefits paid	14	9
Effect of settlement	(1)	(14)
Foreign currency translation	17	(5)
Plan assets at fair value at end of year	$ 233	$ 178

Post-Employment and Other Lo_12

Post-Employment and Other Long-Term Employees Benefits - Estimated Future Benefit Payments (Detail) $ in Millions	Dec. 31, 2023 USD ($)
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
2024	$ 59
2025	63
2026	86
2027	54
2028	60
From 2029 to 2033	375
Other Long-Term Benefits
Defined Benefit Plan Disclosure [Line Items]
2024	7
2025	8
2026	8
2027	9
2028	8
From 2029 to 2033	$ 44

Other Long-Term Liabilities - S

Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Other Liabilities, Noncurrent [Abstract]
Non-current operating lease liabilities	$ 188	$ 141
Contingent consideration on business combinations	20	31
Other employee benefits	92	81
Liabilities related to public funding	196	51
Advances received on capital grants	152	0
Advances from customers	25	73
Derivative instruments	0	4
Others	62	73
Total	$ 735	$ 454
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Total	Total

Other Long-Term Liabilities - A

Other Long-Term Liabilities - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Advances received on capital grants	$ 152	$ 0

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) € / shares in Units, $ / shares in Units, € in Millions, $ in Millions						1 Months Ended	3 Months Ended												12 Months Ended
	May 25, 2023 $ / shares	May 25, 2022 $ / shares	Jul. 01, 2021 USD ($)	May 27, 2021 $ / shares	Jan. 22, 2007	Oct. 31, 2016	Mar. 31, 2024 $ / shares	Dec. 31, 2023 USD ($) $ / shares shares	Sep. 30, 2023 $ / shares	Jun. 30, 2023 $ / shares	Mar. 31, 2023 $ / shares	Dec. 31, 2022 USD ($) $ / shares shares	Sep. 30, 2022 $ / shares	Jun. 30, 2022 $ / shares	Mar. 31, 2022 $ / shares	Dec. 31, 2021 USD ($) $ / shares shares	Sep. 30, 2021 $ / shares	Jun. 30, 2021 $ / shares	Dec. 31, 2023 USD ($) target $ / shares shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2008	Dec. 31, 2023 EUR (€) € / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total authorized share capital \| €																							€ 1,810
Common stock, shares authorized (in shares)								1,200,000,000											1,200,000,000				1,200,000,000
Preferred stock, shares authorized								540,000,000											540,000,000				540,000,000
Common stock, nominal value (in EUR per share) \| € / shares																							€ 1.04
Common stock, shares issued (in shares)								911,281,920				911,281,920							911,281,920	911,281,920			911,281,920
Common stock, shares outstanding (in shares)								902,771,081				903,865,763				906,518,057			902,771,081	903,865,763	906,518,057		902,771,081
Expiration period of options after date of grant, in years					10 years
Expiration extended period of options after date of grant,in years						10 years
Shares issued as a percentage of par value of the preference shares to be issued					25%
Preference shares outstanding maximum period																						2 years
Preferred stock, shares issued (in shares)								0				0							0	0			0
Company owned company stock (in shares)								8,510,839				7,416,157				4,758,863			8,510,839	7,416,157	4,758,863		8,510,839
Transfer of treasury shares to employees under the Company's share based remuneration programs (in shares)								81,022,515											81,022,515				81,022,515
Transfer of treasury shares to employees under the Company's share based remuneration during the year (in shares)																			6,502,300	6,587,002	7,448,615
Payments for repurchase of common stock \| $																			$ 346	$ 346	$ 485
Grant date fair value of shares vested \| $																			226	189	181
Stock-based compensation, excluding payroll tax and social contribution, capitalized as part of inventory \| $								$ 13				$ 11				$ 9			13	11	9
Total unrecognized compensation cost related to the grant of unvested shares \| $								$ 265											$ 265
Employee service share-based compensation, unvested awards, total compensation cost not yet recognized, period for recognition																			10 months
Deferred income tax benefit relating to unvested share based compensation expense \| $																			$ 17	15	14
Dividends, per share (in usd per share) \| $ / shares	$ 0.24	$ 0.24		$ 0.24				$ 0.06	$ 0.06	$ 0.06	$ 0.06	$ 0.06	$ 0.06	$ 0.06	$ 0.06	$ 0.06	$ 0.06	$ 0.06
Dividends payable to stockholders \| $								$ 54				$ 60							54	60
Dividend distribution first installment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend paid \| $																			55	55	54
Dividend distribution second installment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend paid \| $																			54	54	55
Dividend distribution third installment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend paid \| $																			54	48	54
Dividend distribution remaining portion of third installment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend paid \| $																			6
Dividend distribution of last installment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend paid \| $																			54	55
Dividends payable to stockholders \| $								$ 54											$ 54
Scenario forecast
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividends, per share (in usd per share) \| $ / shares							$ 0.06
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of awards																			3 years
Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Transfer of treasury shares to employees under the Company's share based remuneration during the year (in shares)																			6,556,700
Vesting period of awards																			3 years
Supervisory board 2012 plan \| Supervisory board
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards are granted at the nominal value of the share (in EUR per share) \| € / shares																							€ 1.04
Vesting period of awards																			3 years
Vesting schedule for Supervisory Board																			3 months 29 days
Employee plan 2009 \| Employees \| Share-based payment arrangement, tranche one
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sub plan for employees of company's european subsidiaries for statutory payroll tax purposes nonvested shares vested over requisite service period								32%											32%				32%
Employee plan 2009 \| Employees \| Share-based payment arrangement, tranche two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sub plan for employees of company's european subsidiaries for statutory payroll tax purposes nonvested shares vested over requisite service period								32%											32%				32%
Employee plan 2009 \| Employees \| Share-based payment arrangement, tranche three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sub plan for employees of company's european subsidiaries for statutory payroll tax purposes nonvested shares vested over requisite service period								36%											36%				36%
2020 CEO Special Bonus \| Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Transfer of treasury shares to employees under the Company's share based remuneration during the year (in shares)																			5,334
Weighted average grant-date fair value of nonvested shares granted to employees under employee plan (in USD per share) \| $ / shares																			$ 26.64
2020 Employee Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of external targets \| target																			2
Number of internal targets \| target																			1
Weighted average grant-date fair value of nonvested shares granted to employees under employee plan (in USD per share) \| $ / shares																			$ 30.17
2020 Employee Plan \| Performance conditions \| Share-based payment arrangement, tranche six
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares to vest																			100%
2020 Employee Plan \| Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Transfer of treasury shares to employees under the Company's share based remuneration during the year (in shares)																			2,768,945
2021 Employee Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of external targets \| target																			2
Number of internal targets \| target																			1
Weighted average grant-date fair value of nonvested shares granted to employees under employee plan (in USD per share) \| $ / shares																			$ 39.20
2021 Employee Plan \| Performance conditions \| Share based payment arrangement tranche five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares to vest																			66.67%
2021 Employee Plan \| Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Transfer of treasury shares to employees under the Company's share based remuneration during the year (in shares)																			1,716,700
2022 Employee Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of external targets \| target																			2
Number of internal targets \| target																			1
Weighted average grant-date fair value of nonvested shares granted to employees under employee plan (in USD per share) \| $ / shares																			$ 35.92
2022 Employee Plan \| Performance conditions \| Share-based payment arrangement, tranche six
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares to vest																			100%
2022 Employee Plan \| Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Transfer of treasury shares to employees under the Company's share based remuneration during the year (in shares)																			2,065,721
2023 Employee Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of external targets \| target																			2
Number of internal targets \| target																			1
Weighted average grant-date fair value of nonvested shares granted to employees under employee plan (in USD per share) \| $ / shares																			$ 50.96
Shares expected to vest (in shares)								2,589,952											2,589,952				2,589,952
2023 Employee Plan \| Performance conditions \| Share-based payment arrangement, tranche seven
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares to vest																			100%
2023 Employee Plan \| Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Transfer of treasury shares to employees under the Company's share based remuneration during the year (in shares)																			0
2023 Employee Plan \| Executive committee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of awards																			3 years
Share buy-back program launched on july 1, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, remaining authorized repurchase amount \| $			$ 1,040
Period of buy-back program			3 years
Payments for repurchase of common stock \| $																				$ 346	$ 172
Treasury stock, shares, acquired (in shares)																			7,600,000	9,200,000	3,900,000

Shareholders' Equity - Summary

Shareholders' Equity - Summary of Grants under Outstanding Stock Award Plans (Detail)	12 Months Ended
	Dec. 31, 2023 shares
Employees
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	5,449,135
Number of shares waived (in shares)	(153,217)
Employees \| 2020 CEO Special Bonus
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	0
Number of shares waived (in shares)	0
Employees \| 2020 Employee Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	0
Number of shares waived (in shares)	(11,851)
Employees \| 2021 Employee Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	0
Number of shares waived (in shares)	(32,571)
Employees \| 2022 Employee Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	0
Number of shares waived (in shares)	(80,065)
Employees \| 2023 Employee Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	5,449,135
Number of shares waived (in shares)	(28,730)
2011 \| Supervisory board
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	172,500
Number of shares waived, supervisory board (in shares)	(30,000)
2012 \| Supervisory board
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	180,000
Number of shares waived, supervisory board (in shares)	(22,500)
June 17, 2020 \| Employees \| 2020 CEO Special Bonus
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	16,000
Number of shares waived (in shares)	0
Number of shares lost on performance (in shares)	0
July 23, 2020 \| Employees \| 2020 Employee Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	7,437,580
Number of shares waived (in shares)	0
Number of shares lost on performance (in shares)	0
December 24, 2020 \| Employees \| 2020 Employee Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	562,350
Number of shares waived (in shares)	0
Number of shares lost on performance (in shares)	0
July 28, 2021 \| Employees \| 2021 Employee Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	6,327,205
Number of shares waived (in shares)	0
Number of shares lost on performance (in shares)	(920,263)
December 21, 2021 \| Employees \| 2021 Employee Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	213,270
Number of shares waived (in shares)	0
Number of shares lost on performance (in shares)	(60,483)
July 27, 2022 \| Employees \| 2022 Employee Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	6,243,670
Number of shares waived (in shares)	0
Number of shares lost on performance (in shares)	0
December 22, 2022 \| Employees \| 2022 Employee Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	287,675
Number of shares waived (in shares)	0
Number of shares lost on performance (in shares)	0
July 26, 2023 \| Employees \| 2023 Employee Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	5,154,115
Number of shares waived (in shares)	0
December 11, 2023 \| Employees \| 2023 Employee Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted in period (in shares)	295,020
Number of shares waived (in shares)	0

Shareholders' Equity - Summar_2

Shareholders' Equity - Summary of Nonvested Share Activity (Detail) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards vested (in shares)	(6,502,300)	(6,587,002)	(7,448,615)
Supervisory board \| 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, beginning balance (in shares)	0	0
Awards granted (in shares)	172,500
Exercised (in shares)	0	0
Expired/cancelled (in shares)	0	0
Number of shares, ending balance (in shares)	0	0	0
Supervisory board \| 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, beginning balance (in shares)	0	20,000
Awards granted (in shares)	180,000
Exercised (in shares)	0	(5,000)
Expired/cancelled (in shares)	0	(15,000)
Number of shares, ending balance (in shares)	0	0	20,000
Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, beginning balance (in shares)	12,982,169
Awards granted (in shares)	5,449,135
Awards forfeited/waived (in shares)	(153,217)
Awards cancelled on failed vesting conditions (in shares)	0
Awards vested (in shares)	(6,556,700)
Number of shares, ending balance (in shares)	11,721,387	12,982,169
Employees \| 2020 CEO Special Bonus
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, beginning balance (in shares)	5,334
Awards granted (in shares)	0
Awards forfeited/waived (in shares)	0
Awards cancelled on failed vesting conditions (in shares)	0
Awards vested (in shares)	(5,334)
Number of shares, ending balance (in shares)	0	5,334
Employees \| 2020 Employee Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, beginning balance (in shares)	2,780,796
Awards granted (in shares)	0
Awards forfeited/waived (in shares)	(11,851)
Awards cancelled on failed vesting conditions (in shares)	0
Awards vested (in shares)	(2,768,945)
Number of shares, ending balance (in shares)	0	2,780,796
Employees \| 2021 Employee Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, beginning balance (in shares)	3,699,514
Awards granted (in shares)	0
Awards forfeited/waived (in shares)	(32,571)
Awards cancelled on failed vesting conditions (in shares)	0
Awards vested (in shares)	(1,716,700)
Number of shares, ending balance (in shares)	1,950,243	3,699,514
Employees \| 2022 Employee Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, beginning balance (in shares)	6,496,525
Awards granted (in shares)	0
Awards forfeited/waived (in shares)	(80,065)
Awards cancelled on failed vesting conditions (in shares)	0
Awards vested (in shares)	(2,065,721)
Number of shares, ending balance (in shares)	4,350,739	6,496,525
Employees \| 2023 Employee Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, beginning balance (in shares)	0
Awards granted (in shares)	5,449,135
Awards forfeited/waived (in shares)	(28,730)
Awards cancelled on failed vesting conditions (in shares)	0
Awards vested (in shares)	0
Number of shares, ending balance (in shares)	5,420,405	0

Shareholders' Equity - Classifi

Shareholders' Equity - Classification of Pre-Payroll Tax and Social Contribution Stock-Based Compensation Expense Included in Consolidated Statements of Income (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total pre-payroll tax and social contribution compensation	$ 236	$ 215	$ 221
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total pre-payroll tax and social contribution compensation	40	34	34
Research and development expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total pre-payroll tax and social contribution compensation	71	69	70
Selling, general and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total pre-payroll tax and social contribution compensation	$ 125	$ 112	$ 117

Shareholders' Equity - Changes

Shareholders' Equity - Changes in AOCI Attributable to Stockholders (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance	$ 595	$ 440	$ 450	$ 680
Cumulative tax impact	18	20	46	43
Balance, net of tax	613	460	496	723
OCI before reclassifications	153	(211)	(224)
Amounts reclassified from AOCI	2	201	(6)
Other comprehensive income (loss), before tax, portion attributable to parent	155	(10)	(230)
Cumulative tax impact	(2)	(26)	3
OCI Balance, net of tax	153	(36)	(227)
Gains (Losses) on Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance	56	23	(48)	61
Cumulative tax impact	(8)	(3)	6	(8)
Balance, net of tax	48	20	(42)	53
OCI before reclassifications	38	(126)	(90)
Amounts reclassified from AOCI	(5)	197	(19)
Other comprehensive income (loss), before tax, portion attributable to parent	33	71	(109)
Cumulative tax impact	(5)	(9)	14
OCI Balance, net of tax	28	62	(95)
Gains (Losses) on Available- For-Sale Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance	(10)	(16)	0	1
Cumulative tax impact	1	2	0	0
Balance, net of tax	(9)	(14)	0	1
OCI before reclassifications	6	(16)	(1)
Amounts reclassified from AOCI	0	0	0
Other comprehensive income (loss), before tax, portion attributable to parent	6	(16)	(1)
Cumulative tax impact	(1)	2	0
OCI Balance, net of tax	5	(14)	(1)
Defined Benefit Pension Plan Items
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance	(95)	(78)	(162)	(231)
Cumulative tax impact	25	21	40	51
Balance, net of tax	(70)	(57)	(122)	(180)
OCI before reclassifications	(24)	80	56
Amounts reclassified from AOCI	7	4	13
Other comprehensive income (loss), before tax, portion attributable to parent	(17)	84	69
Cumulative tax impact	4	(19)	(11)
OCI Balance, net of tax	(13)	65	58
Foreign Currency Translation Adjustments (“CTA”)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance	644	511	660	849
Cumulative tax impact	0	0	0	0
Balance, net of tax	644	511	660	$ 849
OCI before reclassifications	133	(149)	(189)
Amounts reclassified from AOCI	0	0	0
Other comprehensive income (loss), before tax, portion attributable to parent	133	(149)	(189)
Cumulative tax impact	0	0	0
OCI Balance, net of tax	$ 133	$ (149)	$ (189)

Shareholders' Equity - Schedule

Shareholders' Equity - Schedule of Items Reclassified Out of Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of sales	$ 8,999	$ 8,493	$ 7,435
Selling, general and administrative expenses	(1,631)	(1,454)	(1,323)
Research and development expenses	(2,100)	(1,901)	(1,723)
Pension and Other Postretirement Benefits Cost (Reversal of Cost)	(19)	(11)	(10)
Income tax benefit (expense)	(541)	(520)	(331)
Net income	4,222	3,966	2,006
Attributable to noncontrolling interest	(11)	(6)	(6)
Net income attributable to parent company as reported	4,211	3,960	2,000
Reclassification out of accumulated other comprehensive income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net income	(1)	(173)	5
Attributable to noncontrolling interest	0	0	0
Net income attributable to parent company as reported	(1)	(173)	5
Reclassification out of accumulated other comprehensive income \| Gains (Losses) on Cash Flow Hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income tax benefit (expense)	0	27	(3)
Net income	5	(170)	16
Reclassification out of accumulated other comprehensive income \| Gains (Losses) on Cash Flow Hedges \| Foreign exchange contract
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of sales	1	(129)	15
Selling, general and administrative expenses	1	(15)	1
Research and development expenses	3	(53)	3
Reclassification out of accumulated other comprehensive income \| Amortization of actuarial gains (losses)
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Pension and Other Postretirement Benefits Cost (Reversal of Cost)	(6)	(3)	(12)
Reclassification out of accumulated other comprehensive income \| Amortization of prior service cost
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Pension and Other Postretirement Benefits Cost (Reversal of Cost)	(1)	(1)	(1)
Income tax benefit (expense)	1	1	2
Net income	$ (6)	$ (3)	$ (11)

Revenues - Additional Informati

Revenues - Additional Information (Detail)	12 Months Ended
Revenues - Additional Information (Detail)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Sales revenue, net \| Customer concentration risk \| Apple
Disaggregation of Revenue [Line Items]
Share of companies in consolidated net revenues	12.30%	16.80%	20.50%
Minimum
Disaggregation of Revenue [Line Items]
Revenue recognition and disaggregation payment terms	30 days
Maximum
Disaggregation of Revenue [Line Items]
Revenue recognition and disaggregation payment terms	90 days
Maximum \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-01-01
Disaggregation of Revenue [Line Items]
Performance obligations term	1 year

Revenues - Summary of Consolida

Revenues - Summary of Consolidated Net Revenues Disaggregated by Reportable Segment, Geographical Region of Shipment, Nature and Market Channel (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Total net revenues	$ 17,286	$ 16,128	$ 12,761
Original Equipment Manufacturers (“OEM”)
Disaggregation of Revenue [Line Items]
Total net revenues	11,468	10,764	8,486
Distribution
Disaggregation of Revenue [Line Items]
Total net revenues	5,818	5,364	4,275
Revenues from sale of products
Disaggregation of Revenue [Line Items]
Total net revenues	17,094	15,953	12,560
Revenues from sale of services
Disaggregation of Revenue [Line Items]
Total net revenues	145	130	169
Other revenues
Disaggregation of Revenue [Line Items]
Total net revenues	47	45	32
EMEA
Disaggregation of Revenue [Line Items]
Total net revenues	4,836	3,619	2,557
Americas
Disaggregation of Revenue [Line Items]
Total net revenues	2,724	2,310	1,525
Asia Pacific
Disaggregation of Revenue [Line Items]
Total net revenues	$ 9,726	$ 10,199	$ 8,679

Segment Information - Net Reven

Segment Information - Net Revenues by Product Segment and by Product Line (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Net revenues	$ 17,286	$ 16,128	$ 12,761
Product segments
Segment Reporting Information [Line Items]
Net revenues	17,270	16,108	12,739
ADG \| Product segments
Segment Reporting Information [Line Items]
Net revenues	7,848	5,969	4,350
AMS \| Product segments
Segment Reporting Information [Line Items]
Net revenues	3,991	4,911	4,587
MDG \| Product segments
Segment Reporting Information [Line Items]
Net revenues	5,431	5,228	3,802
Others
Segment Reporting Information [Line Items]
Net revenues	$ 16	$ 20	$ 22

Segment Information - Operating

Segment Information - Operating Income by Reportable Segment (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating loss Others	$ 4,611	$ 4,439	$ 2,419
Product segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating loss Others	5,025	4,536	2,442
AMS \| Product segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating loss Others	690	1,237	1,022
Operating segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating loss Others	5,025	4,536	2,442
Operating segments \| ADG \| Product segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating loss Others	2,497	1,469	512
Operating segments \| MDG \| Product segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating loss Others	1,838	1,830	908
Segment reconciling items
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating loss Others	(414)	(97)	(23)
Segment reconciling items \| Others
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating loss Others	$ (414)	$ (97)	$ (23)

Segment Information - Reconcili

Segment Information - Reconciliation of Operating Income of Reportable Segments to Total Consolidated Operating Income (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating income of reportable segments	$ 4,611	$ 4,439	$ 2,419
Impairment, restructuring charges and other related closure costs	0	0	(2)
Impairment loss on intangible assets acquired through recent business combinations	(42)
Start-up and phase-out costs	134	13	0
Gain on sale of non-current assets	6	2	5
Total operating loss Others	4,611	4,439	2,419
Operating income	4,611	4,439	2,419
Operating segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating income of reportable segments	5,025	4,536	2,442
Total operating loss Others	5,025	4,536	2,442
Operating income	5,025	4,536	2,442
Segment reconciling items
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating income of reportable segments	(414)	(97)	(23)
Impairment, restructuring charges and other related closure costs	0	0	(2)
Impairment loss on intangible assets acquired through recent business combinations	(36)	0	0
Start-up and phase-out costs	134	13	0
Unused capacity charges	(120)	(22)	(16)
Other unallocated manufacturing results	(94)	(57)	1
Gain on sale of non-current assets	4	2	3
Strategic and other research and development programs and other non-allocated provisions	(34)	(7)	(9)
Total operating loss Others	(414)	(97)	(23)
Operating income	$ (414)	$ (97)	$ (23)

Segment Information - Net Rev_2

Segment Information - Net Revenues (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	$ 17,286	$ 16,128	$ 12,761
Switzerland
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	5,755	4,569	3,282
France
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	158	153	126
Italy
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	54	47	56
USA
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	2,279	1,981	1,253
Singapore
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	8,138	8,604	7,442
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	890	758	586
Other countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	$ 12	$ 16	$ 16

Segment Information - Property,

Segment Information - Property, Plant & Equipment (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 10,554	$ 8,201
Netherlands
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	3,996	2,753
France
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	1,837	1,774
Italy
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	2,108	1,683
Other European countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	170	161
USA
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	59	52
Singapore
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	1,347	880
Malaysia
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	478	365
Other countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 559	$ 533

Other Income and Expenses Net -

Other Income and Expenses Net - Other Income and Expenses Net (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Other Income and Expenses [Abstract]
Public funding	$ 201	$ 177	$ 162
Start-up and phase-out costs	(134)	(13)	0
Exchange gain (loss), net	5	15	7
Patent costs	(12)	(8)	(10)
Gain on sale of non-current assets	6	2	5
COVID-19 incremental costs	0	(10)	(19)
Other, net	(11)	(4)	(4)
Total	$ 55	$ 159	$ 141

Interest Income (Expense), Ne_2

Interest Income (Expense), Net - Summary of Interest Income (Expense), Net (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Banking and Thrift, Interest [Abstract]
Income	$ 226	$ 71	$ 13
Expense	(55)	(13)	(42)
Total	$ 171	$ 58	$ (29)

Interest Income (Expense), Ne_3

Interest Income (Expense), Net - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net Investment Income [Line Items]
Income	$ 226	$ 71	$ 13
Expense	55	13	42
Interest and amortization of issuance costs on convertible bonds	1	1	3
Capitalized borrowing cost	0	0	0
Interest income (expense), net	$ 15	$ 1	1
Dual tranche senior unsecured convertible bonds
Net Investment Income [Line Items]
Non-cash accretion expense			$ 34

Income Tax - Income (Loss) befo

Income Tax - Income (Loss) before Income Tax (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income (loss) recorded in the Netherlands	$ (32)	$ (22)	$ (20)
Income (loss) from foreign operations	4,795	4,508	2,357
Income (loss) before income tax benefit (expense)	$ 4,763	$ 4,486	$ 2,337

Income Tax - Income Tax Benefit

Income Tax - Income Tax Benefit (Expense) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
The Netherlands taxes - current	$ 0	$ 0	$ 0
Foreign taxes - current	(528)	(510)	(285)
Total current taxes	(528)	(510)	(285)
The Netherlands taxes - deferred	0	0	0
Foreign taxes - deferred	(13)	(10)	(46)
Total deferred taxes	(13)	(10)	(46)
Income tax expense	$ (541)	$ (520)	$ (331)
Effective tax rate	11%	12%	14%

Income Tax - Additional Informa

Income Tax - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Netherlands statutory income taxes rate	25.80%	25.80%	25%
Effect of changes in tax laws and similar	$ (149)	$ (6)	$ (6)
Effect of the tax benefits on basic earnings per share (in usd per share)	$ 0.05	$ 0.07	$ 0.05
Maximum percentage of tax reduction from tax holidays	100%	100%	100%
Tax loss carryforwards, tax credits and other tax attributes	$ 886	$ 520
Thereafter	872
Deferred tax expense recorded as component of other comprehensive income (loss)	(4)	(26)
Cumulative amount of distributable earnings	7,575	7,140
Distributable earnings becoming taxable upon repatriation amount	607
Indefinitely reinvested by foreign subsidiaries	387
Decrease in long term deferred tax liabilities	22
Unrecognized tax benefits	21	25
Accrued interest and penalties related to uncertain tax positions			$ 1
Interest and penalties of unrecognized tax benefits	6	6
Technological activities
Operating Loss Carryforwards [Line Items]
Effect of changes in tax laws and similar	(52)
Tax loss carryforwards, tax credits and other tax attributes	479
Intangible assets
Operating Loss Carryforwards [Line Items]
Effect of changes in tax laws and similar	(81)
Utilization of tax losses
Operating Loss Carryforwards [Line Items]
Tax loss carryforwards, tax credits and other tax attributes	(126)
2029
Operating Loss Carryforwards [Line Items]
Thereafter	276
2030
Operating Loss Carryforwards [Line Items]
Thereafter	203
Maximum
Operating Loss Carryforwards [Line Items]
Accrued interest and penalties related to uncertain tax positions	1	$ 1
Netherlands
Operating Loss Carryforwards [Line Items]
Cumulative amount of distributable earnings	$ 6,965

Income Tax - Differences in Inc

Income Tax - Differences in Income Taxes Computed at Netherlands Statutory Rate and Effective Income Tax Rate (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income tax benefit (expense) computed at statutory rate	$ (1,229)	$ (1,158)	$ (584)
Non-deductible and non-taxable permanent differences, net	6	22	4
Change in valuation allowances	0	140	(2)
Effect of changes in tax laws and similar	(149)	(6)	(6)
Current year tax credits	29	30	39
Other tax and credits	34	(51)	(22)
Benefits from tax holidays	45	60	49
Net impact of changes to uncertain tax positions	(8)	(12)	(8)
Earnings of subsidiaries taxed at different rates	433	443	187
Income tax expense	$ (541)	$ (520)	$ (331)

Income Tax - Deferred Tax Asset

Income Tax - Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Tax loss carryforwards, tax credits and other tax attributes	$ 886	$ 520
Less unrecognized tax benefits	(21)	(25)
Tax loss carryforwards, tax credits and other tax attributes, net of unrecognized tax benefits	865	495
Inventory valuation	48	42
Fixed asset depreciation	61	55
Increased depreciation incentives	48	83
Capitalized development costs	38	79
Receivables for government funding	152	121
Tax credits granted on capital investments	226	218
Pension	67	62
Stock awards	17	17
Operating lease liabilities	69	50
Commercial accruals	38	27
Other temporary differences	33	27
Total deferred tax assets	1,662	1,276
Valuation allowances	(782)	(416)
Deferred tax assets, net	880	860
Accelerated fixed asset depreciation	(40)	(37)
Acquired intangible assets	(24)	(23)
Advances of government funding	(185)	(177)
Operating lease right-of-use assets	(62)	(50)
Other temporary differences	(31)	(31)
Deferred tax liabilities	(342)	(318)
Net deferred income tax asset	$ 538	$ 542

Income Tax - Gross Deferred Tax

Income Tax - Gross Deferred Tax Assets on Tax Loss Carryforwards and Investment Credits Expiration (Detail) $ in Millions	Dec. 31, 2023 USD ($)
Income Tax Disclosure [Abstract]
2024	$ 3
2025	2
2026	2
2027	4
2028	3
Thereafter	872
Total	$ 886

Income Tax - Reconciliation of

Income Tax - Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$ 61	$ 118	$ 48
Additions based on tax positions related to the current year	0	4	72
Additions based on acquisitions related to the current year	0	0	0
Additions for tax positions of prior years	11	13	1
Reduction for tax positions of prior years	0	(69)	(1)
Settlements	(14)	(2)	0
Reductions due to lapse of statute of limitations	(4)	0	0
Foreign currency translation	1	(3)	(2)
Balance at end of year	$ 55	$ 61	$ 118

Earnings per Share - Summary of

Earnings per Share - Summary of Earnings per Share ("EPS") (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Basic EPS
Net income attributable to parent company as reported	$ 4,211	$ 3,960	$ 2,000
Weighted average number of shares outstanding (in shares)	903,513,952	905,606,885	904,332,429
Earnings per share, basic ( in usd per share)	$ 4.66	$ 4.37	$ 2.21
Diluted EPS
Net income attributable to parent company as reported	$ 4,211	$ 3,960	$ 2,000
Interest expense, net of income tax effect	1	2	0
Net income attributable to parent company as adjusted	$ 4,212	$ 3,962	$ 2,000
Weighted average number of shares outstanding (in shares)	903,513,952	905,606,885	904,332,429
Dilutive effect of stock awards (in shares)	6,858,815	6,789,662	9,107,124
Dilutive effect of convertible bonds (in shares)	33,825,000	33,825,000	11,402,645
Number of shares used in calculating diluted EPS (in shares)	944,197,767	946,221,547	924,842,198
Earnings per share, diluted (in usd per share)	$ 4.46	$ 4.19	$ 2.16

Contingencies, Claims and Leg_2

Contingencies, Claims and Legal Proceedings - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 04, 2023
Long-Term Purchase Commitment [Line Items]
Contractual obligation	$ 800
Loss contingency, estimate of possible loss		$ 32
Foundry purchase
Long-Term Purchase Commitment [Line Items]
Recorded unconditional purchase obligation	$ 1,100

Financial Instruments and Ris_3

Financial Instruments and Risk Management - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($) Customer	Dec. 31, 2022 USD ($) Customer	Dec. 31, 2021 USD ($)
Derivative [Line Items]
Maximum percentage for research and development and corporate costs of the total forecasted transactions	80%
Maximum percentage for manufacturing costs of forecasted transactions	70%
Maximum percentage for designated hedged item of forecasted transactions	100%
Hedge exposure to the variability of cash flows for forecasted transactions	24 months
Deferred gains on derivative instrument, net of tax	$ 55
Period of accumulated other comprehensive income (loss)	12 months
Total asset derivatives	$ 60	$ 69
Fair value of liabilities	$ 4	$ 39
Maximum outstanding amount per instrument with each bank , as percentage of total	20%
Number of customer represented more than 10% of trade accounts receivable \| Customer	0	0
Contingent consideration, liability	$ 20	$ 31
Fair value measurement with unobservable inputs reconciliation non-recurring basis asset liability value	0	0
Impairment charge on investments	0	0	$ 0
Cost of sales
Derivative [Line Items]
Realized gain (loss) on reduction in operating expenses	$ (102)	(59)
Research and development expenses
Derivative [Line Items]
Fair value unobservable input reconciliation in statement of income	Research and Development Expense
Foreign exchange contract \| Gains (Losses) on Cash Flow Hedges \| Reclassification out of accumulated other comprehensive income \| Cost of sales
Derivative [Line Items]
Realized gain (loss) on reduction in operating expenses	$ 1	(129)	15
Foreign exchange contract \| Gains (Losses) on Cash Flow Hedges \| Reclassification out of accumulated other comprehensive income \| Operating expense
Derivative [Line Items]
Realized gain (loss) on reduction in operating expenses	4	$ (68)	4
Currency collars \| Option One
Derivative [Line Items]
Fair value of net assets (liabilities)	7
Total asset derivatives	8
Fair value of liabilities	1
Forward contracts
Derivative [Line Items]
Total asset derivatives	53
Fair value of liabilities	$ 4
Minimum
Derivative [Line Items]
Major customer percentage of trade accounts receivable	10%	10%
Not designated as hedging instrument
Derivative [Line Items]
Notional amount of derivative Instruments	$ 974	$ 931	505
Foreign currency forward contracts maturity term	47 days
Total asset derivatives	$ 5	9
Fair value of liabilities	2	3
Not designated as hedging instrument \| Forward contracts \| Other payables and accrued liabilities
Derivative [Line Items]
Fair value of liabilities	$ 2	3
Not designated as hedging instrument \| Minimum
Derivative [Line Items]
Foreign currency forward contracts remaining terms	3 days
Not designated as hedging instrument \| Maximum
Derivative [Line Items]
Foreign currency forward contracts remaining terms	166 days
Designated as hedging instrument
Derivative [Line Items]
Notional amount of derivative Instruments	$ 2,681	3,192	$ 2,165
Foreign currency forward contracts maturity term	113 days
Total asset derivatives	$ 55	60
Fair value of liabilities	2	36
Designated as hedging instrument \| Currency collars \| Other payables and accrued liabilities
Derivative [Line Items]
Fair value of liabilities	0	9
Designated as hedging instrument \| Currency collars \| Other non-current liabilities
Derivative [Line Items]
Fair value of liabilities	0	1
Designated as hedging instrument \| Forward contracts \| Other payables and accrued liabilities
Derivative [Line Items]
Fair value of liabilities	2	23
Designated as hedging instrument \| Forward contracts \| Other non-current liabilities
Derivative [Line Items]
Fair value of liabilities	$ 0	$ 3
Designated as hedging instrument \| Minimum
Derivative [Line Items]
Foreign currency forward contracts remaining terms	4 days
Designated as hedging instrument \| Maximum
Derivative [Line Items]
Foreign currency forward contracts remaining terms	13 months

Financial Instruments and Ris_4

Financial Instruments and Risk Management - Notional Amounts of Outstanding Derivative Instruments (Detail) - Dec. 31, 2023 - Designated as hedging instrument € in Millions, $ in Millions	EUR (€)	SGD ($)
Forward contracts
Derivative [Line Items]
Notional amount for hedge on forecasted R&D and other operating expenses	€ 445	$ 0
Notional amount for hedge on forecasted manufacturing costs	951	$ 219
Currency collars
Derivative [Line Items]
Notional amount for hedge on forecasted R&D and other operating expenses	240
Notional amount for hedge on forecasted manufacturing costs	€ 640

Financial Instruments and Ris_5

Financial Instruments and Risk Management - Fair Value of Derivative Instruments (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Derivatives, Fair Value [Line Items]
Total asset derivatives	$ 60	$ 69
Fair value of liabilities	(4)	(39)
Forward contracts
Derivatives, Fair Value [Line Items]
Total asset derivatives	53
Fair value of liabilities	(4)
Designated as hedging instrument
Derivatives, Fair Value [Line Items]
Total asset derivatives	55	60
Fair value of liabilities	(2)	(36)
Designated as hedging instrument \| Forward contracts \| Other current assets
Derivatives, Fair Value [Line Items]
Total asset derivatives	46	37
Designated as hedging instrument \| Forward contracts \| Other non-current assets
Derivatives, Fair Value [Line Items]
Total asset derivatives	2	8
Designated as hedging instrument \| Forward contracts \| Other payables and accrued liabilities
Derivatives, Fair Value [Line Items]
Fair value of liabilities	(2)	(23)
Designated as hedging instrument \| Forward contracts \| Other non-current liabilities
Derivatives, Fair Value [Line Items]
Fair value of liabilities	0	(3)
Designated as hedging instrument \| Currency collars \| Other current assets
Derivatives, Fair Value [Line Items]
Total asset derivatives	7	10
Designated as hedging instrument \| Currency collars \| Other non-current assets
Derivatives, Fair Value [Line Items]
Total asset derivatives	0	5
Designated as hedging instrument \| Currency collars \| Other payables and accrued liabilities
Derivatives, Fair Value [Line Items]
Fair value of liabilities	0	(9)
Designated as hedging instrument \| Currency collars \| Other non-current liabilities
Derivatives, Fair Value [Line Items]
Fair value of liabilities	0	(1)
Not designated as hedging instrument
Derivatives, Fair Value [Line Items]
Total asset derivatives	5	9
Fair value of liabilities	(2)	(3)
Not designated as hedging instrument \| Forward contracts \| Other current assets
Derivatives, Fair Value [Line Items]
Total asset derivatives	5	9
Not designated as hedging instrument \| Forward contracts \| Other payables and accrued liabilities
Derivatives, Fair Value [Line Items]
Fair value of liabilities	$ (2)	$ (3)

Financial Instruments and Ris_6

Financial Instruments and Risk Management - Effect on Consolidated Statements of Income of Derivative Instruments (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) deferred in OCI on derivative	$ 57	$ 23
Gain (loss) reclassified from OCI into earnings	5	(197)
Forward contracts \| Cost of sales \| Cash flow hedging
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) deferred in OCI on derivative	35	14
Gain (loss) reclassified from OCI into earnings	1	(83)
Forward contracts \| Selling, general and administrative expenses \| Cash flow hedging
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) deferred in OCI on derivative	4	2
Gain (loss) reclassified from OCI into earnings	1	(9)
Forward contracts \| Research and development expenses \| Cash flow hedging
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) deferred in OCI on derivative	10	4
Gain (loss) reclassified from OCI into earnings	2	(32)
Currency collars \| Cost of sales \| Cash flow hedging
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) deferred in OCI on derivative	5	1
Gain (loss) reclassified from OCI into earnings	0	(46)
Currency collars \| Selling, general and administrative expenses \| Cash flow hedging
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) deferred in OCI on derivative	1	1
Gain (loss) reclassified from OCI into earnings	0	(6)
Currency collars \| Research and development expenses \| Cash flow hedging
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) deferred in OCI on derivative	2	1
Gain (loss) reclassified from OCI into earnings	$ 1	$ (21)

Financial Instruments and Ris_7

Financial Instruments and Risk Management - Effect on Consolidated Statements of Income of Derivative Instruments Not Designated as Hedge (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange forward contracts	$ 2	$ 24
Derivative, gain (loss), statement of income or comprehensive income	Other income and expenses, net	Other income and expenses, net
Forward contracts \| Not designated as hedging instrument
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange forward contracts	$ 2	$ 24
Derivative, gain (loss), statement of income or comprehensive income	Other income and expenses, net	Other income and expenses, net

Financial Instruments and Ris_8

Financial Instruments and Risk Management - Schedule of Financial Assets (Liabilities) Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	$ 31	$ 26
Total asset derivatives	60	69
Fair value of liabilities	(4)	(39)
Contingent consideration on business acquisitions	(20)	(31)
Total	2,928	1,285
U.S. Treasury Bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	1,635	679
Equity securities measured at fair value through earnings
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	31	26
Short-term deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	1,226	581
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	2,892	1,286
Quoted Prices in Active Markets for Identical Assets (Level 1) \| U.S. Treasury Bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	1,635	679
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Equity securities measured at fair value through earnings
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	31	26
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Short-term deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	1,226	581
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	56	30
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration on business acquisitions	(20)	(31)
Total	(20)	(31)
Designated as hedging instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total asset derivatives	55	60
Fair value of liabilities	(2)	(36)
Designated as hedging instrument \| Cash flow hedging
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total asset derivatives	55	60
Fair value of liabilities	(2)	(36)
Designated as hedging instrument \| Significant Other Observable Inputs (Level 2) \| Cash flow hedging
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total asset derivatives	55	60
Fair value of liabilities	(2)	(36)
Not designated as hedging instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total asset derivatives	5	9
Fair value of liabilities	(2)	(3)
Not designated as hedging instrument \| Cash flow hedging
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total asset derivatives	5	9
Fair value of liabilities	(2)	(3)
Not designated as hedging instrument \| Significant Other Observable Inputs (Level 2) \| Cash flow hedging
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total asset derivatives	5	9
Fair value of liabilities	$ (2)	$ (3)

Financial Instruments and Ris_9

Financial Instruments and Risk Management - Schedule of Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3) (Detail) - Significant Unobservable Inputs (Level 3) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Opening position	$ 31	$ 77
Changes in fair value measurement	(12)	(35)
Currency translation adjustment	1	(4)
Payments made		7
Closing position	20	31
Amount of total gains (losses) for the period included in earnings attributable to liabilities still held at the reporting date	$ 12	$ 35

Financial Instruments and Ri_10

Financial Instruments and Risk Management - Fair Value Information on Other Financial Assets and Liabilities Recorded at Amortized Cost (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
ASSETS
Short-term, deposits	$ 1,226	$ 581
Long-term debt
Finance leases:	65
Senior unsecured convertible bonds issued on august 4, 2020
Long-term debt
Debt instrument unamortized debt issuance costs, net	4
Estimated Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1)
ASSETS
Cash and cash equivalents, fair value disclosure	2,879	2,996
Marketable securities	1,635	679
Short-term, deposits	1,226	581
Estimated Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Senior unsecured convertible bonds issued on august 4, 2020
Long-term debt
Dual tranche senior unsecured convertible bonds	1,814	1,561
Estimated Fair Value \| Significant Other Observable Inputs (Level 2)
Long-term debt
Bank loans (including current portion)	1,366	1,165
Finance leases:	65	57
Carrying Amount \| Quoted Prices in Active Markets for Identical Assets (Level 1)
ASSETS
Cash and cash equivalents, fair value disclosure	2,879	2,996
Marketable securities	1,635	679
Short-term, deposits	1,226	581
Carrying Amount \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Senior unsecured convertible bonds issued on august 4, 2020
Long-term debt
Dual tranche senior unsecured convertible bonds	1,496	1,495
Carrying Amount \| Significant Other Observable Inputs (Level 2)
Long-term debt
Bank loans (including current portion)	1,366	1,165
Finance leases:	$ 65	$ 57

Related Party Transactions - Tr

Related Party Transactions - Transactions with Related Parties (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Net revenues	$ 17,286	$ 16,128	$ 12,761
Cost of sales	8,999	8,493	7,435
Trade accounts receivable, net	1,731	1,970
Trade accounts payable	1,856	2,122
Related Party
Related Party Transaction [Line Items]
Trade accounts receivable, net	0	5	2
Trade accounts payable	6	2	0
Related Party \| Sales and services
Related Party Transaction [Line Items]
Net revenues	5	13	8
Related Party \| Purchases and other contributions
Related Party Transaction [Line Items]
Cost of sales	$ 27	$ 25	$ 19

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Other income and expenses, net	$ 55	$ 159	$ 141
ST Foundation
Related Party Transaction [Line Items]
Other income and expenses, net	$ 1	$ 1	$ 0.5

Valuation and Qualifying Acco_2

Valuation and Qualifying Accounts (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounts Receivable
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 21	$ 19	$ 16
Additions/ (Deductions)	(2)	2	3
Balance at end of period	19	21	19
Deferred Tax Assets
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	416	576	638
Translation adjustment	5	(19)	(24)
Charged to costs and expenses	360	(140)	(2)
Additions/ (Deductions)	1	(1)	(36)
Balance at end of period	$ 782	$ 416	$ 576